The roles of annexins 1 and 2 in receptor-mediated endocytosis. by Bailey, L.M.
SHL ITEM BARCODE
REFERENCE ONLY
19 1691500 X
UNIVERSITY OF LONDON THESIS
Degree
P u t ?
Year
Z o o ^ T
Name of Author
B A \ l g Y  ; L . K
COPYRIGHT
This is a thesis accepted for a Higher Degree of the University of London. It is an 
unpublished typescript and the copyright is held by the author. All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
I recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from it or information derived from it may be published without the 
prior written consent of the author.
LOAN
Theses may not be lent to individuals, but the University Library may lend a copy to 
approved libraries within the United Kingdom, for consultation solely on the premises 
of those libraries. Application should be made to: The Theses Section, University of 
London Library, Senate House, Malet Street, London WC1E 7HU.
REPRODUCTION
University of London theses may not be reproduced without explicit written 
permission from the University of London Library. Enquiries should be addressed to 
the Theses Section of the Library. Regulations concerning reproduction vary 
according to the date of acceptance of the thesis and are listed below as guidelines.
A. Before 1962. Permission granted only upon the prior written consent of the
author. (The University Library will provide addresses where possible).
B. 1962 - 1974. In many cases the author has agreed to permit copying upon
completion of a Copyright Declaration.
C. 1975 - 1988. Most theses may be copied upon completion of a Copyright
Declaration.
D. 1989 onwards. Most theses may be copied.
This thesis comes within category D.
□ This copy has been deposited in the Library of
This copy has been deposited in the University of London Library, Senate 
House, Malet Street, London WC1E 7HU.
C:\Documents and Settings\lproctor.ULL\Local Settings\Temporary Internet Files\OLK36\Copyright-thesis.doc

The Roles of Annexins 1 and 2 in Receptor 
Mediated Endocytosis
Lorna Mary Bailey
Division of Cell Biology 
Institute of Ophthalmology 
University College London
Thesis submitted to the University of London 
for the degree of Doctorate of Philosophy
November 2004
/ f iS T x
( 10RMR. ]
\uH Jy
1
UMI Number: U592690
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U592690
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Abstract
Activated EGF receptors (EGFR) are sorted onto internal vesicles of multivesicular 
endosomes/bodies (MVBs), thus removing receptors from the recycling pathway and 
targeting them for degradation. The EGFR tyrosine kinase has two major substrates 
within MVBs, the EGFR itself and annexin 1. Annexins have been proposed to play 
multiple roles in membrane traffic and both annexins 1 and 2 have been localised to 
early transferrin positive endosomes and to MVBs. In these studies a combination of 
gene knockout and RNAi-induced protein depletion was used to investigate the 
effect of loss of annexins 1 and 2 on the formation of MVBs and on EGFR 
trafficking. MVBs form constitutively in unstimulated cells but EGF stimulation 
significantly increased both the number of MVBs formed and the number of internal 
vesicles per MVB. Neither annexin is required for MVB formation, but EGF- 
stimulated inward vesiculation, within a sub-population of EGFR-containing MVBs, 
is mediated through annexin 1. Consistent with a role for annexin 1 in internal 
vesicle formation, annexin 1 and EGFR were present on the same internal vesicles 
within MVBs from EGF stimulated cells, but annexin 2 was not. In annexin 1 -/- 
cells there was no effect on EGF degradation, but a small reduction in EGFR 
degradation was seen. Prolonged MAPK signalling was observed in annexin 1 -/- 
cells, which also exhibited enhanced EGF-stimulated cell motility. Additionally, 
loss of annexin 1 was found to alter the shape of mouse lung fibroblasts. EGF- 
stimulated phosphorylation of annexin 1 was required for annexin 1-mediated 
inhibition of cell motility, but not for annexin 1-mediated regulation of cell shape. 
Therefore, annexin 1 is involved in specific EGF-stimulated effects, including 
internal vesicle formation, downregulation of EGFR signalling and inhibition of cell 
motility.
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Chapter 1 - Introduction
1.1 General Introduction to Growth Factor Receptor Trafficking and Annexins
The cell surface is a dynamic structure and is the site where molecules enter into 
the cell (endocytosis, phagocytosis or pinocytosis) and exit from the cell 
(exocytosis). On the surface of cells are many types of proteins, including various 
receptors through which the cell can sense changes in its extracellular environment. 
Cells are sensitive to small amounts of signalling molecules and as a result 
receptors must be highly regulated. Misregulation of intracellular signalling can 
lead to excessive cell growth or cell division and this is often seen in cancer cells.
Growth factor receptors, such as epidermal growth factor (EGF) receptor (EGFR), 
are found on the surface of many, if  not all, mammalian cells. Ligand binding 
activates the receptor. In the case of the EGFR, this occurs through receptor 
dimerisation, autophosphorylation and activation of the intracellular tyrosine 
kinase, which activates several signalling pathways by initiating phosphorylation 
cascades. Figure 1.1 shows a simplified diagram of EGFR trafficking. Activated 
EGFR are immediately downregulated and the first step is receptor internalisation, 
via clathrin coated pits (CCPs) (Haigler et al., 1979; Hanover et al., 1985). The 
plasma membrane is induced to curve inwards by a complex group of proteins and 
eventually the invagination pinches off to form a clathrin coated vesicle (CCV). 
After shedding their clathrin coats, newly formed endosomes can fuse with each 
other and with pre-existing early endosomes. The term “early endosome” 
encompasses a range of peripherally located membrane bound tubular-vesicular 
structures, which stain positive for Rab5 and EEA1 (early endosomal antigen 1) 
(Mu et al., 1995; Stenmark et al., 1996). In early endosomes, EGFR are present on 
the membrane with their cytoplasmic domains exposed to the cytoplasm and 
extracellular domains within the lumen of the vesicle. Non-kinase receptors, such 
as transferrin receptor (TfR), are also internalised into these early endosomes 
(Futter and Hopkins, 1989; Wiley et al., 1991). Interestingly, newly formed TfR 
are also found in endosomes en route to the plasma membrane (Futter et al., 1995). 
Early endosomes mature to form larger endosomes with a more acidic internal pH.
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Figure 1.1. EGFR trafficking through the endocytic pathway. EGF binds to the 
extracellular domain of cell surface EGFR, inducing receptor dimerisation and 
activation of the cytoplasmic tyrosine kinase, which phosphorylates EGFR 
(autophosphorylation) and downstream molecules, including many signalling pathways. 
Autophosphorylation allows binding of other proteins to EGFR recruiting it to CCPs. A 
protein complex, including clathrin, AP-2, epsin and Epsl5, induces the formation of 
CCVs, which are released into the cytoplasm by dynamin-induced fission. The clathrin 
coat is rapidly removed and vesicles can fuse with each other and pre-existing early 
endosomes (EE). Endosomes mature to form MVBs, larger vacuoles that contain 
internal vesicles. Active EGFR are sorted to the degradative pathway here by 
sequestration onto internal vesicles. MVBs continue to mature and the final stage is 
fusion with the lysosome and degradation of the contents of the MVB. Recycling of 
receptors (TfR) not destined for lysosomal degradation can occur from endosomes (fast 
pathway) or from the perimeter membrane of MVBs (slow pathway through recycling 
endosomes).
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This change in pH causes the ligands of several receptors to dissociate, allowing the 
now empty receptor to be recycled back to the plasma membrane e.g. low density 
lipoprotein (LDL) receptor. Endosomal maturation continues as the outer 
membrane invaginates to form internal vesicles (van Deurs et al., 1993). 
Endosomes containing these internal vesicles are known as multivesicular bodies or 
endosomes (MVBs). Sorting of receptors to the recycling or degradation pathways 
occurs within MVBs. EGFR, and other proteins e.g. LDL, targeted for lysosomal 
delivery, are sorted onto the internal vesicles (Hopkins et a l , 1990), thus removing 
the cytoplasmic domain from the cytoplasm. Meanwhile, constitutively recycling 
receptors e.g. TfR, are retained on the perimeter membrane of the MVB and are 
removed into recycling endosomes and finally back to the cell surface (Yamashiro 
et al., 1984). Once molecules not destined for degradation have been removed 
from the MVB, the final stage of the endocytic pathway is fusion of the MVB with 
the lysosome, which can then regenerate to form whole/new lysosomes (van Deurs 
et al., 1995; Futter et al., 1996; Bright et a l , 1997; Mullock et a l , 1998). This 
results in destruction of the EGF and its receptor, and inhibits the initiation of new 
signalling cascades from the receptor.
The annexins are a large family of calcium (Ca2+) and phospholipid binding 
proteins. The name annexin is derived from the Greek annex meaning “to bring or 
hold together” and was chosen to describe the major physical property of most, if 
not all, annexin family members (for a review see Gerke and Moss, 2002). 
However, the annexins were not discovered as a complete family. In the late 1970s 
and early 1980s, several groups were working independently on unidentified 
proteins, which would later form the annexin family. These proteins were given a 
range of diverse and unrelated names based on their biochemical properties. These 
included synexins (Creutz et al., 1978), chromobindins (Creutz et a l , 1987), 
calcimedins (Moore et a l , 1984), lipocortins (Flower, 1986) and calpactins 
(Glenney, 1986b). More detailed work on these proteins revealed that they shared 
key biochemical properties, as well as gene structure and sequence features. The 
family name annexin was agreed on in 1990 to solve the nomenclature confusion 
(Crumpton and Dedman, 1990). From this date onwards, an annexin was defined 
by two major criteria: (i) it must be capable of binding to negatively charged 
phospholipids in a Ca2+ dependent manner and (ii) it must contain the annexin
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repeat, four of which form a highly a-helical disk called the annexin domain, which 
is conserved throughout the family members. Annexins have been considered of 
interest to those investigating EGFR endocytosis and sorting because they have 
been implicated in many aspects of general membrane trafficking. With respect to 
EGFR-trafficking, annexin 1 (formerly known as lipocortin 1 (Huang et a l, 1986), 
p35 (Brugge, 1986; Isacke et a l, 1989) and calpactin II (Glenney, 1986b; Glenney, 
Jr. et a l, 1987)) has been proposed to play a role in sorting within MVBs and 
annexin 2 (lipocortin II (Huang et a l, 1986), p36 (Brugge, 1986; Isacke et a l, 
1989) or calpactin I (Glenney, 1986b; Glenney, Jr. et a l, 1987)) in the generation 
of MVBs. Annexins 1 and 2 are structurally very similar and Figure 1.2 shows the 
3-D structure of annexin 1.
A. Core and N-terminus B. N-terminally truncated
ft Ga++
repeat It
repeat I
Figure 1.2. 3-D structure o f annexin 1. Ribbon diagrams of one monomer of (A) 
recombinant porcine annexin 1 comprising protein core and the N-terminal domain 
and (B) human annexin 1 lacking the first 32 amino acid residues (Al to 32 annexin I. 
Repeat I is presented in red, repeat II in green, repeat III in blue, repeat IV in purple 
and the N-terminal domain in yellow. The yellow N-terminal helix in (A) is replacing 
the two-turn blue helix in (B). Bound calcium ions in Al-32 annexin 1 are illustrated 
as yellow spheres. This figure was obtained from Rosengarth et a l, 2001.
1.2 Growth Factor Receptor internalisation
Internalisation of growth factor receptors, especially EGFR, has been widely 
studied. Efficient internalisation of EGFR requires multiple signals, including 
active tyrosine kinase function, endocytic signals in the cytoplasmic domain of the 
receptor, and possibly receptor ubiquitination.
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1.2.1 EGFR internalisation signals and tyrosine kinase activity
Several sequences in the EGFR carboxyl terminus have been reported as necessary 
for efficient EGFR internalisation. These sequences, or internalisation motifs, are 
short linear arrays of amino acids generally classed as tyrosine-based or dileucine 
motifs. A region of the EGFR cytoplasmic domain (973-1022) was identified as 
essential for ligand-induced receptor internalisation and contains FYRAL and 
QQGFF motifs (Chen et al., 1989; Chang et al., 1991; Chang et al., 1993). These 
motifs were also shown to efficiently substitute for those found in TfR, indicating 
that common mechanisms are involved in internalisation of ligand dependent and 
ligand independent receptors. Another region of the cytoplasmic tail of EGFR 
contains three tyrosine-based NPXY domains, similar to those found in LDL 
receptors. However, mutations in these motifs failed to inhibit EGFR 
internalisation, thus showing these domains are not essential for internalisation 
(Chang et al., 1993).
The activity of the EGFR cytoplasmic tyrosine kinase domain is necessary for its 
signalling properties (phosphorylation of downstream proteins), but whether it is 
required for receptor internalisation remains a controversial topic. Several studies 
showed that EGF-bound, kinase negative EGFR underwent normal internalisation, 
but were incorrectly processed within the cell resulting in an inhibition of EGF 
degradation and an increase in EGFR recycling (Honegger et al., 1987; Felder et 
al., 1990). In contrast, Glenney et al. (1988) reported a tyrosine kinase mutant 
EGFR that failed to internalise, and also showed that receptor internalisation of 
EGFR was abrogated by inhibition of tyrosine phosphorylation using anti- 
phosphotyrosine antibodies (Glenney, Jr. et al., 1988). Wiley et al. (1991) showed 
that there is a constitutive low level rate of EGFR internalisation and that 
unoccupied EGFR undergo endocytosis at the same rate as receptors lacking the 
cytoplasmic tyrosine kinase domain (Wiley et al., 1991). Ligand binding to wild 
type receptors increased the rate of receptor internalisation (up to 10-fold), but had 
no effect on the internalisation rate of kinase negative receptors (Wiley et al., 
1991).
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From these and other studies, it became apparent that high and low affinity EGFR 
differ in the efficiency with which they are endocytosed. Kinase activity is required 
for an enhanced rate of endocytosis of high affinity receptors and it was shown that 
this system could be saturated using increased amounts of EGF, which reduced the 
overall rate of receptor internalisation (Wiley et al., 1991; Felder et al., 1992). 
Ligand-induced autophosphorylation of EGFR results in a more open conformation, 
which exposes trafficking domains, and this change in conformation is thought to 
allow more proteins involved in internalisation to bind to the receptor (Cadena et 
al., 1994). Much of the controversy over the requirement for kinase activity in 
internalisation may be explained by differences in the cell type and experimental 
conditions used. Those favouring high receptor occupancy, through use of high 
concentrations of EGF, had a tendency to favour measurements of both high and 
low affinity receptor internalisation. EGFR tyrosine kinase activity is not essential 
for receptor endocytosis, but is required for efficient internalisation of high affinity 
receptors.
1.2.2 Clathrin and adaptor proteins
The majority of activated EGFR are internalised via the clathrin-dependent 
endocytic pathway, which is a rapid process compared to the kinetics of the 
clathrin-independent pathway. Investigations into the exact role of clathrin in 
receptor internalisation require low levels of EGF and receptor expression to avoid 
saturation of the clathrin-dependent pathway (Jiang and Sorkin, 2003). Activated 
EGFR are recruited to CCPs through specific adaptors proteins, which have the 
bivalent capacity to interact with clathrin and the cytoplasmic domain of the 
receptor. The cytoplasmic tails o f activated EGFRs interact with adaptor protein 2 
(AP-2), which recruits clathrin to the plasma membrane and is involved in the 
formation of CCPs (Sorkin et al., 1996). Clathrin and AP-2 bind several proteins of 
the endocytic regulatory machinery, including amphiphysin 1, amphiphysin n, 
epsin and Epsl5, thus creating a complex at the membrane (reviewed in Mousavi et 
al. 2004). The action of this complex, together with several other proteins, 
including dynamin, synaptojanin, intersectin, endophilin and syndapin, regulates 
the formation of CCVs (Simpson et al., 1999; Mousavi et al., 2004).
24
AP-2 was originally thought to be the central protein in, and absolutely necessary 
for, clathrin-mediated endocytosis. However, deletion of the yeast equivalent of 
AP-2 had no effect on clathrin-mediated endocytosis or on any other pathway 
investigated (Yeung et al., 1999). Further work in mammalian cells revealed that 
several of the accessory proteins that bind AP-2 are also able to bind clathrin and 
phosphoinositol (4,5) bisphosphate (PIP2), indicating that they may be adaptors in 
their own right. Motley et al. (2003) used RNA interference (RNAi) to knock 
down the AP-2 p2 subunit and clathrin heavy chain and reported that although loss 
of AP-2 led to a decreased number of CCPs, it is not essential for clathrin-mediated 
endocytosis of EGFR (Motley et a l , 2003). It is proposed that other adaptors play a 
role in endocytosis of EGFR and, in the absence of AP-2, these are still recruited to 
the protein complex that forms at the plasma membrane. In contrast, endocytosis of 
TfR was significantly inhibited by loss of AP-2, expression of a mutant form of 
AP-2 unable to bind tyrosine based sorting motifs, or overexpression of adaptor- 
associated kinase that sequestered AP-2, indicating that TfR can only bind AP-2 
and not any other adaptor molecules (Nesterov et a l , 1999; Motley et a l , 2003; 
Conner and Schmid, 2003). Another potential adaptor protein CALM (clathrin- 
assembly lymphoid myeloid leukaemia protein, also known as A PI80) was recently 
proposed to be involved in CCP formation. CALM depletion had a partial but 
specific inhibitory effect on EGFR internalisation. However, there was no effect 
observed on TfR internalisation, indicating that CALM is not an essential part of 
the clathrin-associated endocytic complex (Huang et a l , 2004).
Fission of the CCV is mediated by the GTPase dynamin, releasing it into the 
cytoplasm (van der Bliek et a l , 1993; Damke et a l , 1994; Hill et al., 2001). The 
clathrin coat is rapidly removed by the lipid phosphatase synaptojanin (Hill et a l , 
2001; Rusk et a l , 2003), and the vesicle is now capable of fusing with other 
membrane bound structures within the cell. Many groups have used a dominant 
negative mutant form of dynamin (K44A), which lacks functional GTPase activity, 
to block endocytosis (van der Bliek et al., 1993; Damke et a l , 1994; Ceresa et a l , 
1998; Hill et a l , 2001; Huang et a l, 2004).
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After EGF stimulation many other proteins are also phosphorylated. One such 
protein is Epsl5 (EGFR pathway substrate clone 15), which is recruited to the 
plasma membrane where it is involved in receptor recruitment to the AP-2 complex 
(Benmerah et al., 1995). Interestingly, Epsl5 is absent from CCVs but appears to 
rejoin the endosome after removal of the clathrin coat (Cupers et al., 1998; Torrisi 
et al., 1999). Epsl5 interaction with AP-2 is negatively regulated by its interaction 
with Hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs, also known 
as Hgs). Hrs also interacts with the clathrin coat and is involved with later sorting 
stages of EGFR (Raiborg et a l , 2002). Expression of a dominant negative mutant 
Epsl5 inhibits EGFR endocytosis by trapping receptors in coated pits, yet this has 
no effect on constitutive TfR endocytosis (Confalonieri et a l, 2000).
Rab5a, a member of the membrane bound Rab family of small GTPases, is 
activated by EGF stimulation and has been shown to be essential for endocytosis 
(Barbieri et a l, 2000). Rab5a is present on the cytoplasmic face of the plasma 
membrane and on early endosomes (Chavrier et a l, 1990), and can promote 
endosomal fusion in vitro (Gorvel et a l, 1991). These properties made Rab5a an 
ideal candidate for a role in endocytosis. Interestingly, not only does Rab5a 
regulate the transport of endocytic cargo from the cell surface into endosomes 
(Bucci et a l, 1992), it is also capable of promoting CCP formation as part of a 
complex with GDI (guanine-nucleotide dissociation inhibitor) (McLauchlan et al, 
1998). Rab5a induces the translocation of its effector protein EEA1 from the 
cytoplasm to the plasma membrane (Trischler et a l, 1999). The importance of 
Rab5a in endocytosis was highlighted through studies using a dominant negative 
mutant that blocked both EGF-stimulated receptor mediated endocytosis and fluid 
phase endocytosis (Barbieri et a l, 2000).
1.2.3 Role o f ubiquitination in receptor internalisation
After ligand-induced activation, EGFR is not only phosphorylated but is also 
modified by the addition of ubiquitin, a 76-amino acid protein found in all 
eukaryotic cells. Ubiquitin is added to proteins as a form of post-translational 
modification and is one of the key signals for protein sorting within the endocytic
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pathway. The cbl protein family are ubiquitin ligases, implicated in the regulation 
of receptor trafficking. C-Cbl is a substrate of the EGFR tyrosine kinase and 
phosphorylation on residue 371 activates c-Cbl ubiquitin ligase activity. This 
allows it to bind to activated (phosphorylated) EGFRs via its tyrosine kinase- 
binding (TKB) domain, which contains a unique SH2 (src-homology 2) domain 
(Stang et a l , 2000; Longva et a l , 2002). A separate domain, the RING finger, 
recruits the E2 ubiquitin-conjugating enzymes UbcH7 and mediates the transfer of 
ubiquitin to the receptor (Yokouchi et a l, 1999; Waterman et a l, 1999). The 
proline-rich regions of c-Cbl are involved in interactions with SH3 containing 
adaptor proteins, such as Grb2 and Nek (Meisner et a l, 1995; Fukazawa et al, 
1996; Donovan et a l, 1996; Thien and Langdon, 1997). After EGF stimulation c- 
Cbl mediates monoubiquitination (the addition of a single ubiquitin moiety) of 
EGFR at the plasma membrane (de Melker et a l, 2001). As EGFR passes along 
the endocytic pathway more single ubiquitin molecules are added resulting in the 
desensitisation of the receptor (Mosesson et a l, 2003).
Extensive work has been carried out to elucidate whether c-Cbl activity is required 
for EGFR internalisation. Evidence that c-Cbl is involved in early stages of 
endocytosis comes from the detection of c-Cbl in CCPs after EGFR activation and 
the finding that EGFR ubiquitination occurs before endocytosis (Stang et a l, 2000; 
de Melker et a l, 2001). In support of a role for c-Cbl in receptor internalisation, a 
mutant form of c-Cbl, that still binds Grb2 but is unable to ubiquitinate, was shown 
to inhibit EGFR internalisation (Jiang and Sorkin, 2003). However, contradictory 
data exists that shows c-Cbl activity is not essential for receptor internalisation and 
suggests that there are alternative internalisation routes (Levkowitz et a l, 1998; 
Thien et al, 2001; Duan et al, 2003; de Melker et a l, 2004). Taken together, these 
data suggest that c-Cbl facilitates, but is not essential for, efficient EGFR 
internalisation.
Having established that c-Cbl activity is only required for efficient EGFR 
internalisation, the exact mechanism of its action was investigated. 
Monoubiquitination of EGFR could be sufficient to serve as a signal for 
internalisation, as observed for Growth Hormone Receptor (GHR) in mammalian 
cells and Ste2p, a surface receptor, in yeast (Hicke and Riezman, 1996; Govers et
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al., 1999). Alternatively, the RING finger domain could monoubiquitinate proteins 
associated with EGFR or CCPs. C-Cbl monoubiquitinates CIN85, an adaptor 
protein (Haglund et a l , 2002), which constitutively interacts with endophilins via 
its proline-rich domain. It is proposed that this recruitment to the activated receptor 
complex allows endophilins to bind the lipid bilayer and induce membrane 
curvature. However, while CIN85 would seem to be an important protein in this 
pathway, mutant forms of CIN85 do not affect EGFR internalisation (Jiang and 
Sorkin, 2003). Additionally, the ubiquitin ligase activity of c-Cbl may be required 
for efficient internalisation of EGFR through recruitment of Epsl5, via its ubiquitin 
interacting motif (UIM), either by ubiquitinated receptors or an adaptor protein (de 
Melker et a l , 2004). The final theory is that the RING finger domain may interact 
with other proteins independently of its role in ubiquitylation. C-Cbl is able to 
interact with the adaptor protein Grb2, which also binds EGFR, and together this 
complex is thought to anchor EGFR to the Epsl5 complex at the rim of CCPs 
(Jiang and Sorkin, 2003; Stang et a l , 2004). Therefore, it seems likely that c-Cbl 
mediated ubiquitination of EGFR is required for efficient receptor internalisation 
via a clathrin/Epsl5 dependent route (de Melker et a l , 2004).
1.2.4 Role o f annexins in internalisation
The internalisation of growth factors has been extensively studied, but so far little 
work has been carried out to elucidate potential roles for annexins in this process. 
Annexin 6 (annexin VI) was reported to be involved in the budding of CCPs, after 
depletion of the protein inhibited the budding of CCPs from membranes in vitro 
(Lin et al., 1992). However, it was later shown that annexin 6 is not essential for 
CCP formation or budding, as these process occurred efficiently in A431 cells that 
do not express annexin 6 (Smythe et al., 1994). These findings indicated that there 
might be more than one type of CCP and Kamal et al. (1998) showed that at least 
one type was dependent on annexin 6 activation of a cysteine protease involved in 
dissociation of CCP from the spectrin cytoskeleton (Smythe et al. 1994;Kamal et 
al., 1998). To date, no other annexin family members have been identified as 
having roles in internalisation, although both annexins 1 and 2 have been localised 
to the plasma membrane (Nakata et al., 1990; Traverso et al., 1998).
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1.3 Intracellular sorting of growth factor receptors
While the mechanisms involved in receptor internalisation have been well 
characterised, the later stages of receptor endocytosis remain less well understood. 
Internalisation is the first stage of receptor downregulation and signal attenuation. 
This process continues within MVBs where EGFR and other proteins targeted for 
lysosomal degradation are sorted onto internal vesicles (Hopkins et a l, 1990), 
while recycling receptors, e.g. TfR, are constitutively recycled back to the cell 
surface from the MVB perimeter membrane (Jackie et al., 1991). Recently, there 
has been an increase in published data investigating mechanisms of receptor 
sorting, and a number of signals and proteins involved in the process of receptor 
sorting and/or inward vesiculation have been identified.
1.3.1 EGFR lysosomal targeting signals, tyrosine kinase activity and role o f 
ubiquitination
The exact process of receptor sorting and inward vesiculation are not yet fully 
understood. A number of motifs within the cytoplasmic domain of the EGFR are 
thought to be necessary for lysosomal targeting. A tyrosine-based sorting signal 
(YLVI) was identified at the distal border of the tyrosine kinase domain and is 
similar to those found in lysosomal proteins, such as LAMP-1 and -2  (Opresko et 
al, 1995; Guamieri et a l, 1995). A dileucine motif in the juxtamembrane domain 
of EGFR is also important for lysosomal targeting, as mutation of this region 
reduced degradation efficiency, although had no effect on receptor endocytosis (Kil 
et al, 1999). Additionally, sorting of EGFR onto the internal vesicles of MVBs 
requires its actin binding domain, deletion of which results in the relocalisation of 
EGFR to recycling compartments, rather than lysosomes (Stoorvogel et a l, 2004).
Sorting of EGFR onto the internal vesicles of MVBs removes the active receptor 
tyrosine kinase domain from the cytoplasm, thus limiting the number of 
downstream target molecules available. In addition to its signalling potential, the
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activity of the tyrosine kinase is thought to be necessary for efficient targeting to 
the lysosome. EGFR lacking tyrosine kinase activity were internalised but were 
mostly recycled back to the cell surface (Honegger et a l, 1987; Felder et al., 1990; 
Stoorvogel et al., 2004), suggesting that tyrosine kinase activity is required to 
prevent entry to the recycling pathway by inducing inward vesiculation into MVBs 
(Felder et a l , 1990). In spite of this work, there are reports that the tyrosine kinase 
activity is not essential for lysosomal targeting of EGFR (Opresko et a l , 1995). 
Taken together, the findings of these studies suggest that distinct cytoplasmic 
domains regulate endocytosis and lysosomal delivery of EGFR.
Although the role of ubiquitin in receptor internalisation remains unclear, its role in 
endosomal sorting is less controversial. Several groups have reported that c-Cbl 
mediated ubiquitination of activated EGFR is required for efficient lysosomal 
targeting (Levkowitz et a l , 1998; Longva et a l , 2002; Duan et a l , 2003). Further 
evidence for the role of ubiquitin in receptor sorting comes from the association of 
c-Cbl with EGFR, from the plasma membrane throughout the endocytic pathway, 
including colocalisation on the internal vesicles of MVB, until degradation in the 
lysosome (de Melker et a l , 2001).
1.3.2 Role o f ESCRTs in receptor sorting
Much of the information on the molecular mechanisms involved in sorting within 
MVBs has come from the identification of proteins in yeast vps (vacuolar protein 
sorting) mutants. Class E vps mutants contain characteristic enlarged aberrant 
endosomal structures and exhibit defects in protein sorting to the MVB. In yeast, 
the class E vps proteins were first identified as required for MVB formation and 
sorting of Ste2p into the vacuolar lumen (Odorizzi et al., 1998). Class E vps 
proteins have been shown to form three protein complexes termed ESCRT 
(endosomal sorting complex required for transport)-I, ESCRT-II and ESCRT-HI, 
thought to interact sequentially in sorting within the MVB (Katzmann et al., 2001; 
Babst et al., 2002a; Babst et al., 2002b). A model of vps and ESCRT protein 
function in receptor sorting and MVB formation is presented in Fig. 1.3. To date 
over 70 yeast vps genes, and 18 class E vps mutants, have been identified.
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Mammalian homologues have now been found for all Class E vps proteins, most 
recently Vps37p, part of yeast ESCRT-I (von Schwedler et al., 2003; Bache et al., 
2004). For several yeast proteins, there are two or more human orthologs, implying 
that the mammalian system is more complex. However, not all of the mammalian 
proteins seem to have the same function as their yeast counterparts. Additionally in 
mammalian cells, tyrosine kinase receptors that are not present in yeast, utilize the 
endocytic pathway. It is clear that further work needs to be carried out to elucidate 
the exact properties and functions of these proteins in mammalian cells.
After EGFR internalisation into endosomes, Hrs is believed to be the first of the 
soluble factors recruited, via the interaction of its FYVE domain with 
phosphatidylinositol 3-phosphate (PI3P) molecules on the endosomal membrane 
(Komada et a l , 1997). Recruitment of Hrs may also be mediated via interactions 
between its UIM and ubiquitin on proteins that require sorting (Raiborg et al, 
2002). Hrs is concentrated in flat bilayered clathrin coats on the surface of 
endosomes and is proposed to sort ubiquitinated proteins destined for lysosomal 
degradation, but not recycling receptors (Sachse et a l, 2002; Raiborg et a l, 2002; 
Clague, 2002). This was further confirmed by the retention of ubiquitin tagged TfR 
within endosomes, as normally TfR is not ubiquitinated and recycles back to the 
plasma membrane (Raiborg et a l, 2002). Once Hrs is recruited to the endosome, it 
also recruits STAM 1 and 2, which are involved in receptor sorting (Bache et al, 
2003b). Additionally, Hrs acts as a docking site for ESCRT-1, which is comprised 
of three component proteins Vps23, Vps28 and Vps37 (Katzmann et a l, 2003; 
Bache et a l, 2003a). Vps23 (Tumour susceptibility gene or TsglOl) binds Hrs via 
its UIM (Lu et a l, 2003) and ESCRT-1 is recruited to the endosome. Reduced 
TsglOl protein levels have been shown to impair the efficient downregulation of 
EGFR and result in prolonged signalling through the MAPK (mitogen activated 
protein kinase) pathway (Babst et a l, 2000). ESCRT-II is a smaller protein 
complex (155kDa) comprised of Vps22, two Vps25 molecules and the C-terminus 
of Vps36, which together form a Y shape (Hierro et a l, 2004). This complex 
transiently associates with the endosomal membrane and initiates the formation of 
ESCRT-in (Babst et a l, 2002b). ESCRT-III has two sub complexes: the first, 
Vps20/Snf 7, binds to the endosomal membrane and recruits the second, 
Vps2/Vps24, which, in turn, recruits additional factors (Babst et a l, 2002a).
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ESCRT-III proteins show considerable homology to human CHMP (charged MVB) 
proteins (Babst et a l, 2002a).
Cytoplasm
Hrs/clathrin ESCRT-I ESCRT-II ESCRT-III ESCRT-III 
bilayered coat
Ps l3 STAY TsglOl ^Vps 
37
EGFR
Endosomal/MVB lumen
Figure 1.3. Model o f vps and ESCRT protein mediated EGFR sorting and MVB 
formation. PI3P mediates the localisation of Hrs and its associated proteins Epsl5, 
STAM and clathrin to endosomal membranes. The complex binds to ubiquitinated 
EGFR and retains them in the endosome membrane. Ubiquitinated (Ub) EGFR are 
delivered to ESCRT-I by interacting with TsglOl. EGFR is then relayed to ESCRT-II 
and transported into an intraluminal vesicle, which is formed through polymerisation of 
ESCRT-III complexes. The membrane association of several of these proteins is 
controlled by the AAA ATPase Vps4 (not shown). Before vesicle scission, EGFR is 
deubiquitinated. Arrows indicate the direction of the sorting process. Diagram modified 
from Raiborg et al., 2003.
Vps4 is an AAA type ATPase responsible for disassociation and recycling of the 
ESCRT complex from the endosomal membrane at the same time as inward 
vesiculation occurs (Babst et al., 1998). Vps4p and Doa4p, a deubiquitinating 
enzyme, have both been shown to bind directly to components of ESCRT-III 
(Bowers et al., 2004). Work on yeast Vps4p and mammalian Vps4 suggest that the 
protein is involved in release of components of the bilayered clathrin coat, from the 
endosomal membrane and that this release is coupled to the generation of internal 
vesicles (Sachse et al., 2003).
Another yeast vps protein, Vps31p/Brol, has been identified on endosomes and this 
interaction is dependent on Snf7, part of ESCRT-III (Odorizzi et al., 2003). 
Similarly, the mammalian homologue Ask interacting protein (AIP)-1/ALIX, has 
been shown to interact with ESCRT proteins, and forms an indirect link between
32
ESCRT-I and -ID complexes (Martin-Serrano et al., 2003). In yeast there is a 
direct interaction between ESCRT complexes mediated by the direct binding of 
Vps28 and Vps37p to Vps20 (Bowers et al., 2004).
To clarify the nature of ESCRT protein function in mammalian cells, many studies 
have been conducted using viruses, such as HIV-1, that hijack the endocytic 
pathway in order to propagate from cells. The process of retroviral budding is 
topologically equivalent to inward vesiculation within MVBs, and consequently it 
was proposed that viruses use some of the previously described ESCRT proteins. 
Analysis of HIV particles revealed the presence of the mammalian proteins TsglOl, 
Vps28, ALEX and Vps4B inside virions (von Schwedler et al., 2003). HIV-1 
release can be arrested by the deletion or mutation of at least 8 different mammalian 
Vps proteins. Viral budding requires interaction with TsglOl, a functional ESCRT- 
in  complex and ATPase activity of Vps4. For the release of HIV-1 and several 
other pathogenic human viruses from the cell, a specific tetrapeptide sequence, 
P(S/T)AP or “late” domain, is required. This domain recruits TsglOl, via its N- 
terminal ubiquitin E2 variant (UEV) domain, to facilitate viral budding (Garrus et 
al., 2001). P(S/T)AP sequences have also been identified in several mammalian 
proteins involved in endocytosis, including Hrs and ALIX (Pomillos et al., 2003; 
Bache et al., 2003a). It is therefore suggested that HIV binds TsglOl in order to 
recruit the downstream ESCRT proteins that usually catalyse the formation of 
internal vesicles. Although the UEV domain of TsglOl has been shown to interact 
with the P(S/T)AP sequence found in HIV Gag, TsglOl itself and Hrs, binding to 
the viral protein occurs with a much higher affinity (Pomillos et al., 2003). The 
surrounding sequence appears to influence the binding affinity as several proteins 
containing the P(S/T)AP sequence fail to bind TsglOl. The fact that viral and 
mammalian proteins interact differently with TsglOl could be due to the fact that 
viruses need to exit cells as efficiently as possible, whereas cells need to regulate 
protein sorting. The viral protein appears to be able to out compete its mammalian 
counterpart and recmit the protein it requires to initiate budding.
In most mammalian cell lines vimses bud from the plasma membrane, but in 
macrophages vimses tend to bud into endosomes/MVBs. Deletion of the Vps 
proteins results in a class E phenotype (as observed in yeast) and accumulation of
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viral particles on endosomal membranes (von Schwedler et al., 2003). 
Interestingly, these viral particles/virions, that bud into intracellular compartments, 
can still emerge from the cell via the exosome pathway. The limiting membrane of 
MVBs fuses with the plasma membrane and releases the internal vesicles as 
exosomes (Denzer et al., 2000; Pomillos et al., 2002; Raposo et al., 2002).
1.3.3 PI3P and PI3P binding proteins involved in sorting
Internal membranes of MVBs are enriched in PI3P (Gillooly et al., 2000) and there 
is evidence to suggest that PI3P signalling regulates receptor sorting within MVBs 
(Petiot et al., 2003). Inhibition of PI3 kinase (PI3K), using wortmannin, results in 
enlarged MVBs with few or no internal vesicles (Femandez-Boija et al., 1999; 
Chen and Wang, 2001; Futter et al., 2001). This effect was mimicked using 
antibodies to hVps34, which was identified as the PI3K required for inward 
vesiculation (Futter et al., 2001). EGFRs clustered on the limiting membrane of 
these MVBs. Although delivery to the lysosome was not affected, increased levels 
of tyrosine phosphorylated proteins were observed, indicating that sorting of EGFR 
onto internal vesicles serves to attenuate signal transduction, but is not necessary 
for lysosomal delivery (Futter et al., 2001).
Other groups have reported contrasting results when using wortmannin. Petiot et 
al. (2003) reported that treatment of BHK cells with wortmannin or a double 
FYVE-domain-containing construct, which specifically binds PI3P, inhibits the 
transport of EGFR to lysobisphosphatidic acid (LBPA)-containing late endosomes 
(Petiot et al., 2003). The work of Bright et al. (2001) reported that although 
wortmannin treatment resulted in enlarged late endosomal structures, this did not 
inhibit formation of internal vesicles within LBPA containing MVBs (Bright et al.,
2001). This latter study did not involve EGF stimulation and, taken together with 
the findings of Futter et al. (2001), there is growing evidence for the presence of 
more than one population of MVB/late endosomes within cells, one that is PI3K 
dependent and one that is not, but may contain LBPA. However, the discrepancies 
between the work of Petiot and Futter cannot be due to the investigation of different 
populations of MVB, as both groups used EGFR as a marker. Instead, the
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differences could be due to the timing of PI3K inhibition as Futter et al (2001) pre- 
loaded cells with EGF at 20°C before treating cells with wortmannin and it is 
possible that receptor sorting may occur during this incubation period. Further 
evidence for the heterogeneity of MVBs can be drawn from the work of Kobayashi 
et al. (2002), who found that there were two populations of membranes within 
MVBs, those containing phosphatidylcholine (PC) and those containing LBPA 
(Kobayashi et al., 2002).
The PI3P dependent sorting of EGFR is likely mediated by Hrs (Petiot et al., 2003). 
Hrs contains a FYVE domain that specifically binds PI3P, it is sensitive to 
wortmannin and is involved in EGFR downregulation (Bishop et al., 2002; Lloyd et 
al., 2002; Raiborg et al., 2002). Functional and mutational analysis of Hrs has led 
to the suggestion that the processes of receptor sorting and inward vesiculation are 
linked through the UIM domain of Hrs (Urbe et al., 2003). The primary role of this 
domain is to recruit ubiquitinated receptors into clathrin-coated microdomains on 
endosomes by an active retention mechanism, as a prelude to internalisation into 
lumenal vesicles (Urbe et al., 2003). Overexpression of Hrs inhibits EGFR 
downregulation by trapping EGFR within early endosomes (Raiborg et al., 2002; 
Petiot et al., 2003), indicating that there must be a release step to remove Hrs 
before inward vesiculation occurs. Internal vesicle formation also requires the Hrs 
UIM domain and it has been proposed that a component of ESCRT-I, e.g. TsglOl, 
may compete with Hrs for binding to EGFR (Urbe et al., 2003). The downstream 
recruitment of other ESCRT complexes would result in formation of internal 
vesicles. Hrs is phosphorylated by kinases, downstream of EGFR (Bache et a l,
2002), and phosphorylation induces Hrs to dissociate from the endosomal 
membrane, a process believed to be coupled to the formation of receptor containing 
internal vesicles (Urbe et a l, 2003). This dissociation may also result in the 
movement of newly freed receptors to the edge of the clathrin-coated microdomain, 
where inward vesiculation occurs (Sachse et a l, 2002).
Fabl, a yeast lipid kinase that produces PI(3,5)P2, also contains a FYVE domain 
(Odorizzi et a l, 1998; Gary et a l, 1998; Sbrissa et a l, 2002). A point mutation in 
the lipid kinase domain caused defects in transport of biosynthetic cargo through
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the MVB (Shaw et al., 2003). In cells expressing mutant Fabl, the morphology of 
the yeast vacuole is altered and sorting of endocytic cargo onto internal vesicles is 
defective. Similarly, a dominant negative mutant of the mammalian homologue, 
PIKFYVE, causes enlargement of endosomes in mammalian cells (Ikonomov et al., 
2001). Recent evidence supporting the involvement of PIKFYVE in protein sorting 
came from the discovery that a subunit of ESCRT-III (Vps24) interacts with 
PI(3,5)P2 (Whitley et a l , 2003).
Phox (PX) domains are present in a number of proteins that bind phosphoinositides 
(PI). The sorting nexins (SNX) are a family of cytoplasmic and membrane- 
associated proteins, believed to function in the intracellular trafficking of plasma 
membrane receptors, including EGFR. SNX proteins exert their function through 
PX domain-mediated interaction with PI, although interactions with other proteins 
are thought to contribute to the membrane specificity (Xu et a l , 2001; Cozier et a l , 
2002; Zhong et a l , 2002). SNX1 has been localised to endosomes in a PI3K 
dependent manner and is reported to play a critical role in the sorting of EGFR to 
lysosomes, as overexpression of SNX1 increased receptor degradation (Kurten et 
al., 1996; Haft et a l , 1998; Zhong et al., 2002). Additionally, SNX1 interacts 
specifically with Hrs on endosomes, where they form a complex devoid of EGFR, 
and it is believed that Hrs may negatively regulate EGFR transport through its 
interaction with SNX1 (Chin et a l, 2001). More recently SNX 16 has also been 
reported to be a negative regulator of EGFR-mediated signalling pathway by 
sorting EGFR for degradation (Choi et a l, 2004).
1.3.4 Annexins and sorting
Although annexins, with the exception of annexin 6, have not been reported to be 
involved in the internalisation of growth factor receptors, their common ability to 
bind phospholipid membranes in a Ca2+ dependent manner has made them popular 
candidates to participate in membrane trafficking. However, several annexins have
94 -been ruled out as their Ca requirement for membrane binding far exceeds that of 
cytosolic Ca . Annexins 1, 2 and 6 are able to associate with membranes at much 
lower and more physiological Ca2+ concentrations. Using light and electron
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microscopy annexins 1 and 2 have been localised to early endosomes (Emans et a l , 
1993; Harder and Gerke, 1993; Seemann et al., 1996b; Seemann et al., 1997; 
Diakonova et al., 1997; Rescher et a l , 2000). Annexin 1 has also been localised to 
MVBs (Futter et a l , 1993), while annexin 2 colocalised with R abll in recycling 
endosomes (Zobiack et a l , 2003). Annexin 6 has also been localised to endocytic 
membranes (Jackie et al., 1994; Seemann et a l , 1996b; Pol ef a/., 1997; Ortega et 
al, 1998; Massey-Harroche et a l, 1998). Interestingly, all three annexins were 
identified on phagosomes from macrophages (Desjardins et al, 1994; Diakonova et 
al, 1997) and annexin 2 has also been observed on pinosomes (Merrifield et al,
2001).
At the beginning of this project, no functional studies supporting a role for annexin 
1 in membrane trafficking had been reported, although a plethora of data exists 
regarding the anti-inflammatory role of annexin 1 in glucocorticoid function. 
Meanwhile, the use of a dominant negative mutant pointed to a role for annexin 2 in 
the organisation of early endosomes (Harder and Gerke, 1993). Annexin 2 was also 
shown to be involved in endosome fusion using an in vitro homotypic endosome 
fusion assay (Emans et a l, 1993). More recently, RNAi-induced depletion of 
annexin 2 has been used to further examine its role in membrane trafficking. In 
cells treated with annexin 2 RNAi, there was a dramatic relocalisation of recycling 
endosomes, with little effect on TfR recycling (Zobiack et a l, 2003). These 
findings are consistent with earlier work indicating that annexin 2 plays a role in 
positioning of endosomes (Harder and Gerke, 1993). Zobiack et al (2003) also 
reported that lysosomal delivery was unaffected in annexin 2 depleted cells. 
However, conflicting data reported that knockdown of annexin 2 inhibited MVB 
biogenesis and delivery of EGFR to the lysosome (Mayran et a l, 2003).
Functional studies investigating the role of annexin 6 in later stages of endocytosis 
have revealed its involvement in trafficking of LDL from the pre-lysosomal 
compartment to degradation in the lysosome (Pons et a l, 2001). Expression of 
mutant annexin 6 caused LDL to accumulate in enlarged pre-lysosomal structures, 
which was accompanied by a significant inhibition of LDL degradation.
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1.4 Receptor recycling
There are two recycling pathways, the rapid one from endosomes and the slower 
one through recycling endosomes. The majority of constitutively recycled 
receptors, e.g. TfR, recycle from endosomes but a certain amount are sorted into 
recycling endosomes from the perimeter membrane of MVBs. Sorting to the 
recycling pathway and lysosomal delivery are likely coupled, as lysosomal fusion 
occurs as soon as all the recycling receptors have been removed from the limiting 
membrane (Futter et al., 1996).
In unstimulated cells, unoccupied EGFR are constitutively endocytosed and 
recycled back to the plasma membrane, ready to bind EGF (Herbst et al., 1994). 
Ligand binding enhances endocytosis and also reduces the rate of receptor 
recycling, as active EGFR now become targeted for lysosomal degradation (Wiley 
et al., 1991). Some ligand-bound EGFR are recycled, although this depends on the 
cell type and also on the level of receptor expression. In human A431 cells, which 
express high levels of EGFR, more recycling occurs than in a cell line that 
expresses low levels of receptors. This is due to the saturable nature of the sorting 
mechanisms. Until recently it was believed that the recycling pathway was the 
default pathway for EGFR, a hypothesis derived from many studies showing 
enhanced recycling in the absence of lysosomal targeting signals (Levkowitz et al., 
1998; Kil et al., 1999; Stoorvogel et al., 2004). However, a protein has been 
identified, the role of which suggests that recycling is an active process. Calcium- 
modifying cyclophilin ligand (CAML) is a ubiquitous protein, resident in the 
endoplasmic reticulum (Bram and Crabtree, 1994; Holloway and Bram, 1998). 
CAML was shown to be necessary for the efficient recycling of EGFR (Tran et al.,
2003). Cells lacking CAML fail to recycle EGFR but show normal levels of 
degradation, indicating that EGFR becomes trapped within the cell rather than 
recycled (Tran et al., 2003). These findings suggest that CAML serves an opposite 
function to ESCRT-I, by preferentially binding non-ubiquitinated EGFR and aiding 
their transport back to the cell surface.
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Recycling endosomes are R abll positive, Rab5 negative and are often 
characterized by the presence of TfR (Green et al., 1997). A dominant negative 
Rabl 1 mutant has been shown to inhibit TfR recycling (Ullrich et al., 1996; Ren et 
al., 1998). Annexin 2 has been localised to R abll positive recycling endosomes 
(Pol et al., 1997; Trischler et al., 1999; Zeuschner et al., 2001; Zobiack et al., 2003) 
and is believed to play a role in controlling the localisation of recycling endosomes. 
Annexin 2 was observed associated with recycling endosomes and its depletion 
results in an increased number of endosomal buds that label heavily for clathrin 
(Zeuschner et al., 2001; Zobiack et al., 2003). However, clathrin does not seem to 
be essential for recycling and is believed to play a role in formation or organisation 
of recycling endosomes, rather than in concentrating receptors to be recycled. 
Similarly, little evidence exists for a role of adaptor proteins in recycling although 
in polarised cells AP-l/plB adaptor complex is involved in the efficient recycling 
of TfR and LDL-R to the basolateral membrane (Gan et al., 2002).
1.5 Final stages of endocytosis
After receptors are sorted onto internal vesicles of MVBs and recycling receptors 
have been sorted back to the plasma membrane, the final stage is fusion of mature 
MVBs with lysosomal membranes. The contents of the MVB are exposed to 
internal hydrolases and become degraded (Futter et al., 1996). Lysosomes are 
membrane-bound, hydrolase rich, acidic organelles. They can be distinguished 
from endosomes by their lack of mannose-6-phosphate (M6P) receptors and 
recycling surface receptors. Lysosomes are the final destination for many 
macromolecules taken up by endocytosis from the extracellular milieu and from the 
cell surface. Ligand induced activation of many cell surface receptors triggers 
downregulation of the receptors by internalisation and delivery to the lysosome. 
EGFRs with bound EGF are degraded in the lysosome (Wiley et al., 1991). In 
contrast, receptors lacking the cytoplasmic tail fail to reach the lysosome and are 
recycled rapidly back to the cell surface (Herbst et al., 1994).
For many years it was believed that lysosomes were simply “garbage-disposal 
units” (Luzio et al., 2000). More recently it has been shown that lysosomes can
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fuse with the plasma membrane and secrete their contents (for a review see 
Stinchcombe and Griffiths, 1999). Lysosomes can also be accessed via the 
biosynthetic pathway e.g. newly synthesized acidic hydrolases modified with 
mannose-6-phosphate groups bind to their receptors (MPRs) in the trans-Golgi 
network (TGN), after which they are transported to endosomes via an intracellular 
route. The hydrolase-MPR complex dissociates in the acidic pH of the endosomes 
and hydrolases are thus transported to the lysosome, while the receptors return to 
the TGN for further activity. Transport between late endosomes/MVBs and 
lysosomes has been studied in a cell free system (Mullock et a l , 1994; Mullock et 
al., 1998). Three hypotheses have been proposed for the mixing of contents 
between MVB/late endosomes and lysosomes. The first proposes that there is 
vesicular transport between organelles. The second “kiss and run” hypothesis 
proposes a continuous repeated transient fusion and fission (Storrie and Desjardins, 
1996). The third and most recent proposal is an extension of the kiss and run 
hypothesis as MVBs and lysosomes fuse. Data exists to support the latter 
hypothesis, which suggests that lysosomes and MVBs fuse directly but that 
lysosomes can be regenerated from this hybrid organelle (Mullock et al., 1994; van 
Deurs et a l , 1995; Futter et a l , 1996; Bright et a l , 1997; Mullock et a l , 1998). 
Further evidence supporting the fusion of MVBs and lysosomes comes from both in 
vitro studies and in vivo studies using electron microscopy of cultured cells 
(Casciola-Rosen and Hubbard, 1991; Futter et al., 1996; Tjelle et a l , 1996). 
Therefore, there is extensive evidence to back up the third proposal for 
MVB/lysosome fusion.
The fusion of late endosomes and lysosomes in vitro was found to be ATP, cytosol 
and temperature dependent (Mullock et a l , 1998). These studies also identified a 
requirement for NSF (V-ethylmaleimide sensitive factor) and SNAPs (soluble NSF 
attachment proteins). This fusion was inhibited by Rab-GDI, which implied the 
need for a Rab-GTPase. Both Rab7 and Rab9 have been localized to late 
endosomes (Chavrier et a l , 1990; Lombardi et a l , 1993). As Rab9 also localizes 
to the TGN, it is believed that this Rab GTPase is involved in transport between the 
TGN and lysosomes. More recently, Rab7 has been identified as necessary for the 
proper aggregation and fusion of late endocytic structures in the perinuclear region
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and also for the proper biogenesis and maintenance of lysosomes (Bucci et al., 
2000).
1.6 Endocytosis and signalling
Activated EGFR undergo a conformational change, resulting in activation of the 
intracellular tyrosine kinase domain. In addition to autophosphorylation, this 
domain can phosphorylate a wide range of downstream molecules, a process that 
acts as the initiation step for several signalling pathways. EGF stimulation of cells 
activates a number of pathways, resulting in one of a number of processes, 
including cell proliferation, motility, differentiation and survival. One of the most 
studied pathways is the ERK1/2 (extracellular regulated kinase) MAPK pathway; a 
series of protein kinases to activate ERK1/2, which is able to translocate to the 
nucleus and stimulate mitogenesis.
1.6.1 How does endocytosis affect signalling?
Downregulation of EGFR is important for termination of signals leading to cellular 
growth and proliferation. However, as the rate of receptor internalisation far 
exceeds the rate of receptor degradation, it is clear that receptor internalisation is 
necessary for more than simply targeting receptors to the lysosome. It was 
originally thought that internalisation, and thus removal from the plasma 
membrane, of activated EGFR inhibited the ability of the receptor to signal. This 
theory was quashed by the finding that endocytosed EGFR are 
hyperphosphorylated compared to those at the plasma membrane (Lai et al., 1989; 
Wada et al., 1992; Di Guglielmo et al., 1994; Burke et al., 2001).
Although the majority of mitogenic signals are initiated at the plasma membrane 
(Di Fiore and Gill, 1999), there is growing evidence to suggest that some signalling 
cascades require endocytosis for activation. Inhibition of EGFR internalisation, 
using mutant dynamin, significantly inhibited signalling through the MAPK 
pathway, showing that endocytosis of EGFR is required for full activation of this
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pathway (Vieira et al., 1996). However, this work also showed that phospholipase 
C y (PCLy) signalling was increased by inhibiting EGFR internalisation, indicating 
that endocytosis can also regulate some signalling pathways by separating the 
receptor from its downstream signalling partners at the plasma membrane (Vieira et 
al., 1996). Other signalling pathways do not require receptor internalisation for 
their activation as shown by phosphorylation of IRS 1 (insulin receptor substrate 1) 
in the absence of insulin receptor (IR) internalisation. However, although blocking 
ER internalisation had no effect on Akt kinase phosphorylation or activation, it 
partially inhibited phosphorylation of other downstream substrates, She and 
ERK1/2 (Ceresa et al., 1998)
Several proteins involved in the endocytosis of EGFR also play roles in signalling, 
especially through the MAPK pathway. Grb2 is recruited to the plasma membrane 
in response to receptor activation, either directly through an interaction with the 
receptor or indirectly through She. Grb2 is needed for the transient anchoring of 
EGFR at the rim of CCPs (Stang et al., 2004). Additionally, Grb2 is constitutively 
associated with SOS (son of sevenless), a Ras guanine-nucleotide exchange factor 
(GEF), at the plasma membrane (Egan et al., 1993) and the proximity of this 
complex with Ras is thought to mediate Ras activation. Ras-GTP can now bind to 
its effector Raf-1, thus recruiting it to the plasma membrane. Raf-1 is a MAPK 
kinase kinase, which phosphorylates and activates the MAPK kinase, MEK-1. 
MEK-1 phosphorylates and activates MAPK/ERK1/2. Activated ERK1/2 can 
translocate to the nucleus and stimulate mitogenesis, or it can remain in the cytosol 
and phosphorylate other cytosolic proteins.
The formation of signalling complexes has not only been observed at the plasma 
membrane, but also on endosomal structures. Grb2 and SOS are associated with 
activated EGFR at the plasma membrane and also been localised to endosomal 
membranes (Di Guglielmo et al., 1994; Sorkin et al., 2000; Burke et al., 2001; 
Jiang and Sorkin, 2002). Therefore, Ras activation can occur both at the plasma 
membrane and on endosomes (Jiang and Sorkin, 2002). Other members of the 
ERK1/2 MAPK pathway have also been localised to endosomes, including Raf-1, 
which translocates to endosomes after receptor activation (Di Guglielmo et a l ,
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1994; Pol et a l, 1998; Rizzo et a l, 2000), MAPK and MEK, thus creating a 
signalling endosome (Howe et a l, 2001; Luttrell et a l, 2001). MAPK and MEK 
are recruited to endosomes by kinase-substrate interactions, but also by scaffolding 
proteins. MP1 (MEK1 partner) specifically binds MEK1 and results in ERK1 
activation (Schaeffer et a l, 1998). Recently, an additional scaffold protein, p i4, 
has been shown to interact with MP1 on late endosomes (Wunderlich et a l, 2001) 
and act as an endosomal adaptor protein for MP1. The endosomal localisation of 
pl4/M Pl scaffold complex is required for efficient ERK signalling (Teis et al,
2002).
Activated EGFR are able to tyrosine phosphorylate a wide range of downstream 
molecules at the plasma membrane, many of which are involved in the 
internalisation of the receptor. However, some downstream targets are not 
accessible to EGFR at the plasma membrane and are only phosphorylated once the 
receptor has been internalised. Hrs is involved in EGFR sorting within the 
endosomal clathrin coat. Its phosphorylation, by kinases downstream of the active 
EGFR, occurs at the endosomes, indicating that receptor endocytosis is necessary 
for Hrs phosphorylation to occur (Urbe et al, 2000; Bache et al., 2002). Eps8 is 
another substrate of the EGFR tyrosine kinase and is thought to mediate the transfer 
of signals between Ras and Rac (Scita et al., 1999). Eps8 is only associated with 
internalised EGFR within endosomes, an association that is enhanced by EGF 
stimulation (Burke et a l, 2001). Similarly annexin 1, another substrate of the 
EGFR tyrosine kinase, is only phosphorylated by EGFR, or associated kinases, 
within MVBs (Futter et a l, 1993). Although the exact nature of the role of annexin 
1 in EGFR endocytosis remains unclear, the fact that it is only phosphorylated by 
internalised EGFR provides another example of how endocytosis is necessary for 
signalling.
1.6.2 How does signalling affect endocytosis?
EGFR endocytosis has been shown to be necessary for efficient signal transduction. 
Therefore, the processes of endocytosis and signalling are intimately linked and 
appear to influence each other. The involvement of many proteins in both
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signalling and trafficking raises the question of whether signalling receptors or 
downstream signalling pathways can modulate the endocytic machinery.
Although CCPs form constitutively on the surface of cells, the density of CCPs is 
increased upon EGF stimulation (Connolly et al., 1984). Activation of EGFR 
results in tyrosine phosphorylation of the clathrin heavy chain by a downstream 
kinase, c-src, resulting in clathrin translocation to the plasma membrane and 
formation of CCPs (Beattie et a l, 2000). Additionally, EGFR can activate 
PI(4,5)K1 p, leading to the localised generation of PIP2 and recruitment of PIP2- 
binding proteins involved in clathrin coat formation (Barbieri et a l, 2001). These 
data show that signalling from the EGFR is required for the enhanced formation of 
many CCPs, which in turn are necessary for efficient internalisation of EGFR, and 
thus EGFR controls its own endocytosis. Epsl5 interacts with clathrin-associated 
adaptor proteins and is required for budding of CCPs (Confalonieri et a l, 2000). 
Epsl5 is recruited to the plasma membrane upon EGF stimulation and is 
phosphorylated by the EGFR. Epsl5 phosphorylation is necessary for its activity in 
EGFR endocytosis, but not for constitutive endocytosis (Confalonieri et a l, 2000).
Rab5 participates in both regulation of endocytosis and in signalling. Rab5a is 
activated by EGF stimulation and its activation is essential for EGFR endocytosis 
(Barbieri et a l, 2000). Activation of Rab5a is mediated through RIN1 (Ras 
inhibitor), a Rab5 GEF (Tall et a l, 2001) or by physical separation from RN-tre 
(Related to the N-terminus of TRE), its GTPase activating protein (GAP) (Martinu 
et al, 2002). Grb2 is involved in the activation of Ras but has recently been shown 
to signal to Rab5a through its interaction with RN-tre. Therefore, the signalling 
activity of EGFR activates Rab5a and stimulates internalisation. Activated Rab5 
recruits EEA1 to endosomes, where it acts as a tether and is necessary for 
endosomal fusion (Christoforidis et a l, 1999; Barbieri et a l, 2000). A second 
potential Rab5 effector is PI3K (human homologue of Vps34). Rab5 recruits 
hVps34 to endosomes, where Vps34 is important in the production of PI3P, which 
is necessary for the membrane binding of FYVE-domain containing proteins, such 
as EEA1 and Hrs (Murray et a l, 2002). Additionally, hVps34 has been shown to
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mediate internal vesicle formation within MVBs, which is important in the 
downregulation of EGFR signalling (Futter et al., 2001).
1.7 Properties of annexins -  clue to function?
The annexin family has been well studied over the years, in terms of structure and 
general properties. Some of these properties have given rise to proposed roles for 
annexins in membrane trafficking, in particular annexins 1 and 2, although little 
conclusive evidence has yet been collected.
1.7.1 Regulation o f annexin binding to endosomal membranes
The localisation of several annexins to endosomal structures, coupled with their 
generic membrane binding properties, has led to proposed roles for annexins in 
membrane trafficking. Both annexins 1 and 2 have been localised to endosomal 
membranes and their possible roles in receptor sorting have already been discussed. 
Another common property of the annexin family is Ca binding, although the 
requirement for Ca for membrane binding differs between family members. 
Annexins contain two types of calcium binding motifs, type II and type ID. Type II 
sites appear to have a higher affinity for Ca and are therefore regarded as the 
likely candidates for regulation of annexin function within cells (Thiel et al., 1992;
74-Jost et al., 1994). Inactivation of one type II Ca binding site dramatically 
changed the intracellular distribution of both annexin 1 and 2, from punctate 
membrane or cytoskeletal associated, respectively, to diffuse, cytoplasmic staining 
with no sign of membrane association (Jost et al., 1994; Rescher et al., 2000).
Typically annexins bind membranes in a Ca2+ dependent manner and, in the
7 -4-presence of Ca , annexin 1 has been localised to endosomal membranes in living 
cells (Rescher et a l , 2000). A rise in intracellular Ca2+ is known to alter the 
localisation of several annexins, presumably by allowing annexins to bind 
membranes in a Ca2+ dependent manner (Babiychuk et a l , 1999; Babiychuk and
 ^I
Draeger, 2000). Interestingly, EGF stimulation induces a rise in intracellular Ca
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(Moolenaar et al., 1988; Pandiella et al., 1988; Qiu and Green, 1991; Obermeier et 
al., 1993; Tinhofer et al., 1996). However, the effect of EGF stimulation on
 ^I
annexin localisation has not yet been studied. Although Ca is required for the 
association of annexin 1 with early endosomes, Ca2+ independent membrane 
binding has also been shown in vitro at a more acidic pH (Rosengarth et al., 1998), 
and in vivo by a mutant form of annexin 1 lacking Ca2+-binding sites that was still 
able to bind endosomes in BHK cells (Jost et a l , 1997). Additionally, 
phosphorylation was shown to convert annexin 1 from a Ca independent 
membrane binding protein to a Ca2+ dependent species (Haigler and Schlaepfer, 
1990). Ca2+ independent binding of annexin 1 was also suggested by Futter et al. 
(1993), where MVBs fractionated through a gradient containing EDTA still 
contained annexin 1 (Futter et al., 1993). In vitro phosphorylation reactions of 
isolated MVBs showed that phosphorylated annexin 1 was released from the
I
membrane in the presence of EDTA, but not in the presence of Ca , supporting the 
notion that phosphorylated annexin 1 requires Ca2+ for membrane association 
(Futter et al., 1993). However, it was later shown that in living cells non- 
phosphorylated annexin 1 requires intact Ca2+ binding sites in order to bind to early 
endosomal membranes (Rescher et al., 2000). The discrepancy in these findings
- j i
could be explained by a requirement for Ca for association with endosomes but, 
once associated, annexin 1 is not readily released by treatment with EDTA. 
Furthermore, phosphorylated annexin 1 is more susceptible to N-terminal 
proteolysis (Chuah and Pallen, 1989; Ando et al., 1989). The N-terminal domain 
contains the early endosomal localisation signal and its loss results in a 
relocalisation of annexin 1 from early endosomes to late endosomes (Seemann et 
al., 1996b; Rescher et al., 2000).
Unlike wild type annexin 1, a large fraction of endosomally associated annexin 2 
remains bound to the organelle membrane in the presence of Ca2+ chelating agents 
(Emans et al., 1993; Harder et al., 1997). Annexin 2 can be released from 
membranes, along with a group of actin-binding proteins, by sequestration of 
cholesterol (Harder et al., 1997). It was proposed that the atypical (Ca2+ 
independent) binding of annexin 2 to membranes most likely requires a specific 
membrane composition and configuration. Annexin 2 associates with membrane 
rafts in both a Ca dependent and independent manner. In smooth muscle cells
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annexin 2 binds to lipid rafts following a rise in intracellular Ca2+ (i.e. during 
muscle contraction) (Harder and Gerke, 1994; Babiychuk and Draeger, 2000). 
Interestingly, this rise in Ca2+ induces the relocalisation of annexin 6 from the 
cytoplasm to the plasmalemma in these cells (Babiychuk et a l, 1999).
Annexin 2 interacts preferentially with cholesterol rich membranes and cholesterol 
appears to be necessary for annexin 2 Ca2+ independent membrane binding. The 
plasma membrane and early endosomes contain the largest amounts of cholesterol 
and annexin 2 is found associated with both of these types of membrane (Harder et 
al, 1997). Additionally, the intracellular distribution of cholesterol was found to 
modulate the location of annexin 2, as observed in cells from patients with the 
cholesterol storage disorder, Niemann-Pick C, where annexin 2 was found in 
enlarged MVBs (Mayran et a l , 2003). Annexin 2 has therefore been proposed to 
form cholesterol-containing platforms on early endosomal membranes, which are 
involved in receptor trafficking.
1.7.2 Annexin binding to actin and other cytoskeletal proteins
Microtubules have long been shown to be required for endocytosis, both in the 
positioning of endocytic organelles (Matteoni and Kreis, 1987; McGraw et al, 
1993; Nielsen et a l, 1999) and for transport from early to late endosomes (Aniento 
et a l, 1993). More recently, roles for actin filaments have been identified in the 
initial uptake of ligands and later for their delivery to the lysosome (van Deurs et 
al, 1995; Durrbach et a l, 1996). Inhibition of actin filament assembly impairs 
lysosomal delivery and disrupts the organisation of endosomes (van Deurs et al, 
1995; Barois et a l , 1998). A member of the Diaphanous group of proteins, 
hDia2C, has been identified as the downstream effector of RhoD and together these 
proteins function to position endosomes along actin filaments, which requires the 
recruitment and activation of c-src (Gasman et a l, 2003). Further evidence that 
actin is required for endocytosis comes from the localisation of MM la , a member 
of the myosin family with actin-based motor properties, to both endosomes and 
lysosomes. Expression of a non-functional mutant MM l a  inhibits transport of 
fluid phase cargo to the lysosome. Through its interaction with actin, MM l a  is
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thought to be required for the close apposition of endosomes and lysosomes 
necessary for their fusion (Raposo et al., 1999). In addition to its role in positioning 
endosomes, actin is involved in the movement of intracellular vesicles. Pinosomes 
were identified as having dynamic actin comet tails (Willingham et al., 1981; 
Merrifield et a l, 1999). Sustained actin assembly on the surface of the newly 
formed pinosome is thought to propel it through the cytoplasm. Similarly, actin 
comet tails have been identified on MVBs and lysosomes, and shown to contain N- 
WASP, which is intimately associated with the endosomal membrane (Taunton et 
al., 2000). Movement of these structures is believed to be mediated through actin- 
assembly nucleated by Arp2/3, the downstream effector of N-WASP (Taunton et 
al., 2000). Taken together, these studies highlight the importance of actin both in 
the proper positioning of endosomes and also in their movement through cells.
Although actin-binding, unlike membrane binding, is not a common property of the 
annexin family, several annexins have been shown to interact directly with 
polymerised actin in vitro and this is consistent with proposed annexin functions in 
mediating, stabilising and/or regulating membrane-actin interactions. Both 
annexins 1 and 2 have been shown to bind F-actin in a Ca -regulated manner 
(Gerke and Weber, 1984; Glenney, 1986a; Glenney, 1986b).
Annexin 2 is capable of binding to, and bundling, actin in a Ca2+-dependent 
manner, both as a monomer or as part of a heterotetramer with S100A10 (Gerke 
and Weber, 1985; Glenney, Jr. et al., 1987). Actin binding is mediated through a 
specific 9 amino acid sequence at the end of the C-terminal region of annexin 2 
(Filipenko and Waisman, 2001). Annexin 2 is believed to play a role in the 
organisation of membrane-associated actin at sites of cholesterol-rich 
microdomains, as cholesterol sequestering agents specifically release annexin 2 
along with several other cytoskeleton proteins (Harder et al., 1997). Annexin 2- 
S100A10 forms a complex with actin and AHNAK at the plasma membrane via 
S100A10 (Benaud et al., 2004). AHNAK has been reported to organise the cell 
cytoarchitecture and it has been revealed that annexin 2 is necessary for this to 
occur, as depletion of annexin 2 results in release of AHNAK into the cytoplasm 
(Benaud et al., 2004).
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Like annexin 2, annexin 1 has also been associated with the cytoskeleton through 
its F-actin binding property (Glenney, Jr. et al., 1987; Schlaepfer and Haigler, 
1987). Additionally, annexin 1 binds the G-actin-binding protein, profilin, which 
regulates actin polymerisation, and this provides another link between annexin 1 
and cytoskeleton organisation (Alvarez-Martinez et al., 1996). These later studies 
failed to show any binding of annexin 1 and actin, and proposed that another 
protein might form a bridge between the two. Another interesting finding was that 
annexin 1 binding to profilin is Ca2+ independent, although the binding affinity was 
greater when Ca2+ was present. Work from the same group later showed that 
annexin 1 reduces the inhibitory effect of profilin on actin polymerisation (Alvarez- 
Martinez et al., 1997). Conversely, profilin inhibits annexin 1 binding to 
membranes and this can be disrupted by the addition of PIP2 .
Therefore, the ability of annexins 1 and 2 to bind actin indicates that they may play 
roles in the positioning, or movement, of endocytic structures, as well as providing 
a link between endosomal membrane and the actin cytoskeleton.
1.7.3 Interactions with protein ligands
The localisation of annexin 2 to endosomes is mediated through its specific N- 
terminus and this property can be conferred onto other annexins by switching their 
N-terminal regions (Harder et a l, 1997; Jost et al., 1997; Konig and Gerke, 2000). 
The N-terminal domain also contains binding sites for a member of the S I00 
subfamily of EF hand proteins, several of which form complexes with annexins. 
The formation of a heterotetrameric complex between annexin 2 and S100A10 
(pi 1) is the best characterised so far. The interaction appears to be dependent on 
N-terminal acetylation of annexin 2 (Konig et al., 1998). Co-fractionation of 
annexin 2 with early endosomal membranes does not require Ca or S100A10 
(Konig and Gerke, 2000), although binding of S100A10 is required for stabilisation
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of annexin 2 binding in the absence of Ca (Konig and Gerke, 2000). It is believed 
that annexin 2, as part of a complex with S100A10, provides a link between the 
cytoplasmic face of the plasma membrane and the cortical actin cytoskeleton, and
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that this function is regulated by membrane cholesterol content and by Ca 
concentration (Gerke and Moss, 2002).
Annexin 1 also contains N-terminal binding sites for a SI00 protein, S100A11 
(S100C). The formation of a heterotetrameric complex is based on similar 
principles to annexin 2/S100A10, except that annexin 1/S100A11 binding requires 
Ca2+ (Mailliard et al., 1996; Seemann et a l , 1996a; Rety et al., 2000). Annexin 1 
can target S100A11 to early endosomes (Seemann et al., 1997). However, the in 
vivo interaction of annexin 1 and S100A10 remains to be identified.
Both annexins, in complex with their S I00 binding partners, are thought to be able 
to link membranes, although the exact function of this property has not been 
revealed. The annexin 2/S100A10 complex exists in resting cells and is not 
dependent upon Ca2+, whereas it is predicted that the annexin 1/S100A11 complex 
is dependent on transient intracellular calcium rises and plays an important role in 
Ca2+ regulated membrane transport (Gerke and Moss, 2002).
1.7.4 Modulation o f annexin function by phosphorylation
The annexins are well known targets for post-translational modifications, including 
phosphorylation. Annexin 2 was originally identified as a substrate of v-src protein 
kinase (Erikson et al., 1981). Annexin 2 can also be phosphorylated by the IR 
tyrosine kinase, in a manner that resembles annexin 1 phosphorylation by EGFR 
tyrosine kinase. Annexin 2 is only phosphorylated by IR as it undergoes 
internalisation (Biener et al., 1996), while EGF-stimulated annexin 1-
phosphorylation also occurs at a post-intemalisation stage (Futter et al., 1993). 
Tyrosine phosphorylation (on Tyr-23) of annexin 2 was increased in the presence of
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Ca (Glenney, Jr., 1985), but tyrosine phosphorylation of annexin 2 decreased its 
membrane binding (Powell and Glenney, Jr., 1987; Hubaishy et al., 1995). 
Similarly, annexin 1 phosphorylation alters its membrane binding properties by 
increasing the requirement for Ca2+. Phosphorylation also increases the 
susceptibility of annexin 1 to N-terminal proteolysis (Chuah and Pallen, 1989;
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Ando et al., 1989) and a N-terminally truncated annexin 1-GFP chimera has been 
shown to relocate from early to late endosomes (Rescher et al., 2000).
Protein kinase C (PKC) is a serine/threonine kinase and is known to phosphorylate 
a number of annexins, although annexin 5 is able to inhibit PKC (Schlaepfer et al., 
1992). PKC phosphorylation of annexin 2, as a result of nicotine stimulation, is 
required for Ca2+ regulated exocytosis in adrenal chromaffin cells (Sarafian et al., 
1991; Delouche et al., 1997). However, PKC-induced phosphorylation of annexin 
1 inhibits its ability to aggregate chromaffin granules (Wang and Creutz, 1992) or 
phospholipid vesicles in vitro (Johnstone et al., 1993).
1.7.5 Summary o f annexin property-related functions
The ability of annexins 1 and 2 to bind both membranes and cytoskeletal proteins 
points to a role for these proteins in the organisation of membranes. Although 
structurally similar, annexins 1 and 2 have different binding partners and Ca2+ 
dependencies, reflecting their different intracellular functions. Annexin 1 is 
thought to be involved in a specific aspect of EGFR trafficking, at the level of the 
MVB, and the identification of the annexin 1-S100A11 complexes within these 
structures is awaited. Annexin 2 appears to play a role in the organisation of 
membrane-associated actin at sites of cholesterol-rich membrane domains, but may 
also be involved in the proper positioning of endocytic organelles, through its 
interaction with the actin cytoskeleton.
1.8 Recent technological advances utilised to investigate annexin function
Although the amount of published data on growth factor receptor endocytosis is 
increasing exponentially, there appears to be little conclusive data on the exact 
nature of the roles of annexins in receptor sorting.
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1.8.1 Annexin knockout models
To study the function of annexins further, several have been targeted for the 
creation of knockout mouse models (Srivastava et al., 1999; Herr et al., 2001; 
Hannon et al., 2002; Hawkins et al., 2002; Brachvogel et al., 2003; Ling et al.,
2004). Generally the deletion of a single annexin has little effect on the viability of 
the mice and provides little in the way of clear-cut phenotypes. The exception was 
the annexin 7 -/- mouse described by Srivastava et al. (1999), which was reported 
to be lethal (Srivastava et al., 1999). This group also produced a heterozygous 
mouse, which exhibited an insulin secretion defect and tumour phenotypes. In 
contrast, a second group reported an annexin 7 null strain that was viable, healthy 
and without visible/obvious defects (Herr et al., 2001). However, more recently, 
this group has reported that the loss of annexin 7 affects membrane fusion within 
red blood cells and platelets (Herr et al., 2003).
The annexin 1 knockout mouse was reported to be viable and healthy. However, so 
far the analysis of the annexin 1 knockout mouse has been restricted to studies of 
the inflammatory response (Roviezzo et al., 2002; Hannon et al., 2002). These 
studies reported an increased response to inflammatory stimuli and a decreased 
response to the anti-inflammatory glucocorticoids. Interestingly, several other 
annexins are upregulated in cells taken from these mice (annexins 2, 5 and 6), in 
addition to other genes involved directly in inflammation (COX-2 and CPLA2) 
(Croxtall et al., 2003). The upregulation of other annexins caused concern that the 
actual phenotype is being masked by the compensatory action of other annexin 
family member.
An annexin 2 null mouse has recently been created and used to investigate the role 
of annexin 2 in cell surface plasmin generation. These mice are viable but show 
markedly decreased neovascularization of fibroblast growth factor-stimulated 
cornea and oxygen primed neonatal retina (Ling et al., 2004). An annexin 2 -/- 
DT40 (B lymphocyte) cell line already exists and was created together with an 
annexin 5 -/- cell line to investigate the effects of loss of these annexins in response 
to apoptotic stimuli (Hawkins et al., 2002). However, while the loss of annexin 2
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had no effect on apoptosis, the annexin 5 -/- cells were more resistant to induced 
apoptosis.
1.8.2 RNAi-induced annexin depletion
To overcome the potential problems of compensatory upregulation of alternative 
proteins in knockout mice, a relatively new technology has been utilised. RNA 
interference (RNAi) technology was originally used in insect cell lines to “knock­
down” the expression of specific proteins. RNAi works by transfecting cells with 
short double stranded RNA sequences specifically designed against the desired 
protein. This activates the Dicer complex within cells to destroy the synthetic RNA 
sequence and also any naturally occurring RNA with the same sequence, thus 
destroying the usual cell transcripts. More recently the use of RNAi has been 
extended to mammalian cells (Elbashir et al., 2001) and since this demonstration 
the use of RNAi has become commonplace in many publications. However, its use 
in studies of annexin function has not been widely published. The use of 
conventional RNAi to deplete annexin 2 has been reported by several groups 
(Mayran et al., 2003; Zobiack et al., 2003). Although annexin 1 RNAi has not yet 
been reported to deplete cellular annexin 1, use of annexin 1 antisense cDNA to 
reduce endogenous annexin 1 expression has been used to investigate annexin 1 
inhibition of CPLA2 (Solito et al., 1998).
1.9 Aims of this work
Although the discovery of many members of the annexin family occurred years 
ago, further studies are still needed to identify and confirm specific roles for each 
family member. Annexins 1 and 2 have been implicated in various aspects of 
membrane trafficking, as well as playing roles in other processes that require their 
specific interactions with membranes and cytoskeletal proteins.
Annexin 1 is a well-known substrate of the EGFR tyrosine kinase (Haigler et al., 
1987) and has been shown to become phosphorylated only in MVBs and not at the
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plasma membrane (Futter et al., 1993). Tyrosine phosphorylation of annexin 1 
increases the susceptibility of the protein to N-terminal proteolysis (Haigler et al., 
1987; Chuah and Pallen, 1989; Ando et al., 1989) and loss of the N-terminal 
domain alters the membrane binding capabilities of annexin 1, possibly through 
disruption of the putative heterotetrameric complex with S100A11. Taken together, 
these data led to a proposed role for annexin 1 in formation of internal vesicles 
within MVBs and/or receptor sorting. However, the exact nature of this role 
remains unknown. Recently, annexin 2 has been implicated in MVB biogenesis 
(Mayran et al., 2003). As annexins 1 and 2 share considerable homology, it is 
possible that they are involved in similar processes and may even be able to 
functionally compensate for each other. As a substrate of the EGFR tyrosine 
kinase, annexin 1 is more likely to be involved in a specific aspect of EGFR 
trafficking, while annexin 2, which is a poor substrate for EGFR tyrosine kinase, is 
more likely to play a functionally distinct role.
Therefore, the major aims of these studies were to investigate the effects of loss of 
annexins 1 and 2 on the formation of MVBs, including inward vesiculation, and the 
intracellular sorting of growth factor receptors, concentrating on EGFR. In 
addition, the effects of loss of these annexins on fluid phase endocytosis and 
endocytosis of the non-kinase receptor TfR were explored. During these studies 
RNAi-induced protein depletion, an annexin 1 -/- cell line (derived from the 
annexin 1 knockout mouse), and an annexin 2 knockout DT40 cell line were all 
used to investigate the intracellular morphology and kinetics of receptor trafficking. 
The effects of EGF stimulation on MVB formation and localisation of annexin 1 
were explored using a combination of fluorescence, transmission electron 
microscopy and cryo-immuno electron microscopy. Finally, the effect of loss of 
annexin 1 on cell shape and EGF-stimulated cell motility was investigated by 
comparing the annexin 1 -/- cell line with a cell line derived from a wild type 
mouse.
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Chapter 2 - Materials and Methods
2.1 Materials
2.1.1 Cell Culture
All reagents used in tissue culture were obtained from GibCo and all cell culture 
flasks and plates from Nunclon, except 3cm diameter Mattek™ dishes from BDH.
2.1.2 Molecular Biology
T4 DNA ligase, calf intestinal alkaline phosphatase (CIP), pfu DNA polymerase, 
dNTPs, DNA markers and gel loading buffer were all obtained from Promega UK 
Ltd. Restriction enzymes were from New England Biolabs. XL-1 blue 
supercompetent Escherichia coli were from Stratagene Ltd. TAE and TE buffer 
(5Ox stock) were from National Diagnostics. All primers, Lipofectamine™ and 
Oligofectamine™ were from Invitrogen. pGFP-Nl was from Clontech. Human 
EGFR was a gift from Alexander Sorkin (University of Colorado, Denver, USA). 
All RNAi oligonucleotides were ordered from Qiagen.
2.1.3 Electron Microscopy
Gold (lOnm and 5nm) was obtained from British Biocell International. The anti­
human EGFR antibody (108) was a gift from Joseph Schlessinger (Yale Medical 
School, USA). Protein A gold (lOnm and 15nm) was obtained from the Utrecht 
Medical School (The Netherlands) every 3 months and used at 1:65-80 depending 
on the batch. Thermanox coverslips were from Nalgene.
2.1.4 Miscellaneous
All other chemicals were from Sigma, unless otherwise stated. Biotinylated human 
EGF was from Molecular Probes. 125I-labelled human EGF was from Amersham. 
1251-labelled human Tf was from Perkin Elmer. The Nucleofector™ machine, 
reagents and equipment were obtained from Amaxa Biosystems.
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2.1.4 Antibodies
Mouse antibodies are monoclonal and all other species polyclonal, unless otherwise 
stated. The name of the antibody, the species it was raised in, and the domain it 
was raised against, are given in brackets.
Primary Antibody Use Obtained from
ImmunoEM IF W.blot
Anx 1 (74/3, mouse monoclonal) 1:50 1 :1 0 0 Gift from C. Isacke
Anx 1 (sheep) 1:4000 Gift from J. Croxtall
Anx 2 (HH7, mouse) 1:50 1:500 1:4000 Gift from V. Gerke
EGFR (goat, cytoplasmic) 1 : 1 0 0 0 Santa Cruz
EGFR (sheep, cytoplasmic) 1:250 Europa
GFP (rabbit, full length) 1:90 1:25 Clontech
Mekl/2 (rabbit) 1 : 1 0 0 0 Cell Signaling
p44/42 (rabbit) 1 : 1 0 0 0 Cell Signaling
P-Mekl/2 (rabbit, S217/221) 1:250 Cell Signaling
P-p44/42 (mouse, T202/Y204) 1 : 1 0 0 0 Cell Signaling
Phosphotyrosine (mouse, PY99) 1 : 2 0 0 0 Santa Cruz
TfR (H68.4, mouse, cytoplasmic) 1:25 Zymed
TfR (B3/25, mouse, extracellular) 1 :2 0
a-Tubulin (mouse) 1 :2 0 0 0 Zymed
Secondary Antibody
Sheep HRP (donkey) 1:5000 Sigma
Goat HRP (donkey) 1 :2 0 0 0 DAKO
Mouse HRP (goat) 1 :2 0 0 0 DAKO
Rabbit HRP (goat) 1 : 2 0 0 0 DAKO
Mouse Cy2 (donkey) 1 :1 0 0 Molecular Probes
Mouse IgG (rabbit) 1:180 DAKO
Goat IgG (rabbit) 1:180 DAKO
Rabbit IgG (swine) 1:180 DAKO
Other
EGF - AlexaFluor5 5 5 1 : 1 0 0 0 Molecular Probes
Tf -AlexaFluor555 1:500 Molecular Probes
Phalloidin- AlexaFluor547 1 :2 0 Molecular Probes
2.2 Cell Culture
Standard cell culture conditions (37°C, 5% CO2) were used, unless otherwise 
stated. To serum starve cells, DMEM without foetal bovine serum (FBS) was used.
2.2.1. Human cell lines
HEp2, HeLa and A431 cells were all cultured in DMEM, containing 10% FBS, 
penicillin/streptomycin (5mg/ml) and L-glutamine (20mM). Cells were incubated
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in 25cm2 tissue culture treated flasks to form confluent monolayers. To passage 
cells, medium was removed and cells were washed with lx  PBS before incubating 
with 2ml lx Trypsin/EDTA for 3-5 minutes. Full medium was added to cells to 
inhibit trypsin action before centrifuging at 1200 rpm (Eppendorf Centrifuge 
581 OR, A-4-62 rotor) for 4 minutes. Supernatant was removed and cells were 
resuspended in medium and transferred into fresh flasks at the appropriate dilution.
2.2.2 JACRO cell lines
Mouse lung fibroblasts from wild type and annexin 1 knockout mice (JACRO cells) 
were provided by Jamie Croxtall (St Bartholemew’s Medical School, London, UK). 
Cells were cultured in DMEM F-12 containing 10% FBS, 5mg/ml 
penicillin/streptomycin and lOmM L-glutamine and passaged as described above.
2.2.3 DT40 cell lines
DT40 cells (chicken B lymphocytes) were cultured in suspension in DMEM 
containing 10% FCS, 1% chicken serum, penicillin/streptomycin and L-glutamine. 
DT40 cells were cultured at 40°C in 25ml medium in 25cm2 flasks to a maximum 
density of 1 x 106 per ml before passaging at a dilution of 1:15-1:20.
2.3 Molecular Biology
2.3.1 Annexin 1-GFP Construction
The human annexin 1 gene was amplified using PCR from an I.M.A.G.E. 
Consortium [LLNL] cDNA clone ID3459615, using the following primers designed 
to contain Xhol and BamHl restriction sites (underlined sequences). Bases in 
italics are extra bases or changed bases to keep annexin 1 in frame with GFP, to 
introduce appropriate restriction sites and to change the stop codon to allow read- 
through from annexin 1 into GFP.
Forward: Xhol -  5’-CAAGAAGCTCGAGATAAAGACACG-3’
Reverse: BamHl -  5’-CAAGGGGATCCGCGGTTTCCTCC-3’
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These restriction enzymes were then used to clone annexin 1 into pGFP-Nl, which 
contains the appropriate restriction sites within its multiple cloning site. Full 
annexin 1 sequence, including primers, is shown in Appendix 1 (Fig. S.l):
2.3.1.1 Restriction Digest of pGFP-Nl Plasmid DNA
pGFP-Nl DNA (0.5pg) was digested using 0.5U Xhol and BamHl (in NEB buffer 
2 (lOx), O.lmg/ml acetylated BSA, in a total volume of 25pi) for 2 hours at 37°C. 
Digestion was confirmed by analysis of 5pi of the restriction digest by 
electrophoresis on a 1% agarose gel containing ethidium bromide in cold lx TAE 
buffer. A 1Kb DNA ladder was used as a marker and gels were run at 50V. Gels 
were visualised using Syngene UV Transilluminator and Gene Snap Gene Genius 
software. Bands were excised from the agarose gel and purified using QIAEX® II 
Gel extraction Kit (Qiagen). Digested pGFP-Nl was incubated with lp l CIP for 30 
minutes at 37°C. Excess CIP was removed after incubation using QIAquick PCR 
purification kit according to the manufacturer’s instructions.
2.3.1.2 Ligations and Cell Transformations
For a 3:1 ratio of insert to vector the following calculation was used:
Amount of vector (net x size of insert (kb) x insert = insert (ng)
Size of vector (kb) vector
Ligations were performed in a total volume of lOpl containing plasmid DNA, insert
DNA, T4 DNA ligase (lpl) and buffer (lp l of lOx stock). Reactions were
incubated for 3 hours at room temperature or overnight at 4°C.
Supercompetent E.coli (lOOpl per transformation) were thawed on ice in pre-chilled 
1.5ml microcentrifuge tubes. DNA (approximately lp l of a typical ligation 
reaction) was gently mixed with cells and left on ice for 30 minutes. Cells were 
subjected to heat shock at 42°C for 45 seconds and returned to ice for 2  minutes. 
Pre-warmed LB broth (1ml) was added to cells and the contents of the tubes 
transferred to an incubation tube and incubated at 37°C shaking for 1 hour. 
Transformed cells were plated out onto selective LB agar plates and incubated
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overnight at 37°C. Colonies were picked and plasmid DNA prepared (see 2.3.1.3). 
Purified plasmids were cut using restriction enzymes to check for the presence of 
the insert and suitable clones were sequenced for further verification (see 2 .3 .3 ).
2.3.1.3 Purification o f Plasmid DNA
Plasmid DNA was extracted and purified from picked colonies using the Miniprep 
system from Qiagen according to manufacturers instructions. The same method 
was used to extract and purify plasmid DNA from E.coli grown in LB medium 
(cells were pelleted by centrifugation at 6000g for 15 minutes at 4°C). DNA was 
eluted in 1ml TE buffer. DNA was quantified by measuring absorption at 
A=260nm (1 OD unit = 50pg double stranded DNA).
2.3.2 Annexin 1 Phosphorylation Site Mutation
Primers were designed to create a point mutation (bold underlined) at the site of 
EGFR phosphorylation of annexin 1, to change tyrosine (TAT) to phenylalanine 
(TTT) (Y21F) and abolish the phosphorylation site. For full annexin 1 sequence, 
including amino acids, see Appendix 1 (Fig. S.2).
Forward: 5’-GAA GAG CAG GAA TTT GTT CAA ACT GTG AAG TC-3* 
Reverse: 5’-CTT CTC GTC CTT AAA CAA GTT TGA CAC TTC AG-3’
2.3.2.1 Mutagenesis PCR
QuikChange™ Site directed Mutagenesis kit (Stratagene) was used to create the 
point mutation in annexin 1 (within the pGFP-Nl vector). The experimental 
reaction and a control mutagenesis reaction were prepared according to 
manufacturers instructions. Mutagenesis reactions were carried out in an 
Eppendorf Master Cycler Gradient PCR Machine as follows: 95°C 30 seconds; 
{95°C 30 seconds, 55°C 1 minute, 6 8 °C 11 minutes} xl2; 4°C 2 minutes. Dpnl 
(10U) was then added to each mutagenesis reaction and incubated at 37°C for at 
least 1 hour to degrade parental supercoiled dsDNA.
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2.3.2.2 Cell Transformations
Transformations were performed using E.coli XLl-Blue supercompetent cells and 
2pi of Dpnl digested DNA according to manufacturers instructions. In addition a 
transformation efficiency control was performed using lp l pUC18 (0.1 ng). 
Colonies were picked from sample mutagenesis plates and incubated in LB broth, 
containing kanamycin, overnight at 37°C. The following day plasmid DNA was 
purified using Qiagen spin miniprep kit (as described in 2.3.1.3). Each DNA 
sample was sequenced (see 2.3.3) to check for presence of the desired mutation.
2.3.3 Sequencing
To sequence annexin 1-GFP, primers were designed for the multiple cloning site of 
pGFP-Nl (Primer 1) and for the middle of annexin 1 (Primer 2). Primer 1 was used 
to sequence Y21F annexin 1-GFP to check for the presence of the desired mutation. 
For the sequence of primers and results of sequencing see Appendix 1 (Fig. S.3 &
S.4). Sequencing reactions were carried out in lOpl volume according to the Big 
Dye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). DNA was 
purified by adding 2.5pl 125mM EDTA, 25pl 100% ethanol and transferring to 
1.5ml microcentrifuge tubes for 15 minutes room temperature. Tubes were 
centrifuged at 13000rpm in an Eppendorf Centrifuge 5415D using a F-45-24-11 
rotor at 4°C for 15 minutes, before carefully discarding supernatants and washing 
DNA pellets with 70% ethanol. After a repeat spin pellets were resuspended in 
12pl HiDi formamide and loaded onto the ABI sequencing machine.
2.4 Transfections of cell lines
2.4.1 Lipofectamine™ Ttransfection ofHEp2 cells
Annexin 1-GFP plasmid DNA was transiently transfected into HEp2 cells using 
Lipofectamine™, according to the manufacturer’s instructions, and expression of 
the construct confirmed using the BioRad confocal to visualise annexin 1-GFP.
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2.4.2 Calcium Phosphate Transfection to create a stable cell line
HEp2 cells were seeded into wells of a 6 -well plate to reach -30% confluency after 
24 hours. The following day cells were transfected with annexin 1-GFP plasmid 
DNA as follows: DNA (20pg) was added to 0.5ml 2x HEPES buffer (0.5M
HEPES pH7.1, 3M NaCl, 1M NaP0 4 , freshly made and filter sterilised) and 
vortexed continuously whilst adding 0.5ml CaCl2 dropwise to precipitate DNA. 
The precipitate was allowed to form at room temperature for 30 minutes before 
vortexing and adding 1ml to cells. Cells were incubated at 37°C for 10 minutes 
before a further 2.5ml medium was added to each well and plates incubated 
overnight under standard conditions. The following day medium was removed and 
l-2ml 12.5% glycerol (filter sterilised, in medium containing lOmM Hepes pH7.4) 
added for 2 minutes at room temperature. Glycerol was removed, cells washed 
twice in PBS and full medium added. Cells were incubated at 37°C for 48 hours. 
At this point normal medium was removed and full medium containing 0.5mg/ml 
G418 was added to select for transfected cells. Cells were left for approximately 
10-14 days and medium changed every 3-5 days to removed dead cells. Single 
transfected cells grew into colonies, which were picked using a small amount of 
trypsin to detach cells within an area defined using sterile cloning rings. Cells were 
transferred into wells of a new 24 well plate. Expression of annexin 1-GFP was 
determined using fluorescence microscopy and a cell line derived from a single 
clone was chosen for its uniform low expression of the plasmid.
2.4.3 Nucleofection o f JACRO cells
JACRO wild type and annexin 1 -/- cells (5x 105) were transfected with 2.5pg 
hEGFR, wild type or Y21F annexin 1-GFP DNA using Normal Human Dermal 
Fibroblast™ kit and programme U-23 according to manufacturers instructions.
2.5 RNAi
2.5.1 Annexin 2 RNAi
For annexin 2 siRNA, the first oligonucleotide was ordered using the published 
sequence (Mayran et al., 2003). The second oligonucleotide was designed against
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human annexin 2 using the Qiagen protocol. For experiments, the two 
oligonucleotides were used together. Full human annexin 2 sequence is shown in 
Appendix 1 (Fig. S.6 ):
RNAil -  start 131 - 5 ’-AAGTGCATATGGGTCTGTCAA-3 ’
RNAi2 -  start 820 - 5 ’-AACCTGGTTCAGTGCATTCAG-3 ’
A431, HeLa, HEp2 or JACRO wild type cells (4x 104) were seeded in 12 well 
plates and incubated overnight. The following day medium was replaced with 
500pl antibiotic free medium and RNAi was prepared as follows (per well). Each 
RNAi oligonucleotide (20pM) was added to 50pl OptiMEM in tube 1. In tube 2, 
3pi Oligofectamine™ was added to 12pl OptiMEM. Tubes were incubated at room 
temperature for 7-10 minutes before the contents of tubes 1 and 2 were mixed and 
incubated for 25 minutes at room temperature. OptiMEM (32pl) was added to the 
mixture and lOOpl of the transfection mixture was added to cells. Cells were 
incubated with RNAi for 3 days, or split 1:3 on day 3 and allowed to settle for 1 
hour before re-transfecting with RNAi for a further 3 days. Cells were collected for 
western blot analysis by scraping 2 wells into lOOpl 2x reducing sample buffer. 
Cell lysates were blotted for tubulin as a loading control and annexin 2 (see 2.6).
2.5.2 Annexin 1 RNAi
The first 4 oligonucleotides were designed against human annexin 1 using the 
Dharmacon protocol. The final oligonucleotide was designed against human and 
mouse annexin 1 using the new Qiagen protocol. All oligonucleotides were used to 
transfect cell lines, as described in 2.4.1. Full annexin 1 sequence including 
oligonucleotide sequences is shown in Appendix 1 (Fig. S.5).
LBA1A -  start 201 -  5’-AATCCATCCTGGATGTCGCT-3’
LBA1B -  start 291 -  5’-AACAATGCACAGCGTCAACAG-3’ - Control 
LBA1C -  start 247 -  5’-AAGGTGTGGATGAAGCAACCA-3’
LBA1D -  start 1048 -  5’-AAGCCATCCTGGATGAAACCA-3’
LBA1X -  start 240 -  5’ -ATGGTTAAAGGTGTGGATGAA-3 ’
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LBA1A and LBA1X were also used to transfect HeLa and A431 cells using 
nucleofection (2.3.3). Cells (lxlO6) were nucleofected with 5pl of each 
oligonucleotide using Kit V and programme T-28, as per manufacturers 
instructions, and left to settle for 24 hours in antibiotic free medium. After 24 
hours, cells were trypsinised, resuspended in lOOpl solution V and re-nucleofected. 
Cells were plated (1:10) onto wells of 24-well plate or onto coverslips and left for 
48 hours before collection for western blotting (section 2.6) or experimentation.
2.5.3 Annexin 1 and 2 RNAi
HeLa cells were treated with both annexin 2 oligonucleotides and annexin 1 
oligonucleotides LBA1A and LBA1X, using nucleofection, as described in 2.5.2.
2.6 Western blotting
2.6.1 Preparation o f Samples
To investigate the effects of EGF stimulation, cells were serum starved for 1 hour 
before stimulating with lOOng/ml EGF for the appropriate length of time. In the 
absence of EGF-stimulation, cells were washed with PBS before scraping into 2x 
RSB. DNA was sheared using a 0.6 gauge needle before boiling samples at 95°C 
for 5 minutes and briefly centrifuging to remove any debris.
2.6.2 SDS Polyacrylamide Gel Electrophoresis (PAGE)
Typically 1 OjlxI of each sample or 8 pl of rainbow molecular weight markers 
(Amersham) was loaded in each well. Samples were resolved by SDS-PAGE using 
a 10% polyacrylamide gel run at 0.25A (per mini-gel) for 50 minutes.
2.6.3 Western blotting
After SDS-PAGE, proteins were transferred to Protran nitrocellulose transfer 
membrane (Schleicher and Schuell) using the BioRad Transfer unit at 100V for 50
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minutes. Membranes were washed in PBS and then blocked in 5% (w/v) dried 
powdered skimmed milk, or 5% BSA for phosphotyrosine antibodies, for 30 
minutes at room temperature. After blocking, membranes were incubated with 
primary antibody for at least 1 hour at room temperature or overnight at 4°C. 
Membranes were washed in PBS/Tween before incubation with secondary 
antibody-HRP conjugate for 45 minutes at room temperature. Membranes were 
washed thoroughly in PBS/Tween before 1 minute incubation with Supersignal 
West Pico Chemiluminescent substrate (Pierce). Antibody binding was visualised 
using Fujifilm intelligent dark box II and Las-1000 Pro software (version 2.3).
2.6.4 Semi-Quantitative Analysis o f Western Blots
To compare the effect of RNAi treatment on protein levels, western blot images 
were analysed using AIDA 2D densitometry software. For each experiment tubulin 
was used as a loading control. The intensity of tubulin bands and the appropriate 
protein band were measured and the background signal subtracted. Results were 
each protein assayed were normalised against that for tubulin. The difference in 
intensity of the desired band was then compared between treated and control cells 
and recorded as a percentage of the control. The mean ± SEM were calculated 
from at least 5 independent experiments.
2.7 Reverse Transcriptase PCR of annexin 2
Total RNA was isolated from lxlO7 wild type or annexin 2 knockout DT40 cells 
using RNeasy Mini Kit protocol (Qiagen) and used to synthesise cDNA using 
ProStar First Strand RT-PCR kit (Stratagene). At the same time a control reaction 
(supplied with the kit) was performed. For both control and experimental cDNA 
synthesis random primers were used. Control cDNA was used in the control PCR 
amplification reaction to produce a 1.3Kb PCR product. Primers were designed to 
run from exon 1 to exon 4 across introns to produce a 239bp product (full chicken 
annexin 2 sequence is shown in Appendix 1, Fig. S.7).
Forward: 5’- TTAAGGCTTACTCAAACTTTGATGCTGACCG-3’
Reverse: 5’-TGGTGTCTTCAGCAAGCCCAA-3’
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Reactions were performed according to manufacturers instructions. Experimental 
and control PCR reactions were run on 1% agarose gel containing ethidium 
bromide to visualise DNA. Experimental samples were run alongside PCR markers 
(New England Biolabs) and control samples with 1Kb markers.
2.8 Iodinated EGF and Tf experiments
2.8.1 EGF recycling & degradation in JACRO cells
JACRO cells were seeded on 3cm diameter dishes overnight and serum starved for 
1 hour. To measure EGF degradation, cells were incubated with 6 ng/ml 125I-EGF 
for 10 minutes at 37°C in serum free medium containing 0.5% BSA (binding 
medium). After incubation cells were placed on ice and washed 5 times using pre­
chilled binding medium to removed excess 125I-EGF. Surface bound EGF was 
stripped during 2x 3 minute ice-cold acid washes (0.1M glycine, 0.9% NaCl 
pH3.0). The acid washes were collected into labelled screw-capped 1.5ml tubes. 
Cells were washed twice with cold binding medium before adding 250pl warm 
medium and returning to 37°C. For EGF recycling and degradation experiments 
cells were chased (with warm binding medium) for 10, 35, 50, 80 and 110 minutes. 
At each time point, medium was collected into a labelled tube and replaced with 
fresh warm medium. After the final time point cells were lysed using 250pl ice- 
cold 1% TxlOO for 10 minutes at 4°C. Cell lysates were collected into tubes. 
Counts per minute (cpm) were measured for each sample using a Packard Cobra II 
Gamma counter, counting for 2 minutes. After counting, medium samples were 
replaced on ice and TCA added, to a final concentration of 20%, for 1 hour. Tubes 
were centrifuged for 10 minutes at 14000rpm in an Eppendorf Centrifuge 5415D, 
using a F-45-24-11 rotor, at 4°C. Supernatants were collected into fresh tubes and 
cpm counted.
2.8.2 EGF recycling & degradation in annexin 2 RNAi treated HeLa cells
HeLa cells were seeded at 1.5xl04 cells per well of a 4 well plate overnight. The 
following day 2 wells were treated with annexin 2 RNAi and the other 2 with
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control RNAi. After 3 days of RNAi treatment cells were serum starved for 1 hour. 
125I-EGF (lng/ml) was added to each well in 250pl binding medium. The 
experiments were performed as described above for JACRO cells (section 2.8.1).
2.8.3 Tf Recycling
JACRO cells were plated, as described in 2.7.1, and preloaded with 0.3pg/ml of 
125I-Tf for 1 hour at 37°C before washing off excess ligand with cold medium. 
Surface bound Tf was removed, by incubating cells with ice-cold acid wash for 2x 
3 minutes, collected and cpm measured. Cells were incubated with warm binding 
medium for 10, 25, 30, 60 and 120 minutes, medium was collected and cpm 
measured. Cell lysates were collected to count Tf remaining in cells.
2.8.4 Calculating percentage o f I  ligand degraded or recycled
To calculate the total (in cpm) amount of Tf or EGF internalised, the cpm from the 
cell lysates sample was added to the combined cpm total of the media samples.
Total cpm internalised = all media samples + cell lysates
To determine the percentage internalised, the total cpm internalised was divided by 
the combined total of cell lysates plus media samples plus both acid washes.
% internalised = Total cpm internalised xlOO 
Total cpm + acid washes
To calculate the percentage Tf recycled, the medium sample from that time point 
(or the cumulative media samples up to that time point) was divided by the total 
cpm internalised.
% T f recycled = cpm in medium sample xlOO 
total cpm internalised
At each time point recycled EGF is found in the TCA precipitate, while the TCA 
soluble supernatant contains the iodotyrosine released from degraded EGF. As the 
pellet is not counted with the same efficiency as liquid samples, the cpm in the 
supernatant was subtracted from the cpm in the pre-TCA medium sample. This
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figure gave the cpm recycled at that time point. Therefore, to calculate the 
percentage EGF recycled at a given time point:
% EGF recycled = com medium -  com TCA supernatant xlOO
total cpm internalised
The cpm from degraded EGF are present in the TCA supernatant so to calculate the 
percentage EGF degraded at a given time point, this figure was divided by the total 
cpm internalised.
% EGF degraded = com TCA supernatant x 100 
total cpm internalised
Finally, to calculate the total percentage of Tf or EGF recycled, or EGF degraded:
Total % recycled = cpm all medium -  com all TCA supernatants x 100 
Total cpm internalised
Total % degraded = all TCA supernatants x 100 
Total cpm internalised
2.9 Live cell imaging
2.9.1 Phase and Fluorescent Imaging
JACRO cells were plated on 3cm Mattek™ dishes, allowed to settle and serum 
starved overnight. Cells were visualised using a Zeiss Axiovert 100M microscope 
(x20 objective). To visualise cells and fluorescent ligands, cells were washed 
thoroughly to remove DMEM and medium replaced with phenol red free L-15, as 
phenol red affects visibility of green fluorescence.
2.9.2 Cell Area Quantitation
Phase images of unstimulated or EGF-stimulated JACRO cells were taken using a 
Zeiss Axiovert 100M microscope and Improvision OpenLabs software. 
MetaMorph 4.6r9 was used to measure cell area and cell perimeter. Each cell was 
outlined and, once calibrated for the appropriate microscope and objective,
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MetaMorph Integrated Photometric analysis used to calculate the area of each cell 
and its perimeter.
2.9.3 Cell Motility assay
JACRO wild type, annexin 1 -/- or transfected annexin 1 -/- cells were serum 
starved overnight. The following day cells were washed; for cells transfected with 
annexin 1-GFP constructs serum free medium was replaced with phenol red free L- 
15 medium. Unstimulated or EGF-stimulated cells were imaged every 5 minutes 
for 90 minutes using a Zeiss Axiovert 100M microscope (x20 objective) and 
Improvision OpenLabs software. The object tracking mode (MetaMorph v4.6r9) 
was used taking the nucleus as the centre point of the cell. Any movement of the 
nucleus was recorded and the total distance per cell (pm) recorded after 90 minutes. 
The average velocity (pm per second) was also calculated and recorded. For each 
transfection or treatment the movements of at least 2 0  cells were recorded.
2.10 Immunofluorescence
Cells were plated out in full medium onto 13mm glass coverslips overnight to reach 
approximately 70% confluency. The following day cells were serum starved for 1 
hour before incubation with appropriate ligand. Cells were washed using PBS 
before fixing in 1ml 3% paraformaldehyde (in serum free medium) for 20 minutes. 
Coverslips were washed with PBS and free aldehyde groups quenched using 15mM 
glycine (in PBS) for 2x 10 minutes before blocking and permeabilising using 
PBS/1 % BSA/0.1% saponin for 30 minutes. All antibodies were diluted in 
PBS/1% BSA/0.01% saponin. For antibody incubations, coverslips were turned 
(cells facing down) onto 40pl drops of diluted antibody and incubated for 1 hour 
(primary) or 45 minutes (secondary) at room temperature in a humidified chamber. 
Between antibodies and after secondary antibody incubation coverslips were 
washed 4x PBS/saponin and finally 2x PBS. Coverslips were mounted onto glass 
slides using anti-fade mounting medium (90% glycerol, 3% N-propyl-galate in 
PBS) and nail varnish before storing at 4°C.
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Cells were visualised using a Radiance 2000 AGR-3 (Q) confocal microscope 
(BioRad) attached to an inverted microscope (model Axiovert S100TV; Carl Zeiss 
Microimaging Inc.) and LaserSharp (version 5) software. Images were analysed 
using LaserPix (version 5) or Metamorph Image Analysis package 4.6r9 (Universal 
Imaging).
2.11 Transmission Electron Microscopy
2.11.1 Preparation o f EM markers
2.11.1.1 Anti-human EGFR (108)-10nm gold
The pH of lOnm gold was adjusted to 9.3 using 0.2M K2CO3. 108 (anti-human 
EGFR antibody) was passed through PD10 column pre-equilibriated with 2mM 
borax. To determine the minimum amount of antibody necessary to stabilise the 
gold, increasing amounts of antibody were diluted in borax to a final volume of 
12pl in 1.5ml microcentrifuge tubes and 250pl gold was added to each tube. Tubes 
were vortexed and incubated at room temperature for 5 minutes. NaCl (50pl of 
20% solution) was added to aggregate any gold that had not been stabilised. All 
tubes were vortexed and centrifuged at 14000rpm, in an Eppendorf 5415D 
centrifuge, for 1 minute. 150jnl supernatant was removed into wells of 96 well 
plate and the most pink fraction determined by eye. This corresponds to the lowest 
concentration of antibody that will stabilise the gold and was used to calculate the 
amount of antibody necessary to make a larger quantity of anti-EGFR-gold. The 
appropriate amount of gold was placed into a sterile tube and stirred vigorously 
whilst the minimum amount of antibody was added. After 5 minutes of stirring the 
antibody-gold was stabilised further using 10% BSA (in H2O, pH9.0 filtered 
0.45pm filter) to a final concentration of 1% BSA. The gold conjugate was 
centrifuged at 45000 rpm in a Sorval RC M l50 GX centrifuge (using a S80At3- 
0051 rotor) for 10 minutes at 4°C to remove any free antibody and the fluid pellet 
resuspended in an appropriate volume (1/10) of 20mM Tris, 1% BSA pH 8.3, 
0.02% azide. When using anti-hEGFR-gold, an appropriate volume was taken, 
diluted in serum free medium containing 0.5% BSA and centrifuged at 45000rpm,
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4°C for 15 minutes to remove azide. The fluid pellet was resuspended in serum 
free medium containing BSA before incubation with cells at 37°C.
2.11.1.2 BSA-5nm gold
BSA-gold was prepared in the same way as described above for anti-EGFR-gold 
with the following changes. 1 mg/ml BSA was dissolved in 2mM borax. The pH of 
5nm gold was adjusted to 5.5, the pi of BSA. BSA-gold was pelleted by 
centrifuging at 65000 rpm, 4°C, 15 minutes and resuspended in serum free medium 
containing BSA before incubation with cells at 37°C.
2.11.1.3 Chick B-cell receptor-1 Onm gold
Anti-chicken IgMx (Southern Biotechnology Associates Inc. clone M-4- 0.5mg/ml 
in borate buffered saline pH 8) was passed through PD10 column pre-equilibriated 
with 2mM borax. Fractions (0.5ml) were collected and the Pierce Protein Detection 
Kit was used to determine which fraction(s) contained the antibody. Antibody-gold 
conjugation was performed as described for anti-hEGFR in section 2.11.1.1.
2.11.1.4 EGF-HRP
Biotinylated EGF (0.328pg) was mixed with Streptavidin-HRP (5pg) in lOOpl 
PBS, to achieve a 1:1 molar ratio, and incubated rotating at 4°C overnight. To test 
EGF-HRP, cells were cultured in a 24-well plate overnight to reach -80% 
confluency. Cells were serum starved for 1 hour and incubated with increasing 
dilutions of EGF-HRP for 30 minutes at 37°C. For each concentration a 
competition reaction was set up, where cells were also incubated with lOOx excess 
of non-labelled human EGF. Cells were washed thoroughly after incubation and 
solubilised in 200pl 0.5% TxlOO (in PBS containing protease inhibitor cocktail) for 
10 minutes at 4°C. Solubilised cells were collected and centrifuged at 13000rpm in 
an Eppendorf Centrifuge 5415D (using a F-45-24-11 rotor) at 4°C for 5 minutes to 
pellet nuclei. The supernatant (35pi) was added to 65pi OPD reaction mix (lmg/ml 
OPD in 10ml citrate buffer pH 4.5 and 7.7pl H2O2, added immediately prior to 
reaction) and colour change allowed to develop. Reactions were stopped using
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lOOpl 1M H2SO4 . Absorbance at A,=450nm was read using a Satire Plate Reader. 
In the competition reaction, excess EGF should out-compete EGF-HRP and prevent 
binding. In the non-competition reaction EGF-HRP binding, as measured by 
increased amounts of EGF-HRP within cells and increased absorbance reading, 
should reach a plateau as >90% of receptors become saturated. The lowest 
concentration, where binding plateaued and could be prevented by addition of 
excess non-labelled EGF, was chosen as the concentration of EGF-HRP to use for 
experiments.
2.11.1.5 Tf-HRP
SPDP (N-succinimidyl 3-(2-pyridyldithio)propionate), 30mM, was added to a 2mg 
solution of iron-saturated human-Tf, in 1ml 0.1 M phosphate buffer. In a separate 
tube SPDP was added to 5mg HRP (in 1ml 0.1M phosphate buffer and 0.15M 
NaCl). Both tubes were rotated at room temperature for 30 minutes. To remove 
the unbound SPDP, PD10 columns were pre-equilibriated using 0.1M phosphate 
buffer and 0.15M NaCl for Tf, or 0.1M sodium acetate pH 4.5 for HRP. Tf-SPDP 
or HRP-SPDP mixtures were passed through the appropriate column and 0.5ml 
fractions collected. HRP was visible as coloured fractions, which were collected 
and pooled. For Tf, fractions were analysed using the Pierce Protein Detection Kit, 
according to manufacturers instructions, and the absorbance read at A,=450nm to 
identify the Tf containing fraction. Meanwhile, DTT was added to the HRP 
mixture (final concentration 8  mg/ml) before rotating at room temperature for 2 0  
minutes. To remove free HRP, the mixture was passed through a PD10 column 
pre-equilibriated with 0.1M phosphate buffer. HRP-containing fractions were 
collected. Tf-SPDP fractions and reduced HRP were mixed and incubated rotating 
overnight at 4°C.
Tf-HRP was tested as described above for EGF-HRP (see 2.11.1.4) and used at the 
chosen concentration, diluted in serum free medium.
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2.11.2 Embedding o f  HeLa and JACRO cells
Cells were seeded onto sterile cell culture coated Thermanox coverslips. On the 
day of treatment cells were serum starved for 1 hour before incubation with HRP, 
anti-hEGFR-gold, Tf-HRP or EGF-HRP in serum free medium containing 0.5% 
BSA, to limit non-specific binding. After incubation, cells were washed thoroughly 
with PBS before fixation with 2% PFA/2% glutaraldehyde (in 0.1M cacodylate) for 
30 minutes at room temperature. For cells incubated with HRP, or HRP conjugates, 
a DAB (diaminobenzidine) reaction (1% DAB in 10ml 0.1M Tris + 7.7pl H2O2) 
was performed, after fixation, for 30 minutes at room temperature in the dark to 
cross-link HRP molecules. Cells were then incubated with 1% osmium/1.5% 
potassium ferricyanide in 0.1M cacodylate for 1 hour at 4°C in the dark. To 
increase membrane resolution cells were incubated with 1% tannic acid (freshly 
made in 0.05M cacodylate) for 40 minutes at room temperature. Cells were washed 
thoroughly with cacodylate between each step. Cells were dehydrated using 70%, 
90% and, finally 2x 10 minute washes in 100% ethanol with special care taken to 
prevent coverslips from drying out. After the second 100% ethanol wash, 
coverslips were placed into foil dishes containing 1:1 mixture of propylene oxide 
(PO) and EPON resin for 1 hour at room temperature. After an hour PO/EPON was 
removed and replaced with EPON for a further hour. EPON was changed once 
more before placing coverslips cell side down onto EPON stubs and baking 
overnight at 60°C. Coverslips were removed by heating, leaving the layer of cells 
on face of the stub.
2.11.3 Embedding o f DT40s
DT40 cells were grown in suspension to a concentration of 2 xlO6 cells/ml. Cells 
were incubated with lmg/ml HRP for 2 or 4 hours at 42°C. For incubation with 
BSA-5nm gold, 4ml cells were resuspended in 1.5ml medium and 1.5ml BSA-gold 
diluted 1:5 for 4 hours followed by a 20 hour chase in full medium at 42°C. For 
washes, cells were centrifuged for 3 minutes at lOOOrpm in an Eppendorf 
Centrifuge 5415D (using a F-45-24-11 rotor). Cells were washed three times 
before fixation in 2% PFA/2% glutaraldehyde (in 0.1M cacodylate) for 30 minutes.
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After fixation cells were washed at a higher speed (4000rpm). After washing cells 
were incubated with DAB (as described in section 2.10.2). DAB reaction mixture 
was washed off cells during three washes in 0.1M cacodylate and cells were 
incubated with 1% osmium/1.5% potassium ferricyanide for 1 hour at 4°C. Cells 
were washed three times before dehydration using 70%, 90% and finally two 10 
minutes incubations in 100% ethanol. After the 90% ethanol step, cells were 
transferred from 1.5ml screw capped microcentrifuge tubes to 0.4ml thin centrifuge 
tubes. Cells were pelleted by centrifuging horizontally at lOOOOrpm in a Biofuge 
Primo centrifuge (Heraeus Instruments) using a HTA 13.8 rotor for 5 minutes. 
Ethanol was removed and 1:1 mixture of PO/EPON added for 1 hour at room 
temperature. PO/EPON was removed and excess PO allowed to evaporate for 10 
minutes. EPON was added for another hour, removed and fresh EPON added for a 
further hour. Tubes were baked overnight at 60°C. The following day pellets were 
cut out of tubes, re-embedded in EPON coffins and baked overnight at 60°C.
2.11.4 Ultrathin sectioning and staining
Samples were sectioned using a Leica microtome and a Diatome Ultra diamond 
knife (size 4). Ultrathin sections (60-70nm) were stained using Reynold’s lead 
citrate for 5 minutes at room temperature. Sections were then observed using a 
JEOL 1010 transmission electron microscope.
2.11.5 Morphometric Analysis o f MVBs
To calculate the number of MVBs per unit cytoplasm (pm2), at least 25 photos were 
taken of cells, chosen at random at a low magnification. The area of cytoplasm per 
photo was measured using LaserPix and the number, area and internal vesicle 
frequency of MVBs per photo was also recorded. MVBs were defined as vacuoles 
> 200nm in diameter and containing > 1 internal vesicle. For each experiment the 
total number of MVBs was divided by the total area cytoplasm to calculate the 
number of MVBs per pm2. For each cell line or each treatment at least three 
independent experiments were performed.
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2.12 Immuno Electron Microscopy
Cells were grown in 92mm diameter tissue culture treated dishes overnight and 
serum starved for 1 hour the following day. After EGF stimulation, cells were 
fixed in 4% PFA/0.1% glutaraldehyde for 2 hours at room temperature and then 
0.5% PFA for at least an hour at room temperature or overnight at 4°C. Free 
aldehyde groups were quenched by 5 washes using 20mM glycine (in 0.1M 
phosphate buffer). Cells were scraped into 500pl 1% gelatin and centrifuged 
horizontally at 1500rpm in a Biofuge Primo centrifuge (Heraeus Instruments) using 
a HTA 13.8 rotor for 1 minute. Cell pellet was resuspended in 10% gelatin and 
immediately centrifuged horizontally at 5000rpm for 1 minute. Most of the gelatin 
was removed and the tube was placed on ice for 15 minutes. The pellet was then 
cut out of the tube, placed in a fresh tube containing 2.3M sucrose and rotated 
vertically for 15 minutes at 4°C. Cell pellets were then cut into 4-6 blocks, 
depending on size of pellet, and incubated in sucrose for a further 2 hours at 4°C. 
Pellet blocks were placed onto pins (scuffed and washed in acetone) and 
immediately stored in liquid nitrogen.
2.12.1 Immunolabelling o f cryosections
Ultra thin cryosections (60-70nm) were cut using a Leica cryo ultra microtome and 
Diatome Cryo P diamond knife. Sections were stored in 1:1 mixture of 
methylcellulose (MC) and 2.3M sucrose on Formvar/carbon coated hexagonal mesh 
grids at 4°C. For immunolabelling, grids were turned over onto lOOpl 2% gelatin 
(in PBS) for 20 minutes at room temperature, followed by 2x 5 minutes 15mM 
glycine. Sections were blocked using 1% BSA (from 10% stock centrifuged for 1 
hour at 45000rpm and filtered)/0.1% BSA-c before primary antibody incubation for 
1 hour. Sections were washed in 0.1% BSA/0.01% BSA-c before incubation with a 
bridging antibody (30 minutes at room temperature). After a second round of 
washing sections were incubated with protein A gold (45 minutes at room 
temperature). For double labelling sections were washed thoroughly after gold 
incubation and fixed in 1% glutaraldehyde for 10 minutes. Sections were washed 
in PBS and free aldehyde groups quenched using 5x 2 minutes on 20mM glycine.
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Antibody incubations were carried out in the same way as for the first antibody. 
After the second fixation in glutaraldehyde sections were washed 8x in double 
distilled H2O before being placed onto a drop of 1:4 uranyl acetate (UA)/MC on 
ice. Grids were moved through 3 drops of UA/MC before 5 minute incubation on 
the final drop in the dark. Grids were picked up using small wire loops, excess 
UA/MC drained onto filter paper and allowed to dry before storage.
2.13 Scanning electron microscopy
JACRO cells were seeded onto glass coverslips overnight. The following day cells 
were serum starved for 1 hour. Cells were fixed in 1% PFA/2% glutaraldehyde in 
0.08M cacodylate for 1 hour at room temperature. After fixation cells were treated 
with 1% osmium in 0.08M cacodylate for 1 hour at 4°C. Cells were dehydrated in 
70%, 90% and finally 2x 10 minutes in 100% ethanol. Finally cells were washed 
for 3x 2 minute incubations in hexamethyl disilazane (HMDS) and allowed to dry 
by evaporation. After fixation, coverslips were mounted onto stubs using 
conductive silver paint and sputter coated with gold. Specimens were then 
examined in a JOEL 6100 scanning electron microscope.
2.14 Flow cytometry
Jacro wild type or annexin 1 -/- cells (1x10s) were collected, resuspended in 
PBS/2mM EDTA (to avoid clumping) and placed on ice. Cell size was analysed by 
FACS (Flow assisted cell sorting) analysis using FAC SCAN (Becton Dickinson) 
and 25,000 events were recorded passing a A,=488nm argon ion laser. Forward and 
side scatter were measured and plotted on XY axis. The mean value for each axis 
was recorded for each cell type.
To compare the two cell lines at the same time, wild type cells were incubated with 
Vybrant™ CFDA SE (carboxy-fluorescein diacetate, succinimidyl ester) for 10 
minutes at 37°C. Cells were washed and then left to rest for 30 minutes at room 
temperature. Cells were washed again and then mixed with annexin 1 -/- cells 
before analysis using FACS (see above).
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Chapter 3 -  Annexin 1 and MVB formation
3.1 Introduction
Annexins 1, 2 and 6 have been proposed to play roles in MVB formation and/or 
sorting within MVBs. The work described in this chapter focuses on annexin 1. 
Annexin 1 was proposed as a candidate protein in receptor sorting and/or MVB 
formation on the basis of its properties. Firstly, it interacts with both phospholipid 
membranes and the actin cytoskeleton (Glenney, Jr. et al., 1987), and can promote 
vesicle fusion in vitro (Blackwood and Ernst, 1990). Secondly, annexin 1 is a 
major substrate for EGFR within MVBs, but not at the plasma membrane, 
providing a link between annexin 1 and endocytosed receptors (Futter et al., 1993). 
Thirdly, EGFR-mediated phosphorylation of annexin 1 N-terminus is proposed to 
modulate the membrane binding activity of annexin 1.
Phosphorylation of annexin 1 is believed to have two major effects. The first is the
 ^I
increased requirement for Ca in order to bind endosomal membranes (Haigler and 
Schlaepfer, 1990; Futter et al., 1993). An element of controversy over the Ca2+ 
dependency of annexin 1 for membrane binding exists, but experiments in living
' yi
cells showed that non-phosphorylated annexin 1 required intact Ca binding sites 
in order to bind to early endosomal membranes (Rescher et al., 2000). The 
discrepancy between these and earlier fractionation studies can be reconciled by the 
explanation that annexin 1 requires Ca2+ for association with endosomes, but once 
associated annexin 1 is not readily released by treatment with EDTA. The second 
effect of annexin 1 phosphorylation is an increased susceptibility to N-terminal 
proteolysis (Chuah and Pallen, 1989; Ando et al., 1989). The N-terminal domain 
contains both the early endosomal localisation signal and the S100A11 binding site 
(Seemann et al., 1996b; Rosengarth et al., 2001). Loss of the N-terminus results in 
a relocalisation of annexin 1 from early endosomes to late endosomes (Seemann et 
al., 1996b; Rescher et al., 2000).
It has been proposed that annexin 1 and S100A11 could organise the limiting 
membrane for inward vesiculation. However, it is important to note that the 
heterotetrameric complex between annexin 1 and S100A11 has only been
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demonstrated in vitro and it is not known whether it exists in vivo. Loss of the N- 
terminus, and thus loss of the S100A11 binding site, has been proposed to disrupt 
the heterotetrameric complex and allow internal vesicle fission (Gerke and Moss, 
2002). Additionally, it was proposed that the release of annexin 1, through 
phosphorylation induced Ca2+ dependency, may be required for the release of 
vesicles into the lumen of the MVB (Gerke and Moss, 2002).
The aim of this work was to identify the exact nature of the role of annexin 1 in the 
formation of MVBs. Initially, an annexin 1 -/- cell line derived from an annexin 1 
knockout mouse was used for this work (Hannon et al., 2002; Croxtall et al., 2003), 
but more recently it was possible to deplete levels of annexin 1 using RNAi 
technology. In cells lacking annexin 1, or with decreased levels of annexin 1, there 
was a reduction in numbers of internal vesicles in MVBs, although internal vesicles 
could still form. In the first set of experiments, EGF-stimulated cells were used so 
that an anti-EGFR antibody coupled to gold could be used as a marker of MVBs. 
Subsequently, by comparing EGF-stimulated cells with unstimulated cells, it was 
demonstrated that EGF stimulation increases inward vesiculation within MVBs. 
Basal inward vesiculation was unaffected by loss of annexin 1, but EGF stimulation 
of inward vesiculation is dependent on tyrosine phosphorylation of annexin 1.
3.2 Results
3.2.1 Loss o f annexin 1 does not affect MVB formation
JACRO cells are lung fibroblast cell lines derived from either a wild type mouse or 
an annexin 1 -/- mouse (Hannon et al., 2002; Croxtall et al., 2003). To confirm that 
annexin 1 -/- cells did not express annexin 1, JACRO cell lysates were collected 
and blotted for tubulin, to ensure equal protein loading, and annexin 1 (Fig.3.1a). 
Annexin 1 protein was undetectable in annexin 1 -/- cells, compared with JACRO 
wild type cells. The same cell lysates were also blotted for other annexins to 
observe whether the loss of annexin 1 affected the expression of other annexin 
family members (Fig. 3.1a). Annexin 1 -/- cells show increased levels of annexins 
2 and 6 compared with wild type cells, which is consistent with published data 
(Croxtall et al., 2003). The expression of EGFR varies between cell lines and, as
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one of the aims of this work was to investigate EGFR trafficking in the absence of 
annexin 1, the level of EGFR expression by JACRO cells was compared with that 
of HeLa cells, a human cell line known to express moderate levels of receptor (Fig. 
3.1b). Both JACRO cell lines express much lower levels of EGFR than HeLa cells.
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Figure 3.1. Expression o f annexins in JACRO cells. JACRO wild type (WT) and 
annexin 1 -/- (-/-) cell lysates were blotted with antibodies against tubulin and 
annexin 1 to confirm -/- cells did not express annexin 1 (A). Lysates were also 
blotted for annexin 2 and annexin 6, both of which were upregulated in annexin 1 - 
/- cells. To compare levels of EGFR expression, HeLa (H) and JACRO cell lysates 
were blotted with anti-EGFR, anti-tubulin and anti-annexin 1 (B). JACRO cells 
expressed lower levels of EGFR compared to HeLa cells.
A major reason for investigating annexin 1 was to follow up a published study that 
identified annexin 1 as a substrate for EGFR within MVBs, and led to the proposal 
that annexin 1 participates in the formation of internal vesicles within MVBs 
(Futter et al., 1993). To observe whether loss of annexin 1 had an effect on MVB 
formation, JACRO cells were serum starved, incubated with EGF conjugated to 
HRP (horseradish peroxidase) for 1 hour, and processed for transmission electron 
microscopy (TEM), as described in Materials & Methods section 2.11.2, including 
the DAB reaction to visualise HRP. EGF-HRP, visible as the dark DAB reaction 
product, was visible in many structures in both cell lines. The morphology of EGF- 
HRP containing MVBs was observed in wild type cells (Fig. 3.2) and revealed the 
presence of multiple EGF-HRP positive internal vesicles. EGF-HRP was also 
present in the lysosomes of wild type cells. In annexin 1 -/- cells, the morphology 
of MVBs was noticeably different, as they contained fewer internal vesicles than 
those seen in wild type cells. However, some of the small number of internal 
vesicles that formed still labelled with EGF-HRP, which was also found in the 
lysosomes of annexin 1 -/- cells.
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Figure 3.2. Analysis o f MVB morphology in JACRO cells. JACRO cells were 
serum starved for 1 hour before stimulation with EGF-HRP for a further hour at 
37°C. Cells were processed for TEM, including the DAB reaction. Ultrathin 
sections were cut and the morphology of MVBs analysed. Electron micrographs 
show typical EGF-HRP containing MVBs and lysosomes (L) from both cell lines. 
MVBs from annexin 1 -/- cells contained fewer internal vesicles, although EGF- 
HRP was present in lysosomes in both cell lines. Bar = 200nm.
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These findings indicate that loss of annexin 1 inhibits the formation of internal 
vesicles within MVBs. However, the HRP/DAB reaction product can obscure the 
internal membranes of the MVB making it difficult to identify individual vesicles. 
To follow traffic of EGFR by TEM, a human specific anti-EGFR antibody (108) 
coupled to lOnm gold (anti-hEGFR-gold) (Bellot et a l , 1990) has previously been 
used and shown not to affect the trafficking of EGFR (Futter et al., 1993; Futter et 
al., 1996; Futter et al., 2001). However, as the 108 antibody is human specific, it 
will not recognise the endogenous (mouse) EGFR expressed by JACRO cells. 
Therefore, it was necessary to transfect JACRO cell lines with human EGFR 
(hEGFR). This enabled the use of anti-hEGFR-gold, allowing individual internal 
vesicles to be counted, and also increased receptor expression to a level comparable 
with human cell lines, in which TEM detection of EGFR has been successful (Fig.
3.3 A).
To further analyse the effect of loss of annexin 1 on the formation of MVBs, 
JACRO cells were transfected with hEGFR for 24 hours. Cells were serum starved 
for 1 hour before stimulation with EGF, in the presence of anti-hEGFR-gold, for a 
further hour. Cells were processed for TEM and successfully transfected cells were 
identified by the presence of anti-hEGFR-gold, as the antibody does not recognise 
endogenous (mouse) receptors. The morphology of MVBs was observed (Fig. 
3.3B). MVBs were present in both cell lines but in annexin 1 -/- cells anti-hEGFR- 
gold positive MVBs contained fewer internal vesicles, as previously observed in 
MVBs from non-transfected -/- cells incubated with EGF-HRP. The electron 
micrographs in Fig. 3.3B represent typical MVBs from each cell line. The size of 
MVBs was not markedly different as larger MVBs were observed in both cell lines 
and images have been included to illustrate the size range of MVBs found in 
JACRO cells. There was less anti-hEGFR-gold in many of the annexin 1 -/- cells, 
and consequently less gold in MVBs, due to the fact that annexin 1 -/- cells were 
more difficult to transfect than wild type cells. However, in annexin 1 -/- cells that 
contain comparable amounts of hEGFR to wild type cells, anti-hEGFR-gold was 
visible in clusters at the perimeter membrane of MVBs containing few internal 
vesicles (Fig. 3.3B).
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Fig. 3.3. MVBs form in the absence o f annexin 1 but contain fewer internal 
vesicles. JACRO wild type (WT) and annexin 1 -/- (-/-) cells were transfected 
with hEGFR for 24 hours. HeLa (H) and JACRO cell lysates were blotted with 
antibodies against tubulin (to ensure equal loading), annexin 1 and EGFR, to 
detect receptor expression. Transfected JACRO cells expressed EGFR at a more 
comparable level to HeLa cells (A). Cells from these transfections were serum 
starved and stimulated with EGF (lOOng/ml), in the presence of anti-hEGFR- 
gold, for 1 hour. Cells were processed for TEM and the morphology of anti- 
hEGFR-gold containing MVBs observed (B). MVBs in annexin 1 -/- cells 
contained fewer internal vesicles than MVBs from wild type cells. Arrows point 
to areas of clustered gold at the perimeter membrane. Bar = 200nm.
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To quantify any effect of loss of annexin 1 on MVB formation, photos were taken 
at random of successfully transfected (i.e. anti-hEGFR-gold containing) JACRO 
cells. The area of cytoplasm per photo was measured and the number of MVBs 
containing anti-hEGFR-gold per photo recorded. MVBs were defined as vacuoles 
with a diameter > 200nm and containing one or more internal vesicles. The final 
number of MVBs was expressed per pm2 cytoplasm. Wild type cells contained an 
average of 0.065 MVBs per pm cytoplasm compared with 0.047 in annexin 1 -/- 
cells (Fig. 3.4), however this difference was not statistically significant. The area 
of each MVB was also measured (nm ), the mean calculated for each experiment 
and finally the mean of three experiments determined. Although MVBs in annexin 
1 -/- cells were slightly larger than in wild type cells, this difference was not 
significant (Fig. 3.5).
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Figure 3.4. Comparing numbers o f MVBs in JACRO cells. JACRO cells were 
transfected with hEGFR, serum starved and stimulated with EGF (lOOng/ml), in the 
presence of anti-hEGFR-gold, for 1 hour. Cells were processed for TEM and at least 20 
photos taken at random in anti-hEGFR-gold containing cells. The area of cytoplasm per 
photo was measured (nm2). Number of MVBs per experiment were counted and 
expressed as number of MVB per pm2 cytoplasm. Wild type cells contained slightly 
more MVBs than annexin 1 -/- cells but this difference was non-significant. Graph 
shows the mean ± SEM of three independent experiments.
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Figure 3.5. Loss o f annexin 1 does not alter the area o f MVBs. JACRO cells 
were transfected with hEGFR, serum starved and stimulated with EGF 
(lOOng/ml), in the presence of anti-hEGFR-gold, for 1 hour. Cells were processed 
for TEM and at least 20 photos taken at random in anti-hEGFR-gold containing 
cells. The area of MVBs was measured (nm2). The loss of annexin 1 did not alter 
the mean area of MVBs. Graph shows the mean ± SEM of three independent 
experiments.
3.2.2 Loss o f annexin 1 inhibits internal vesicle formation within MVBs.
In the above experiments, the number of internal vesicles in each MVB was also 
counted and the mean number per MVB calculated for each experiment (Fig. 3.6A). 
The mean number of internal vesicles per MVB in annexin 1 -/- cells was 
significantly reduced compared to that of wild type (12.3 ± 0.9 compared to 21.6 ±
1.5), confirming the results of the MVB morphology described above (Fig. 3.2 & 
3.3B). Although the mean number of internal vesicles per MVB was consistent 
between three independent experiments, within a single experiment there was a 
wide variation in the number of internal vesicles per MVB. Therefore, the effect of 
loss of annexin 1 on the distribution of number of internal vesicles per MVB was 
investigated, to observe whether loss of annexin 1 affected all MVBs or just those 
that contained higher numbers of internal vesicles.
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MVBs from both cell lines were divided into categories based on different numbers 
of internal vesicles (Fig. 3.6B). As different numbers of MVBs were counted in 
each experiment, the number of MVBs in each group was expressed as a percentage 
of the total number of MVBs. The majority of MVBs from wild type cells 
contained 16 or more internal vesicles and the major effect of loss of annexin 1 was 
a shift in this trend towards the lower vesicle number categories. A significantly 
smaller percentage of MVBs from annexin 1 -/- cells contained more than 16 
internal vesicles and instead the majority contained between 6 and 15 internal 
vesicles. These data show that loss of annexin 1 inhibits internal vesicle formation 
and results in fewer MVBs that contain high numbers of internal vesicles.
As JACRO wild type and annexin 1 -/- cells were derived from two different mice, 
it was possible that the differences observed in numbers of internal vesicles per 
MVB were due to factors other than the presence or absence of annexin 1. In order 
to provide further evidence that the reduction in numbers of internal vesicles per 
MVB was due to the loss of annexin 1, a method was devised to manipulate 
annexin 1 levels in cells so that the effects of annexin 1 depletion on internal 
vesicle formation could be examined in a single cell line.
The use of RNAi technology to deplete protein levels has increased rapidly since 
the beginning of these studies. Use of RNAi to knockdown annexin 1 has not been 
published; therefore it was necessary to optimise the design of RNAi 
oligonucleotides, and the methods and timing of transfections to obtain consistent 
annexin 1 depletion. Annexin 1 is an abundant protein and, in some cell types, the 
annexins constitute up to 1% of total cell protein. Unlike many other proteins, 
annexins are relatively stable proteins with long half lives, and work from the Moss 
group has shown that depletion of other members of the annexin family requires at 
least 3 days (Tomas et al., 2004).
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Figure 3.6. Loss o f annexin 1 reduces the number o f internal vesicles per MVB. 
JACRO cells were transfected with hEGFR, serum starved and stimulated with 
EGF (lOOng/ml), in the presence of anti-hEGFR-gold, for 1 hour. Cells were 
processed for TEM and at least 20 photos taken at random in anti-hEGFR-gold 
containing cells. The mean number of internal vesicles per MVB was calculated 
(A). MVBs from these experiments were divided into groups according to number 
of internal vesicles, and expressed as a percentage of the total number of MVBs, to 
show the distribution of internal vesicles per MVB (B). MVBs from annexin 1 -/- 
cells contained fewer internal vesicles than those of wild type cells. Graph shows 
mean ± SEM of three independent experiments. ** p<0.01
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Figure 3.7 shows the results of annexin 1 RNAi experiments using different 
oligonucleotides designed against annexin 1, different cell lines and different 
methods of transfection. Cells were transfected with RNAi for 3 days, lysates 
collected on day 3 and blotted for tubulin and annexin 1. In the same experiment, 
cells were split 1:3 on day 3, allowed to settle and re-transfected with RNAi for a 
further 3 days. The first 3 oligonucleotides tested had no effect on annexin 1 levels 
in HeLa cells after 3 or 6 days (Fig. 3.7A). Therefore, oligonucleotide LBA1B was 
used as a control in subsequent experiments. A new annexin 1 oligonucleotide 
(LBAIX) was designed and used in HeLa, HEp2 and A431 cells, as published data 
reported successful knockdown of annexin 11 in A431 cells after 3 days (Tomas et 
al., 2004). Indeed, after 3 days there was a visible reduction in annexin 1 levels in 
HeLa and A431 cells, but no change was observed in HEp2 cells (Fig. 3.7B).
At this time a new method of transfection, nucleofection, became available to the 
lab (see Materials and Methods section 2.4.2) and was reported to efficiently 
deliver RNAi oligonucleotides into cells that are difficult to transfect. 
Subsequently, nucleofection was used to transfect a combination of 
oligonucleotides (LBA1A and LBA1X) into cells (Fig. 3.7C). Ideally this method 
would have been used to knockdown annexin 1 in JACRO wild type cells, to 
provide a direct comparison with the annexin 1 -/- cell line, but although LBA1X 
was designed against the human and mouse annexin 1 sequence, there was no 
reduction of annexin 1 in JACRO wild type cells after 3 days (Fig. 3.7D). 
Nucleofection with these oligonucleotides proved to be the most successful method 
in human cell lines and was used to deplete annexin 1 in HeLa cells for all 
subsequent annexin 1 RNAi experiments. The same cell lysates were also blotted 
with an anti-annexin 2 antibody, to determine whether annexin 1 depletion altered 
levels of annexin 2. In cells treated with annexin 1 RNAi, levels of annexin 2 were 
slightly increased (Fig. 3.7D). Semi-quantitative analysis of several independent 
experiments showed that annexin 1 RNAi treatment reduced annexin 1 levels by 
-60% in HeLa cells (Fig. 3.6E).
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Figure 3.7. RNAi-induced depletion o f annexin 1. A. HeLa cells were transfected with 
annexin 1 RNAi oligonucleotides (LB A IB, -C, -D) or no RNAi (N) for 3 days and 
lysates blotted for tubulin (loading control) and annexin 1, or transfected, split on day 3, 
retransfected & collected on day 6. No decrease in annexin 1 was observed. B. HeLa, 
HEp2 and A431 cells were treated with LBA1B (control) or LBA1X (annexin 1). After 
3 days annexin 1 was slightly reduced in HeLa and A431 cells. C. HeLa, A431 and 
JACRO wild type cells were nucleofected with control or LBA1A & LBA1X for 24 
hours, re-nucleofected and plated out for 48 hours before collecting for western blotting. 
There was significant reduction in annexin 1 levels in HeLa and A431 cells. D. Lysates 
were blotted for annexin 2 expression to determine whether it was upregulated in 
annexin 1 depleted HeLa cells. E. Semi-quantitative analysis of annexin 1 depletion was 
performed by measuring and comparing intensity of annexin 1 signals from at least 5 
independent RNAi experiments in HeLa cells (see Materials & Methods section 2.4.2). 
*** p<0.001. All blots are representative of several experiments.
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Control and annexin 1 RNAi-treated HeLa cells were serum starved, stimulated 
with EGF, in the presence of anti-hEGFR-gold, for 1 hour and processed for TEM. 
As observed in JACRO annexin 1 -/- cells, RNAi-induced annexin 1 depletion had 
little effect on the number of anti-hEGFR-gold containing MVBs formed. In 
control RNAi-treated HeLa cells there were 0.064 MVBs per pm2 cytoplasm (Fig. 
3.8). This number was slightly reduced (to 0.053) in annexin 1 RNAi-treated cells 
but this difference was not significant. Similarly, there was no difference in the 
area of MVBs between control and annexin 1 RNAi-treated cells (Fig. 3.9). The 
mean area of MVBs from control cells was slightly larger than that of MVBs from 
annexin 1 RNAi treated cells, but this was not significant (91000nm compared to 
89000nm2).
However, when comparing the morphology of MVBs from cells depleted for 
annexin 1 with control cells, it was noted that many MVBs from annexin 1 RNAi- 
treated cells contained fewer internal vesicles (Fig. 3.10A). To quantitate this 
difference, the number of internal vesicles per anti-hEGFR-gold containing MVB 
was recorded and the mean per experiment calculated, as described previously for 
JACRO cells. MVBs from annexin 1 RNAi-treated HeLa cells contained 
significantly fewer internal vesicles on average compared to MVBs from control 
cells (12.4 ± 0.74 in RNAi-treated cells compared to 19.5 ± 1.1 in control cells) 
(Fig. 3.10B). When MVBs from annexin 1 RNAi-treated HeLa cells were 
categorised based on numbers of internal vesicles, the trend observed was similar to 
that seen previously in JACRO annexin 1 -/- cells (Fig. 3.11). In control cells the 
majority of MVBs contained between 11 and 25 internal vesicles, whereas in 
annexin 1 RNAi-treated cells the majority shifted to between 6 and 15 internal 
vesicles. These data confirm that loss of annexin 1 affects inward vesiculation in 
EGF-stimulated cells.
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Figure 3.8. Comparing numbers o f MVBs in control and annexin 1 RNAi treated 
cells. HeLa cells were transfected with control or annexin 1 RNAi for 3 days, serum 
starved and treated with EGF (lOOng/ml), in the presence of anti-hEGFR-gold, for 1 
hour. Cells were processed for TEM and at least 20 photos were taken of cells at 
random. The area of cytoplasm per photo was measured. Numbers of anti-hEGFR- 
gold containing MVBs per experiment were counted and expressed as number of 
MVB per pm2 cytoplasm. There was a slight, non-significant, reduction in number of 
MVBs in annexin 1 RNAi treated cells. Graph shows the mean ± SEM of three 
independent experiments.
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Figure 3.9. Annexin 1 depletion does not alter area o f MVBs. HeLa cells were 
transfected with control or annexin 1 RNAi for 3 days, serum starved and treated with 
EGF (lOOng/ml), in the presence of anti-hEGFR-gold, for 1 hour. Cells were 
processed for TEM and at least 20 photos were taken at random of cells. The area 
(nm2) of each anti-hEGFR-gold containing MVB was measured. There was no 
difference in the average area of MVBs from control or annexin 1 RNAi treated cells. 
Graph shows the mean ± SEM of three independent experiments.
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Figure 3.10. Annexin 1 depletion reduces the number o f internal vesicles per MVB. HeLa 
cells were transfected with control or annexin 1 RNAi for 3 days, serum starved and treated 
with EGF (lOOng/ml), in the presence of anti-hEGFR-gold, for 1 hour. Cells were 
processed for TEM to analyse the morphology of MVBs (A). At least 20 photos were taken 
at random and the number of internal vesicles per hEGFR-gold containing MVB was 
recorded (B). RNAi-induced annexin 1 depletion resulted in fewer internal vesicles per 
MVB. Graph shows mean ± SEM of three independent experiments. * p<0.05.
Bar = 200nm.
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Figure 3.11. Annexin 1 depletion alters the distribution o f number o f internal vesicles 
per MVB. Number of internal vesicles per MVB was calculated as described 
previously. For each experiment MVBs were divided into groups depending on how 
many internal vesicles they contained. For each group the number of MVBs was 
expressed as a percentage of total number of MVBs. Annexin 1 depletion resulted in 
a higher percentage of MVBs containing less than 11 internal vesicles. Graph shows 
mean ± SEM of three independent experiments. ** p<0.01 * p<0.05.
3.2.3 EGF-stimulated MVB formation occurs independently o f annexin 1
Annexin 1 is a major substrate of the EGFR tyrosine kinase (Haigler et al., 1987; 
Futter et al., 1993), but it was not clear from the above experiments whether EGF- 
stimulated phosphorylation of annexin 1 was required for the process of inward 
vesiculation as all cells were stimulated with EGF. EGFR is frequently used as a 
marker of MVB formation and so many studies investigating MVB formation and 
function have used EGF-stimulated cells. Unpublished observations, from the 
Futter group, have noted a much higher frequency of MVBs in EGF-stimulated 
cells, but these effects have never been documented. Therefore, experiments were 
designed that would both quantitate the effects of EGF stimulation on MVB 
formation and inward vesiculation, and determine whether these effects were 
dependent upon annexin 1.
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To explore the effect of EGF stimulation on MVB formation, the above 
experiments were repeated using JACRO cells transfected with hEGFR, and 
comparing the effects of serum starvation with serum starvation followed by EGF 
stimulation. In these experiments it was necessary to count all MVBs, rather than 
only those that contain anti-hEGFR-gold, as in serum starved cells EGFR is not 
found in MVBs. EGF stimulation induced a significant increase in numbers of 
MVBs in both wild type and annexin 1 -/- cells (Fig. 3.12). In unstimulated cells 
the mean number of MVBs per pm2 cytoplasm was the same (-0.028) in both cell 
lines. After EGF stimulation this number increased in both wild type and annexin 1 
-/- cells, to 0.082 ± 0.009 and 0.067 ± 0.003, respectively. The small difference 
between numbers of MVBs in EGF-stimulated wild type and annexin 1 -/- cells was 
shown to be non-significant using Student’s t test analysis, indicating that EGF 
stimulated MVB formation occurs independently of annexin 1.
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Figure 3.12. EGF stimulates MVB formation in JACRO cells. JACRO cells were 
transfected with hEGFR, serum starved and incubated in serum free medium for a further 
hour or stimulated with EGF (lOOng/ml), in the presence of anti-hEGFR-gold, for 1 hour. 
Cells were processed for TEM and at least 20 random photos taken of cells. The area of 
cytoplasm per photo was measured, the total number of MVBs per experiment counted 
and expressed per pm cytoplasm. EGF stimulation increased the number of MVBs in 
both cell lines. Graph shows the mean ± SEM of three independent experiments.
*** p<0.005 **p<0.01
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The area of MVBs in unstimulated and EGF-stimulated cells was measured, and the 
mean per experiment calculated. EGF stimulation significantly increased the mean 
area of MVBs in both cell lines (Fig. 3.13). The effect of EGF stimulation 
observed in annexin 1 -/- cells was more extreme; the average area of MVBs 
increased from 79720 nm2 ± 13900 to 119700 nm2 ± 2097. However, the 
difference between cell lines was not significant, showing that the EGF-stimulated 
increase in MVB area does not require annexin 1.
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Figure 3.13. EGF stimulation increases the mean area o f MVBs. JACRO cells were 
transfected with hEGFR, serum starved and incubated in serum free medium for a 
further hour or stimulated with EGF (lOOng/ml), in the presence of anti-hEGFR-gold, 
for 1 hour. Cells were processed for TEM and at least 20 photos taken of cells at 
random. The area of all MVBs (nm2) was measured. EGF stimulation increased the 
mean area of MVBs in both cell lines. Graph shows mean ± SEM of three independent 
experiments. * p<0.05
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3.2.4 EGF stimulation increases internal vesicle formation in an annexin 1- 
dependent manner.
The data shown here provides evidence that loss of annexin 1 reduced numbers of 
internal vesicles in MVBs from EGF-stimulated cells (Fig. 3.6). To examine the 
full effect of EGF stimulation on inward vesiculation, the morphology of MVBs 
from unstimulated and EGF stimulated cells was observed using TEM (Fig.3.14A), 
and the mean number of internal vesicles per MVB calculated (Fig. 3.14B). EGF- 
stimulation of wild type cells significantly increased the mean number of internal 
vesicles per MVB over that of unstimulated cells (12.5 ± 0.8 increased to 17.5 ± 
1.1). However, in EGF-stimulated annexin 1 -/- cells no increase was observed in 
the number of internal vesicles compared to unstimulated cells. Although the slight 
difference in number of internal vesicles between unstimulated wild type and 
annexin -/- cells (12.5 compared to 10.5) was non-significant, the difference 
between EGF-stimulated wild type and annexin -/- cells was statistically 
significant.
The data above show that EGF induced an increase in numbers of internal vesicles 
per MVB in wild type cells. That this did not occur in annexin 1 -/- cells 
demonstrates that EGF stimulation of inward vesiculation is mediated through 
annexin 1. To further investigate the effect of EGF stimulation on the process of 
inward vesiculation, the distribution of numbers of internal vesicle per MVB was 
observed and compared between unstimulated and EGF stimulated cells (Fig. 3.15). 
In unstimulated cells, the majority of MVBs from both cell lines contained between 
6 and 16 internal vesicles, which is consistent with the average number of internal 
vesicles (~11 per MVB). However, EGF stimulation altered the distribution of 
number of internal vesicles per MVB in wild type cells so that a large proportion 
contained more than 16 internal vesicles (Fig. 3.15a). This EGF-mediated increase 
is also consistent with the increase observed in the average number of internal 
vesicles.
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Figure 3.14. Loss o f annexin 1 inhibits EGF-stimulated increase in internal vesicle 
formation. JACRO cells were transfected with hEGFR for 24 hours and serum starved 
for 1 hour. Cells were either kept in serum free medium or stimulated using EGF 
(lOOng/ml), in the presence of hEGFR-gold, for 1 hour. Cells were processed for 
TEM and the morphology of MVBs in unstimulated or EGF-stimulated cells observed
(A). Electron micrographs show typical MVBs from wild type and annexin 1 -/- cells. 
The number of internal vesicles per MVB was recorded for all MVBs in both 
unstimulated (white) and stimulated (black) cells. EGF stimulated an increase in 
number of internal vesicles in MVBs from wild type cells only. Graph shows mean ± 
SEM of three independent experiments. * p<0.05.
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Figure 3.15. EGF increases number o f internal vesicles per MVB in JACRO wild 
type cells. MVBs were divided into groups according to numbers of internal 
vesicles. For each group the number of MVBs was expressed as a percentage of 
total MVBs. Graph shows mean ± SEM of three independent experiments 
comparing unstimulated and EGF-stimulated wild type (A) or annexin 1 -/- cells
(B). EGF stimulation altered the distribution of internal vesicles per MVB in wild 
type cells only. ** p<0.01, * p<0.05
In EGF-stimulated annexin 1 -/- cells no difference was observed in the distribution 
of numbers of internal vesicles per MVB compared with unstimulated cells (Fig. 
3.15B). This finding is consistent with that derived from the previous figure, which 
showed that EGF stimulation had no effect on the average number of internal
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vesicles per MVB. Therefore, these data further confirm that EGF stimulation 
increases internal vesicle formation in an annexin 1-dependent manner.
The above data show that EGF stimulation increases the number of MVBs, and also 
the number of internal vesicles per MVB, in JACRO wild type cells. Only the 
latter phenotype is affected by loss of annexin 1. Whilst performing these 
experiments, it was noted that not all MVBs, in EGF-stimulated cells, contained 
anti-hEGFR-gold. Having observed that the number of MVBs and internal vesicles 
per MVB was unaffected by loss of annexin 1 in unstimulated cells, annexin 1 is 
clearly not essential for formation of all MVBs or inward vesiculation within these 
structures. Taken together these findings posed the interesting question of whether 
annexin 1 mediates the formation of internal vesicles in all MVBs after EGF 
stimulation, or just the sub-population that contains EGFR. Therefore, MVBs from 
JACRO cells transfected with, and expressing, hEGFR were divided into those 
containing anti-hEGFR-gold and those that did not (Fig. 3.16).
In EGF-stimulated JACRO wild type cells, comparison of the mean number of 
internal vesicles in the two MVB sub-populations revealed that those containing 
anti-hEGFR-gold had significantly more internal vesicles than those without anti- 
hEGFR-gold (21.16 ± 0.67 compared to 14.1 ± 1.46). In EGF-stimulated annexin 1 
-/- cells, two sub-populations were also observed i.e. those that contained anti- 
hEGFR-gold and those that did not. In contrast to wild type cells, there was no 
difference observed in the number of internal vesicles per MVB between those 
containing anti-hEGFR-gold and those without gold in annexin 1 -/- cells (10.89 ± 
1.141 compared to 10.78 ± 1.71). These findings are consistent with earlier data 
showing that EGF-stimulates inward vesiculation through annexin 1, and provide 
evidence that this is only in a sub-population of MVBs that contain EGFR.
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Figure 3.16. MVBs with hEGFR-gold contain more internal vesicles in wild type 
cells. From the previous experiment MVBs from EGF-stimulated hEGFR-expressing 
(i.e. anti-hEGFR-gold containing) JACRO cells were divided into MVBs containing 
one or more anti-hEGFR-gold particles (black), and MVBs that did not contain gold 
(grey). The average number of internal vesicles in these MVBs was calculated. Anti- 
hEGFR-gold containing MVBs from wild type cells contained more internal vesicles 
than MVBs without gold, but no difference was observed in annexin 1 -/- cells. 
Graph shows mean ± SEM of three independent experiments. * p<0.05 ** p<0.01 
ns = non significant.
3.2.5 Reversal o f phenotype observed in annexin 1 -/- cells
The data described above is consistent with previous published data implicating 
annexin 1 in the formation of internal vesicles within MVBs (Futter et al., 1993). 
Although annexin 1 was found not to be necessary for formation of MVBs, it is 
necessary for EGF-stimulated inward vesiculation. To confirm that the phenotype 
observed in JACRO annexin 1 -/- cells was a direct consequence of the loss of 
annexin 1, it was necessary to re-express annexin 1 in annexin 1 -/- cells, to try to 
reverse the phenotype.
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For use in these phenotype reversion experiments, and in future localisation studies, 
an annexin 1-GFP chimera was created (see Materials and Methods section 2.3.1). 
Annexin 1 was amplified by PCR using primers designed to contain Xhol and 
BamHl restriction sites, respectively (Fig. 3.17a). Annexin 1 and pGFP-Nl were 
digested with Xhol and BamHl and digested pGFP-Nl was incubated with calf 
intestinal phosphatase (CIP) to prevent plasmid religation. Digested annexin 1 and 
pGFP-Nl were used (3:1) in ligation reactions and the product was used to 
transform supercompetent E. coli. Colonies that grew on selective LB agar were 
assumed to contain annexin 1-GFP constructs (and thus the antibiotic resistance 
gene). Twelve colonies were picked and plasmids extracted, purified and digested 
with Xhol and BamHl to check for presence of annexin 1 insert (Fig. 3.17). One 
contained the correct size insert (lane 7). DNA from this colony was used to make 
more copies of the plasmid, and second round plasmids were checked by restriction 
digests (Fig. 3.17). Single digestions (with Xhol, BamHl or Xmal) resulted in 
linearisation of the plasmid construct and a band of ~5.5kb, visible on 1% agarose 
gel. Double digestion with Xhol and BamHl cut out the annexin 1 insert, which 
was visible as 1.2kb band. The annexin 1-GFP construct was sequenced to check 
for the presence of mutations and none were found when compared with wild type 
annexin 1 sequence (see Appendix 1, Fig. S.3).
Initially JACRO annexin 1 -/- cells were transiently transfected with annexin 1- 
GFP, to test the expression of this construct (Fig. 3.18). In cells expressing high 
levels of annexin 1-GFP, the construct was visible in the nucleus and throughout 
the cytoplasm, with little intracellular detail. In cells expressing lower levels of 
annexin 1-GFP, punctate labelling was observed in the cytoplasm. JACRO 
annexin 1 -/- cells were then transfected with annexin 1-GFP to make a stable cell 
line. However, creation of a stable cell line proved difficult due to cell death 
(personal observations and communication with Jamie Croxtall). Therefore, 
transient transfections had to be used. Despite obtaining an adequate level of 
transient transfection efficiency (-65%), this was insufficient to assume that the 
majority of cells would be transfected, especially as there was no way to determine 
which cells were expressing annexin 1-GFP in intact cells using TEM.
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Figure 3.17. Annexin 1-GFP construction. Primers were designed to amplify 
annexin 1 and create Xhol and BamHl restriction sites (A). Bases in italics indicate 
bases changed to allow restriction site but keep annexin 1 in frame. Underlined 
sequences show restriction sites. Annexin 1 and pGFP-Nl were digested with Xhol 
and BamHl, treated with CIP and used in a ligation reaction. Ligations were used to 
transform supercompetent E.coli and plasmids were purified from these bacterial 
colonies. These samples were digested using Xhol and BamHl to check for the 
presence of the correct size plasmid and insert (B). Lane 7 shows a band of 1.2kb that 
corresponds to annexin 1. DNA from samples 2 and 7 were digested again (C). 
Digested pGFP-Nl and annexin 1 were also loaded in lane A as a control. Sample 7 
(annexin 1 -GFP) was digested with Xhol (Lane 2), BamHl (3), Xhol and BamHl (4) 
or Xmal (5). Lanes 1 & 6 were loaded with X marker and lkb marker respectively. 
Lanes 2, 3 & 5 show the presence of linearised plasmid (~5.5kb), whereas lane 4 
shows a smaller linearised plasmid (~4.3kb) and annexin 1 insert (1.2kb)
Forward primer -  5 ’ -C AAGAAGCTCGAGATAAAGACACG-3 ’ 
Reverse primer -  5 ’ -CAAGGGGATCCGCGGTTTCCTCC-3 ’
1 2 3 4 5 6 7 8 9 10 11 12
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Figure 3.18. Transient expression o f  annexin 1-GFP in annexin 1 -/- cells. JACRO 
annexin 1 -/- cells were transiently transfected with annexin 1-GFP using 
nucleofection. Cells were imaged using confocal microscopy 24-hours post­
transfection. Annexin 1-GFP expression was observed throughout the cytoplasm and 
in the nucleus of some cells. Stars indicate cells non-expressing cells. Bars = 20pm.
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Figure 3.19. Re-expression o f  annexin 1 in JACRO annexin 1 -/- cells. JACRO 
annexin 1 -/- cells were transfected with annexin 1-GFP or annexin 1-GFP and 
hEGFR. Cell lysates were collected and blotted with anti-annexin 1 and anti-tubulin. 
Non-transfected JACRO wild type and annexin 1 -/- cells are included for 
comparison. Transfected cells blotted with an anti-annexin 1 antibody showed a band 
of approximately ~65kDa, which corresponds to the size of annexin 1-GFP.
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Therefore, JACRO annexin 1 -/- cells were co-transfected with hEGFR and annexin
1-GFP, to be able to identify successfully transfected cells using anti-hEGFR-gold, 
assuming that cells expressing hEGFR would also express annexin 1-GFP. Figure 
3.19 shows western blot analysis of non-transfected JACRO cells and JACRO 
annexin 1 -/- cells transfected with either annexin 1-GFP or co-transfected with 
annexin 1-GFP and hEGFR (co-transfected cells). Annexin 1 -/- cells transfected 
with annexin 1-GFP express relatively low levels of annexin 1-GFP, compared with 
endogenous annexin 1 levels in JACRO wild type cells. Annexin 1 -/- cells co­
transfected with annexin 1-GFP and hEGFR expressed similar levels of annexin 1- 
GFP to those only transfected with annexin 1-GFP, but expressed higher levels of 
EGFR.
Co-transfected JACRO annexin 1 -/- cells were serum starved and stimulated with 
EGF, in the presence of anti-hEGFR-gold, for 1 hour. As loss of annexin 1 had 
little or no effect on the total number of MVBs, this was not measured. Instead, the 
morphology of MVBs was observed and the number of internal vesicles per MVB 
was recorded, both for hEGFR expressing cells (i.e. those containing gold) and for 
non-expressing cells (devoid of gold) (Fig. 3.20). In successfully co-transfected 
cells (identified by the presence of anti-hEGFR-gold), many MVBs had regained 
the appearance of those observed in wild type JACRO cells, i.e. contained more 
internal vesicles. In contrast, MVBs from co-transfected but non-expressing cells 
had fewer internal vesicles. These MVBs resembled those observed in annexin 1 - 
/- cells that had been transfected with hEGFR alone (Fig. 3.3B). The average 
number of internal vesicles per MVB from hEGFR-expressing, co-transfected cells 
was significantly higher than the average number in co-transfected but non­
expressing cells (Fig. 3.21 A).
Data from wild type and annexin 1 -/- cells, transfected with hEGFR only, were 
collected for comparison and show that there was no difference in the average 
number of internal vesicles per MVB between cells expressing hEGFR and non­
expressing cells (Fig. 3.21 A). This confirms that overexpression of hEGFR in 
JACRO cells had no effect on inward vesiculation and also shows that the increase 
in numbers of internal vesicles per MVB observed in successfully co-transfected
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Figure 3.20. MVB morphology after re-expression o f annexin 1 in -/- cells. JACRO 
annexin 1 -/- cells were co-transfected with annexin 1-GFP and hEGFR to re-express 
annexin 1 and reverse the effect of loss of annexin 1 on the number internal vesicles. 
After 24 hours cells were serum starved and stimulated with EGF (lOOng/ml), in the 
presence of anti-hEGFR-gold, for 1 hour. Cells were processed for TEM and the 
morphology of MVBs analysed. (A) Typical MVBs in co-transfected annexin 1 -/- 
cells not expressing hEGFR. These MVBs contained few internal vesicles. (B) 
Typical MVBs from co-transfected annexin 1 -/- cells expressing hEGFR, showing 
increased numbers of internal vesicles. Bars = 200nm.
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annexin 1 -/- cells is solely due to the expression of annexin 1-GFP. Although the 
mean number of internal vesicles per MVB was increased in successfully co­
transfected cells, this number was significantly less than that observed in wild type 
cells (either expressing or non-expressing). Therefore, only a partial reversion of 
phenotype was observed. The lack of total reversion could be due to the fact that 
while some cells express hEGFR they may not also express annexin 1-GFP and 
would therefore possess MVBs with few internal vesicles, characteristic of annexin 
1 -/- cells. Another possible reason for the partial reversal could be that, although 
cells were expressing annexin 1-GFP, expression may not be at sufficient levels to 
reverse the phenotype fully.
To further investigate whether re-expression of annexin 1 in annexin 1 -/- cells 
could reverse the decrease in internal vesicle formation, the distribution of number 
of internal vesicles per MVB was analysed in co-transfected cells, comparing cells 
expressing hEGFR and those not expressing hEGFR (Fig. 3.2IB). Successfully co­
transfected (hEGFR expressing) cells contained a significantly higher percentage of 
MVBs with more than 16 internal vesicles compared to untransfected cells (not- 
expressing hEGFR). In these non-expressing cells, the majority of MVBs 
contained between 6 and 15 internal vesicles, which is comparable to annexin 1 -/- 
cells only transfected with hEGFR from previous experiments.
Finally, MVBs from successfully co-transfected cells were divided into the two 
sub-populations (with or without anti-hEGFR-gold), to observe whether re­
expression of annexin 1 increased the number of internal vesicles in all MVBs or 
just the EGFR-containing population (Fig. 3.22). MVBs containing anti-hEGFR- 
gold contained significantly more internal vesicles compared to MVBs that did not 
contain EGFR-gold (16.25 ± 0.58 compared to 9.78 ± 0.46). Expression of hEGFR 
alone in JACRO cells had no effect on inward vesiculation compared to non­
expressing cells (Fig. 3.21). Similarly, there was no increase observed in the 
number of internal vesicles per anti-hEGFR-gold containing MVB in annexin 1 -/- 
cells, only transfected with hEGFR, compared to that seen in wild type cells (Fig. 
3.16). Taken together these results provide further confirmation that, following co­
transfection, a significant proportion of hEGFR-expressing annexin 1 -/- cells also 
express annexin 1.
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Figure 3.21. Re-expression o f annexin 1 in -/- cells increases the mean number o f 
internal vesicles. JACRO wild type and annexin 1 -/- cells transfected with hEGFR and 
annexin 1 -/- cells co-transfected with hEGFR and annexin 1-GFP (to reverse the 
phenotype seen in annexin 1 -/- cells) were serum starved and stimulated with EGF 
(lOOng/ml) and anti-hEGFR-gold for 1 hour. For each cell type or transfection all 
MVBs were counted in cells expressing hEGFR (black) or not expressing (grey) (A). 
MVBs from successfully co-transfected annexin 1 -/- cells (expressing hEGFR) 
contained more internal vesicles than non-expressing cells. MVBs from annexin 1 -/- 
cells co-transfected with annexin 1 and hEGFR were divided into categories according 
to numbers of internal vesicles (B). Graph shows mean ± SEM of three independent 
experiments. * p<0.05 ** p<0.01.
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Re-expression of annexin 1 in annexin 1 -/- cells resulted in a partial reversion of 
phenotype by increasing the number of internal vesicles in EGFR-containing MVBs 
in response to EGF stimulation.
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Figure 3.22. hEGFR-gold containing MVBs from co-transfected -/- cells have 
more internal vesicles. The average number of internal vesicles in MVBs from 
hEGFR-expressing annexin 1 -/- cells, co-transfected with annexin 1-GFP, was re­
calculated dividing MVBs into those containing anti-hEGFR-gold and those that 
did not. Unlike annexin 1 -/- cells transfected only with hEGFR, in co-transfected 
cells expressing hEGFR there was a significant difference between the number of 
internal vesicles in MVBs with or without anti-hEGFR-gold. *** p<0.005
3.3 Discussion
3.3.1 EGF stimulation increases MVB formation in an annexin 1 independent 
manner
The formation of MVBs occurs as part of a maturation process (van Deurs et al., 
1993), whereby the limiting membrane of an endosome is induced to invaginate 
and forms internal vesicles. Many proteins have been implicated in the formation 
of internal vesicles, or sorting of lysosomally directed receptors onto these vesicles, 
and some proteins have been implicated in both e.g. Hrs (Urbe et al., 2003; Bache 
et al., 2003a). It is widely believed that the membrane binding properties of 
annexin 1 allow the protein to play a role in the formation of MVBs, although the 
exact nature has not been fully investigated (Gerke and Moss, 2002).
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The results of the studies performed here show that MVBs are present in 
unstimulated cells, consistent with published work, which reports that MVBs form 
continuously (van Deurs et al., 1993). These published studies were performed 
using HRP as a fluid phase marker and show that, while the average diameter of 
these structures does not alter significantly with time, the number of internal 
vesicles increases as the structure matures (van Deurs et al., 1993). The data 
presented here, in both JACRO cell lines, show for the first time that EGF- 
stimulation significantly increases the total number of MVBs formed and the 
average MVB area, compared to unstimulated cells. These findings are consistent 
with unpublished work from the Futter group, using a human cell line (White et al., 
under revision), and indicate that EGF-stimulated MVB formation is a widespread 
phenomenon. Although there was a slight decrease in the total number of MVBs 
formed in annexin 1 -/- cells, this difference was not significant and indicates that 
the process of MVB formation occurs independently of annexin 1. The small 
decrease in numbers of MVBs could be explained by the fact that when MVBs 
containing few internal vesicles from annexin 1 -/- cells are sectioned, there is a 
possibility that in any given section there may be no internal vesicles and these 
structures will not be counted as MVBs.
The increase in numbers of MVBs upon EGF stimulation in JACRO cell lines is 
such that at least some MVBs must be formed de novo. However, these findings do 
not rule out the possibility that EGFR can also enter pre-existing MVBs and further 
work is required to determine whether this is true. The increased numbers of 
internal vesicles per MVB, coupled with the increased numbers of MVBs, indicate 
that there is a substantial increase in the amount of cell membrane being delivered 
to the lysosome for degradation.
3.3.2 Annexin 1 is required for the EGF-stimulated increase in inward vesiculation
In addition to increasing MVB formation, EGF-stimulation also increases the 
number of internal vesicles per MVB. These findings regarding EGF stimulation 
were made in mouse lung fibroblasts, but are consistent with unpublished work 
using a human cell line (White et al., under revision). As discussed above, neither 
the basal formation nor the EGF-stimulated formation of MVBs requires annexin 1.
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While formation of internal vesicles in MVBs from unstimulated cells occurs 
independently of annexin 1, EGF-stimulated inward vesiculation is mediated 
through annexin 1. The use of RNAi to deplete annexin 1 in HeLa cells confirmed 
that the EGF-stimulated formation of internal vesicles is inhibited in cells lacking 
annexin 1. These data show that MVB formation and inward vesiculation within 
MVBs are separate processes that are regulated independently.
The formation of internal vesicles was believed to be necessary for lysosomal 
delivery of EGFR, but more recently it was shown that while inhibition of inward 
vesiculation had little effect on receptor degradation, it led to enhanced signalling 
from the activated receptor (Futter et al., 2001). Therefore, it is possible that loss 
of annexin 1 could also enhance EGFR signalling through a failure to remove the 
tyrosine kinase domain from the cytoplasm.
3.3.3 Possible mechanisms for inward vesiculation
These data provide evidence that the mechanisms whereby EGF stimulation 
increases MVB formation and internal vesicle formation are distinct. However, it is 
probable that both mechanisms involve substrates of the EGFR tyrosine kinase or 
proteins that interact with phosphorylated EGFR. EGFR-mediated phosphorylation 
of c-Cbl activates c-Cbl ubiquitin ligase activity and induces receptor 
ubiquitination, which is believed to mediate receptor sorting onto internal vesicles 
of MVBs (Levkowitz et al., 1998; de Melker et al., 2001; Longva et al., 2002). Hrs 
is believed to mediate sorting of ubiquitinated receptors, and is a substrate of a 
kinase downstream of activated EGFR (Bache et al., 2002; Raiborg et al., 2002; 
Katzmann et al., 2003; Bache et al., 2003b). Work on Hrs has provided evidence to 
link the processes of receptor sorting and inward vesiculation (Urbe et al., 2003). 
However, EGF-stimulated phosphorylation of Hrs does not appear to 
modulate/enhance inward vesiculation as overexpression of a phosphorylation 
defective mutant has the same inhibitory effect on this process as wild type Hrs 
(Urbe et al., 2003). Instead phosphorylation of Hrs releases it from the endosome, 
and is thought to allow other proteins to bind to the EGFR and mediate the actual 
process of inward vesiculation (Urbe et al., 2003).
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Annexin 1 is also a substrate for internalised EGFR, within MVBs, and has been 
proposed to mediate inward vesiculation (Futter et al., 1993). Although loss of 
annexin 1 reduces the number of internal vesicles per MVB in EGF-stimulated 
cells, the studies here provide no conclusive evidence as to the specific role for 
annexin 1 within this process. Inward vesiculation can be divided into two stages: 
firstly, invagination of the endosomal membrane into the lumen of the 
endosome/MVB to form a vesicle, and secondly there is scission of the newly 
formed vesicle and its release into the lumen. The ESCRT complexes have been 
implicated in both processes. Vps4 is able to bind ESCRT-HI (Bowers et a l , 2004) 
and is thought to induce the dissociation of ESCRT complexes and components of 
the endosomal clathrin coat, processes that appear to be linked to formation of 
internal vesicles (Babst et al., 1998; Sachse et al., 2003). To date there is no data to 
suggest that annexin 1 is involved, or interacts, with the ESCRT proteins. 
Furthermore, it is unclear whether annexin 1 promotes ESCRT/Vps4-mediated 
internal vesicle formation in response to EGF or whether there are two mechanisms 
of internal vesicle formation, one of which is annexin 1-dependent.
Overexpression of Hrs, downregulation of TsglOl or disruption of ESCRT 
complex formation results in the inhibition of receptor sorting (Babst et al., 2000; 
Bishop et al., 2002; Lloyd et al., 2002; Lu et al., 2003; Urbe et al., 2003; Morino et 
al., 2004). In many cases MVBs are significantly enlarged and contain few internal 
vesicles. While loss of annexin 1 inhibits EGF-stimulated inward vesiculation, 
some vesicles still form and contain EGFR. These data suggest that receptor 
sorting still occurs but that annexin 1 might act downstream of Hrs/ESCRT 
proteins.
Annexin 1 may participate in membrane invagination or in scission of the newly 
formed vesicle. However, if  annexin 1 is only involved in the latter process, 
membrane invagination should proceed normally and result in formation of budding 
profiles at the edge of MVBs (vesicles that fail to pinch off into the lumen). These 
structures were not observed in MVBs from cells lacking annexin 1, suggesting that 
annexin 1 is not involved in the scission step. It is, however, also possible that 
budding profiles are not stable and disassemble if  fission fails to occur. Further 
evidence against a role for annexin 1 in vesicle scission comes from the observation
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that in the absence of annexin 1 some internal vesicles still form. Therefore, it 
seems more likely that annexin 1 is involved in some aspect of membrane 
invagination, presumably controlled by EGFR-mediated phosphorylation.
3.3.4 Models o f annexin 1-mediated internal vesicle formation
In a recent review, Gerke and Moss (2002) proposed a potential model for the 
mechanism by which EGFR-induced phosphorylation of annexin 1 mediates inward 
vesiculation (Fig. 3.23A). Annexin 1 is known to target its binding partner 
S100A11 to early endosomes (Seemann et a l , 1997) and is believed to form a 
heterotetrameric complex with S100A11 in a Ca2+ dependent manner, through 
which annexin 1 is able to bind to more than one membrane. The heterotetrameric 
complex is proposed to bring membranes together as other proteins e.g. ESCRT 
proteins, induce the actual process of membrane invagination. In this model, 
phosphorylation of annexin 1 by lysosomally targeted EGFR occurs just before the 
process of vesicle scission. Tyrosine phosphorylation of annexin 1 increases the 
susceptibility of annexin 1 to N-terminal proteolysis (Haigler et al., 1987; Chuah 
and Pallen, 1989; Ando et al., 1989). The N-terminal domain of annexin 1 contains 
the binding site for S100A11 and thus EGFR-mediated phosphorylation of annexin 
1 could result in the loss of this site and disruption of the heterotetramer, which 
would in turn affect membrane binding. Evidence for loss of the N-terminus in 
MVB formation comes from the relocation of an N-terminally truncated annexin 1 
from early to late endosomes (Seemann et al., 1996a; Rescher et a l , 2000). 
Therefore, it is possible that the disruption of the heterotetrameric complex is 
coupled to vesicle fission.
A second model is proposed here based on the ability of annexin 1 to aggregate on 
membrane surfaces (Janshoff et al., 2001) (Fig. 3.23B). Annexin 1 is known to 
bind to early endosomes and recruits S100A11 (Seemann et a l, 1996b; Seemann et 
al, 1997; Rescher et a l, 2000). In this model, the annexin 1/S100A11 
heterotetramer acts to stabilise the endosomal membrane. After receptor sorting, it 
is proposed that EGFR-mediated phosphorylation of annexin 1 disrupts annexin 1 
binding to the endosomal membrane, through disruption of the heterotetramer as 
described in the above model. In a study using solid-supported membranes to 
observe the effect of annexin 1 in binding vesicles, it was shown that vesicle
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adsorption to membrane-bound annexin 1 is mediated through two-dimensional 
annexin 1 clusters (Kastl et al., 2004). N-terminally truncated annexin 1 showed a 
decrease in vesicle binding, thought to be due to the loss of binding sites (Kastl et 
al., 2004). Release of annexin 1 from the endosomal membrane could destabilise 
the membrane allowing membrane invagination. However, this is unlikely because 
in the absence of annexin 1, this would lead to an increased number of internal 
vesicles within MVBs, the opposite effect to that observed in these studies. A 
modified version of the second model proposes that phosphorylation of annexin 1 
alters its ability to cluster, through loss of its N-terminus, which may destabilise the 
membrane without loss of annexin 1, and/or allow members of the ESCRT 
complexes, involved in inward vesiculation, to bind. This is consistent with the 
localisation of N-terminally truncated annexin 1-GFP to late endosomes (Rescher et 
al., 2000). However, as some internal vesicles form in the absence of annexin 1, it 
seems possible that ESCRT proteins may only mediate inward vesiculation within a 
subpopulation of MVBs.
Finally, a third hypothesis is proposes that Hrs-mediated EGFR sorting brings 
EGFR into close contact with annexin 1 (Fig. 3.23C). Phosphorylation of annexin 
1 could result in a change in the conformation of annexin 1, through N-terminal 
proteolysis and disruption of the heterotetramer. In turn, this conformational 
change could recruit members of the ESCRT proteins, or other as yet unidentified 
proteins, to bind and form internal vesicles. In the absence of annexin 1, this 
recruitment would not occur, thus inhibiting inward vesiculation. However, as 
internal vesicles form normally in MVBs from unstimulated annexin 1 -/- cells, and 
some still form in EGF stimulated cells, it is unlikely that annexin 1 mediated 
inward vesiculation is solely dependent on the ESCRT proteins.
All three models are based on the known properties of annexin 1, but all include the 
formation of the putative heterotetrameric complex, which in the absence of 
annexin 1 would not form. From the data presented in this chapter, annexin 1 is 
promoting inward vesiculation in response to EGF stimulation. It is assumed that 
EGF-mediated phosphorylation of annexin 1 controls this process. Although 
annexin 1 is known to be phosphorylated by EGFR within MVBs, the role of 
phosphorylation in internal vesicle formation is unclear. More data is required to
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Figure 3.23. Models o f annexin 1-dependent inward vesiculation. A - Gerke & Moss 
proposed that heterotetrameric complexes (containing annexin 1 (red) and S100A11 
(blue)) on the surface of endosomes function to bring membranes together and 
stabilise this membrane-membrane interaction, as other proteins induce membrane 
invagination. The final stage of inward vesiculation is vesicle scission and this is 
proposed to be coupled to EGFR (green)-mediated phosphorylation of annexin 1, 
which disrupts the heterotetrameric complex. In Model B, annexin 1/S100A11 
complexes form clusters on the cytoplasmic surface of the endosome, thus stabilising 
the membrane. Phosphorylation of annexin 1, by EGFR, disrupts this complex and 
either 1. releases annexin 1 from the membrane, causing membrane destabilization 
and allowing membrane invagination, or 2. alters the conformation of annexin 1, 
releasing S100A11, which may also destabilise the membrane and/or allow the 
binding of ESCRT proteins. Model C is based on Hrs-mediated EGFR sorting, 
allowing phosphorylation of annexin 1. Phosphorylation of annexin 1 induces a 
conformational change, which releases S100A11 and recruits ESCRT proteins, or 
unknown proteins, to induce formation of internal vesicles.
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determine whether any of these models are true and the exact mechanism by which 
annexin 1 induces EGF-stimulated internal vesicle formation.
3.3.5 Sub-populations o f MVBs
That EGF stimulation increased the total number of MVBs shows that at least some 
EGFR containing MVBs are formed de novo, rather than from EGFR-containing 
endosomes fusing with pre-existing MVBs. Further investigation into the effect of 
EGF stimulation on MVB formation has revealed the presence of two sub­
populations of MVBs, those that contain EGFR and those that do not. The EGF- 
stimulated increase in number of internal vesicles was shown to be limited to those 
containing the EGFR, rather than a general increase in all MVBs, and this increase 
required annexin 1. That annexin 1 only effects inward vesiculation in response to 
EGF, and only within EGFR-containing MVBs, is consistent with published data 
for annexin 1. It is well known as a major substrate for activated EGFR tyrosine 
kinase (Haigler et al., 1987) and the fact that annexin 1 is phosphorylated by EGFR 
within MVBs, but not at the plasma membrane, indicates that EGF-induced 
phosphorylation may control annexin 1 function (Futter et al., 1993).
The idea that more than one population of MVB exists is consistent with the work 
of several other groups. Treatment of cells with wortmannin, a PI3K inhibitor, 
resulted in an inhibition of inward vesiculation within EGFR-containing MVBs 
(Futter et al., 2001) but did not inhibit the formation of internal vesicles in LBPA 
containing MVBs (Bright et al., 2001). Therefore, it seems likely that EGFR are 
trafficked through a Vps34, annexin 1 dependent MVB pathway, but that a separate 
group of MVBs that contain LBPA exist and these do not require Vps34. 
Furthermore, unpublished work confirmed that EGFR-containing MVBs are 
distinct from LBPA-containing MVBs, but that the two populations are 
morphologically identical (White et al., under review). Interestingly, both sub­
populations also labelled for the tetraspanin CD63 and this indicates that CD63 may 
be a more reliable MVB marker than EGFR or LBPA.
Wortmannin inhibited the formation of internal vesicles and caused EGFR to 
cluster at the perimeter membrane (Futter et al., 2001). The phenotype observed in
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annexin 1 -/- cells was similar but less drastic and was limited to EGFR-containing 
MVBs, whereas wortmannin treatment affected both constitutive and EGF- 
stimulated inward vesiculation. Additionally wortmannin treatment induced a 
marked enlargement of MVBs that could not be explained solely by the inhibition 
of inward vesiculation and was thought to be due to the inhibition of membrane exit 
from MVBs. This latter phenotype was not observed in annexin 1 -/- cells, 
although MVBs were slightly larger than those from wild type cells. If the only 
effect of loss of annexin 1 on MVBs was the inhibition of inward vesiculation, then 
some enlargement would be expected. That no significant vacuolar enlargement 
was observed suggests that loss of annexin 1 might have some additional effect on 
the delivery of membrane to the MVB. Retention of EGFR on the perimeter 
membrane of MVBs from wortmannin treated cells resulted in enhanced levels of 
tyrosine phosphorylation, due to an inhibition of signal attenuation. In control cells 
EGFR were sequestered onto internal vesicles and this is believed to attenuate 
signalling (Futter et al., 2001). Therefore, it seems likely that annexin 1 mediated 
inward vesiculation in EGF-stimulated cells is necessary for attenuating its 
signalling properties.
3.3.6 Summary o f findings
To summarise, this work shows that EGF stimulation increases both MVB 
formation and inward vesiculation within MVBs. Annexin 1 is not required for 
MVB formation but plays a specific role in formation of internal vesicles within 
MVBs. While annexin 1 is not required for the basal formation of MVBs or the 
EGF-mediated increase in MVB formation, it is necessary for the EGF-stimulated 
formation of internal vesicles. That annexin 1 is not involved in inward 
vesiculation within all MVBs is consistent with the recent idea that there is more 
than one population of MVBs. Therefore annexin 1 is necessary for the EGF- 
stimulated formation of internal vesicles in a sub-population of MVBs, which 
contain EGFR.
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Chapter 4 -  Does annexin 2 play a role in MVB formation?
4.1 Introduction
The results of the previous chapter showed that annexin 1 mediates the EGF- 
stimulated increase in inward vesiculation in a sub-population of MVBs. Although 
EGF stimulation also caused an increase in MVB formation, no evidence was found 
for a role of annexin 1 in MVB formation, either in the presence or absence of EGF. 
A recent published report suggested that annexin 2 is required for the biogenesis of 
MVBs and that annexin 2 depletion caused a failure of MVBs to “bud o ff’ from 
endosomes (Mayran et al., 2003). This morphological change was also reported to 
inhibit transport from early to late endosomes. In contrast, the findings of Zobiack 
et al. (2003) reported annexin 2 depletion had no effect on lysosomal delivery, but 
that the localisation of TfR positive recycling endosomes was altered (Zobiack et 
al, 2003).
This chapter presents the results of a detailed investigation into the effect of loss, or 
depletion, of annexin 2 on MVB formation and inward vesiculation. Annexin 2 
was depleted in HeLa cells using RNAi and the morphology of anti-hEGFR-gold 
containing MVBs observed. No difference was detected in the number of MVBs 
formed or the size of these MVBs between control and annexin 2 RNAi treated 
cells. Unlike annexin 1, annexin 2 is not required for the formation of internal 
vesicles in MVBs from EGF-stimulated cells. As the phenotype observed 
following RNAi-induced depletion is critically dependent on the efficiency of 
depletion, the effect of loss of annexin 2 was also investigated in a DT40 annexin 2 
-/- cell line, where annexin 2 was completely absent due to the disruption of the 
annexin 2 gene. Experiments in these knockout cells further confirmed that 
annexin 2 is not required for any aspect of MVB formation examined.
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4.2 Results
4.2.1 MVB formation occurs independently o f annexin 2
To investigate whether annexin 2, unlike annexin 1, plays a role in MVB formation 
the effect of loss of annexin 2 on this process was investigated. RNAi has 
previously been used to deplete levels of annexin 2 in HeLa cells (Mayran et al., 
2003; Zobiack et al., 2003). Therefore, HeLa cells were treated with annexin 2 or 
control RNAi for 3 days (see Materials and Methods section 2.5.1). Lysates were 
collected and blotted for annexin 2 to check the efficiency of knockdown (Fig.
4.1 A). Cells treated with annexin 2 RNAi were significantly depleted of annexin 2 
and semi-quantitative analysis of western blots from several independent RNAi 
experiments showed that annexin 2 RNAi treatment decreased protein levels by 70- 
80% in HeLa cells (Fig. 4.IB). Lysates were also blotted for annexin 1 and a small 
increase in the amount of annexin 1 was observed.
Coverslips from these RNAi experiments were processed and stained with an anti- 
annexin 2 antibody and fluorescent phalloidin to label actin and help to visualise 
annexin 2 depleted cells (Fig. 4.1C). Interestingly, while control HeLa cells grew 
in smooth-edged, round patches, annexin 2 RNAi treated cells tended to grow as 
single cells or as groups of cells without tightly formed cell-cell contacts (Fig. 
4.1c). Levels of annexin 2 were reduced by approximately 75% in all experiments 
used, as shown by western blotting and by immunofluorescence. It is important to 
note that in 75% of cells annexin 2 was undetectable, while the remaining 25% of 
cells showed annexin 2 staining similar to control cells.
To observe the effect of annexin 2 depletion on MVB formation, HeLa cells were 
treated with control or annexin 2 RNAi. After 3 days cells were serum starved, 
incubated with EGF in the presence of anti-hEGFR-gold, or with EGF-HRP, for 1 
hour and processed for TEM (see Materials & Methods section 2.11.2). Initially, 
the morphology of anti-hEGFR-gold, or EGF-HRP, containing MVBs was 
observed in both cell lines using TEM.
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Figure 4.1. Use o f RNAi to deplete annexin 2 in HeLa cells. HeLa cells were treated 
for 3 days with control (C) or annexin 2 RNAi oligonucleotides (A2). Cell lysates 
were collected and blotted with antibodies against tubulin, as a loading control, 
annexin 2 (anx2), to confirm the efficiency of knockdown, and annexin 1 (A). Semi- 
quantitative analysis if annexin 2 depletion was performed by measuring and 
comparing intensity of annexin 2 signal from control and annexin 2 RNAi treated cells 
(see Materials & Methods section 2.6.4) (B). Graph shows data ± SEM from at least 5 
independent RNAi experiments. *** p<0.001. (C) Cells from the same experiment 
were fixed for immunofluorescence and labelled with anti-annexin 2 (top panel). 
Actin was stained using phalloidin-AlexaFluor 547. These are typical images of 
RNAi-treated cells at low power (left panels) or high power (right panels). White 
stars indicate cells apparently totally depleted of annexin 2. Bars = 20pm.
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No difference was observed between MVBs from cells treated with control or 
annexin 2 RNAi (Fig. 4.2). Mature MVBs containing anti-hEGFR-gold or EGF- 
HRP, visible by the DAB reaction, were observed in all control and annexin 2 
RNAi-treated cells. There was no obvious difference in the morphology of MVBs, 
as the size of MVBs and number of internal vesicles looked to be approximately the 
same. There was also no difference observed in the amount of anti-hEGFR-gold 
particles per MVB.
Having observed no immediately obvious difference in MVB formation in cells 
depleted of annexin 2, quantitative analysis of the number of MVBs formed was 
performed to reveal any subtle difference. As described in Chapter 3 for annexin 1, 
control or annexin 2 RNAi treated HeLa cells were incubated with EGF, in the 
presence of anti-hEGFR-gold, for 1 hour to label MVBs. At least 20 cells were 
photographed for each treatment in three independent experiments. The area of 
cytoplasm in each photo was measured (nm ) and the number of anti-hEGFR-gold 
containing MVBs was counted. The mean number of MVBs per pm2 cytoplasm 
was calculated, and compared between control and annexin 2 RNAi treated cells 
(Fig. 4.3). There was no significant difference in the number of MVBs formed in 
EGF-stimulated control or annexin 2 RNAi treated cells (0.075 compared to 0.078).
These data show that annexin 2 is not required for EGF-stimulated MVB formation. 
In spite of this, RNAi-induced depletion of annexin 2 does not target 100% of cells 
and, as a result, there are at least 20% of cells in each experiment that express wild 
type levels of annexin 2. The counting of a large number of cells should be 
adequate to overcome this problem. However, although in 80% of cells annexin 2 
was reduced below the levels of detection, it may still be present at sufficient levels 
to perform its function. Therefore, it was necessary to analyse MVB formation in a 
cell line devoid of annexin 2 to confirm the above findings. DT40s are chick B 
lymphocytes and the annexin 2 -/- cell line does not express annexin 2 due to the 
disruption of the gene by the insertion of a neomycin cassette (Hawkins et al., 
2002). DT40 cell lysates were collected and blotted with an anti-annexin 2 
antibody, against human placental annexin 2, but no signal was observed in either 
cell line, presumably because this antibody does not recognise the chicken protein.
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Figure 4.2. Effect o f annexin 2 depletion on MVB morphology. HeLa cells were 
treated with control or annexin 2 RNAi. After 3 days cells were serum starved, 
stimulated with EGF (lOOng/ml), in the presence of anti-hEGFR-gold (A), or EGF- 
HRP (B) for 1 hour, and processed for TEM. The morphology of MVBs was 
analyzed in many cells from several experiments. Electron micrographs show 
typical MVBs for control and RNAi-treated cells, and lower panels in B show 
typical EGF-HRP containing lysosomes. Bars = 200nm.
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Figure 4.3. Annexin 2 depletion has no effect on numbers o f MVBs formed. 
HeLa cells were treated with control or annexin 2 RNAi for 3 days. Cells were 
serum starved before stimulation with EGF (lOOng/ml), in the presence of anti- 
hEGFR-gold, for 1 hour. Cells were processed for TEM and at least 20 photos 
taken of cells at random. The area of cytoplasm per photo was measured. The 
number of anti-hEGFR-gold containing MVBs per experiment were counted and 
expressed per pm2 cytoplasm. There was no difference in number of MVBs 
between control and annexin 2 RNAi treated cells. Graph shows the mean ± 
SEM of three independent experiments.
To confirm that DT40 annexin 2 -/- cells were not expressing annexin 2, RT-PCR 
was performed (as described in Materials & Methods section 2.7) (Fig. 4.4). 
Forward and reverse primers were designed, using the chick annexin 2 cDNA 
sequence, to span the exon disrupted by the insertion of the antibiotic resistance 
genes and produce a 239 base pair product. These primers were used in a PCR 
reaction using cDNA derived from total RNA isolated from wild type and annexin 
2 -/- DT40s. In the wild type cells there was a visible band at the correct size 
(~239bp) that was not observed in annexin 2 -/- cells. This confirmed that there 
was no detectable annexin 2 expression in the annexin 2 -/- cells.
Control Anx2 RNAi
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Figure 4.4. RT-PCR analysis o f annexin 2 expression in DT40 cells. Total RNA 
was isolated from wild type and annexin 2 -/- DT40 cells and used to synthesize 
first strand cDNA. cDNA was used in a PCR reaction using primers designed 
against the chick annexin 2 sequence to produce a 239bp product. Wild type cells 
(WT) contained a band of the correct size (*), whilst annexin 2 -/- cells (-/-) did 
not (A). A control RT-PCR reaction (+) was also carried out to test the RT-PCR 
reaction and a 1.3Kb product is seen in lane 5 (B). Experimental samples were 
run alongside PCR markers (Ml) and control reaction with X 
DNA/EcoR 1 +Hindlll markers (M2).
DT40 cells are chick cells and, consequently, do not express EGFR suitable for use 
of human EGF and anti-hEGFR-gold. To overcome this problem DT40 cells were 
transfected with hEGFR using nucleofection, but proved difficult to transfect due to 
high levels of spontaneous apoptosis (personal observations) and low transfection 
efficiency. Instead, an endogenous lymphocyte cell surface receptor was chosen. 
DT40 cells express high levels of cell surface IgM (B-cell receptor), which 
becomes internalised when activated by antigen binding. To investigate the 
internalisation of this receptor, an anti-chicken IgM antibody was conjugated to 
lOnm gold (Materials & Methods section 2.11.1.3). Cells were incubated with anti- 
IgM-gold for different lengths of time before processing for TEM. However, even 
after 2 hours, little gold was observed in cells and this may have been taken up by 
fluid phase endocytosis, rather than by receptor mediated endocytosis.
Therefore, to observe the effect of loss of annexin 2 on MVB formation, DT40 cells 
were incubated with markers taken up by fluid phase endocytosis. DT40s were 
incubated with HRP for 2 hours and processed for TEM (Material & Methods 
section 2.11.3). The morphology of MVBs was analysed but no difference was 
observed between wild type and annexin 2 -/- cells (Fig. 4.5).
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Figure 4.5. Effect o f loss o f annexin 2 on MVB morphology. DT40 cells were 
incubated with HRP for 2 hours, processed for TEM, including DAB reaction, and the 
morphology of MVBs analyzed. Electron micrographs show typical mature HRP- 
containing MVBs from each cell line. Loss of annexin 2 did not alter the morphology 
of HRP-containing MVBs, compared to those from wild type cells. Bar = 200nm.
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Both cell lines contained MVBs with multiple internal vesicles, and the HRP/DAB 
reaction product was visible within these structures. MVBs from these DT40 cells, 
incubated with HRP, were counted to quantify the number of MVBs, as described 
above for RNAi-treated HeLa cells. No significant difference was observed in the 
number of MVBs formed in wild type or annexin 2 -/- cells (0.09 ± 0.003 compared 
to 0.085 ± 0.012) (Fig. 4.6). The number of MVBs per pm2 cytoplasm was slightly 
higher than that seen in HeLa cells, but all MVBs were counted in DT40s, while in 
HeLa cells only those containing EGFR-gold were counted.
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Figure 4.6. Loss o f annexin 2 has no effect on MVB formation. DT40 cells were 
incubated with HRP for 2 hours, processed for TEM, including DAB reaction, and a 
number of random photos taken of each cell line. The area of cytoplasm per photo 
was measured. The number of MVBs per experiment were counted and expressed per 
pm2 cytoplasm. There was no difference between cell lines. Graph shows the mean 
± SEM of three independent experiments.
4.2.2 Loss o f annexin 2 does not affect the size o f MVBs formed
The depletion, or loss, of annexin 2 had no effect on the number of MVBs formed 
in either HeLa cells or DT40 cells. To analyse whether loss of annexin 2 altered 
the size of MVBs, the area of MVBs was measured in HeLa cells treated with 
control or annexin 2 RNAi, and also in both wild type and annexin 2 -/- DT40s. 
Fig. 4.7 shows that loss of annexin 2 does not affect the mean area of MVBs in
Wild type Annexin 2 -/-
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either HeLa or DT40 cells. The mean area of MVBs in annexin 2 RNAi-treated 
cells was slightly larger than that of control cells but this difference was not 
statistically significant. The mean area of MVBs in DT40 cells was smaller than 
that in HeLa cells (70000nm2 in DT40s compared to 90000 nm2 in HeLa cells), 
likely due to differences between species and/or cell types.
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Figure 4.7. Loss o f annexin 2 has no effect on the area o f MVBs. The area (nm ) of 
each MVB from the previously described HeLa annexin 2 RNAi and DT40 
experiments was measured. For each cell line, the mean area of MVBs per experiment 
was calculated. The depletion, or total loss, of annexin 2 did not affect the area of 
MVBs. Graph shows the mean ± SEM of three independent experiments.
4.2.3 Inward vesiculation occurs independently o f annexin 2
For each cell type (control or annexin 2 RNAi treated HeLa or wild type or 
knockout DT40), the number of internal vesicles per MVB was counted and the 
mean of 3 or more independent experiments calculated. There was a slight increase 
in the mean number of internal vesicles formed per MVB in annexin 2 RNAi 
treated cells, compared to control HeLa cells (26 ±1.5 compared to 22.8 ± 1.3) but 
this was not significant (Fig. 4.8). Similarly, there was no difference in the mean 
number of internal vesicles between wild type and annexin 2 -/- DT40s (Fig. 4.8). 
Both cell lines contained MVBs with an average of 17 internal vesicles. MVBs in
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DT40 cells contained fewer internal vesicles than HeLa cells, but this was again 
probably due to the differences between species and/or cell type.
Control Anx2 RNAi Wild type Anx2 -/- 
HeLa DT40
Figure 4.8. Loss o f annexin 2 does not alter inward vesiculation. For each 
experiment the number of internal vesicles per MVB was counted and the mean per 
experiment calculated for HeLa cells and DT40s (A). Figure B shows the distribution 
of internal vesicles in a typical experiment. Loss of annexin 2 did not inhibit inward 
vesiculation. Graph shows the mean ± SEM of three independent experiments.
Although the mean number of internal vesicles per MVB did not differ between 
control and RNAi treated HeLa cells, or wild type and annexin 2 knockout DT40s, 
within a single experiment there was a range of MVBs containing different 
numbers of internal vesicles. To observe whether loss, or depletion, of annexin 2 
altered the distribution of numbers of internal vesicles, MVBs were divided into 
different groups, based on number of internal vesicles, and expressed as a 
percentage of the total number of MVBs (Fig. 4.9). There was no significant 
difference between the percentages of MVBs in any group between control or 
RNAi-treated HeLa cells, or DT40 cell lines. The majority of MVBs in control or 
annexin 2 RNAi-treated HeLa cells contained 16 or more internal vesicles, and this 
was consistent with data from EGF-stimulated HeLa cells from the previous 
chapter investigating annexin 1. These data provide further confirmation that loss 
of annexin 2 has no effect on the process of inward vesiculation within MVBs.
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Figure 4.9. Loss o f annexin 2 does not affect the distribution o f number o f internal 
vesicles per MVB. The numbers of internal vesicles per MVB were counted and 
MVBs divided into groups based on different numbers of internal vesicles in HeLa 
cells (A) and DT40s (B). Loss or depletion of annexin 2 had no effect on number of 
internal vesicles per MVB. Graphs show the mean ± SEM of three independent 
experiments
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4.2.4 Depletion o f  annexin 1 and 2 has the same effect as loss o f annexin 1 alone
RNAi-induced annexin 2 depletion, or total loss of annexin 2 through gene 
knockout, had no effect on MVB formation or inward vesiculation with MVBs in 
unstimulated or EGF-stimulated cells. As shown in the previous chapter, annexin 2 
is upregulated in annexin 1 -/- cells, but cannot compensate for the loss of annexin 
1 in EGF-stimulated internal vesicle formation. However, it is still possible that 
annexins 1 and 2 could compensate for each other in the process of MVB 
formation. Therefore, to investigate this possible functional redundancy, RNAi was 
used to deplete cells of both annexins 1 and 2. HeLa cells were treated with a 
combination of annexin 1 and annexin 2 RNAi oligonucleotides using 
nucleofection (described in Materials & Methods section 2.5.3). After 3 days, cell 
lysates were collected and blotted with anti-tubulin (loading control), anti-annexin 
1 and anti-annexin 2 antibodies to determine the efficiency of knockdown (Fig. 
4.10). Depletion of both annexins was similar to that observed in single RNAi 
experiments.
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Figure 4.10. RNAi-induced depletion o f annexins 1 and 2 in HeLa cells. HeLa 
cells were nucleofected with control (-) or a combination of annexin 1 and 2 RNAi 
oligonucleotides (+). After 24 hours, cells were re-transfected and left for 48 hours. 
On day 3, cell lysates were collected and blotted with anti-tubulin, anti-annexin 1 
and anti-annexin 2. RNAi-treated cells were depleted for both annexins.
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Having determined that depletion of both annexins at the same time did not affect 
cell viability, double RNAi-treated cells were serum starved, stimulated with EGF, 
in the presence of anti-hEGFR-gold, for 1 hour and processed for TEM. The 
morphology of anti-hEGFR-gold containing structures was observed in both control 
and double RNAi-treated cells. In both control cells and cells treated with annexin
1 and 2 RNAi, anti-hEGFR-gold containing MVBs were observed and there 
appeared to be no difference in the number or size of these structures. However, in 
the majority of cells treated with both annexin RNAi oligonucleotides, anti- 
hEGFR-gold containing MVBs contained few internal vesicles (Fig. 4.11). These 
MVBs were similar in morphology to those observed previously in annexin 1 
RNAi-treated cells. These data indicate that neither annexin 1 nor annexin 2 is 
required for MVB formation. These findings provide further evidence that annexin
2 does not participate in EGF-stimulated inward vesiculation.
4.3 Discussion
4.3.1 Annexin 2 is not required for the proper formation o f MVBs
The rationale behind investigating the role of annexin 2 in MVB formation came 
from a combination of (i) the results of a recently published study that reported an 
inhibition of MVB biogenesis after annexin 2 depletion (Mayran et al., 2003), and 
(ii) data presented in the previous chapter, which reported that annexin 1 is 
necessary for EGF-stimulated inward vesiculation within MVBs. As annexins 1 
and 2 are closely related, it has been proposed that they might play similar roles. 
However, the data presented in this chapter shows that neither RNAi-induced 
annexin 2 depletion nor loss of annexin 2, through gene knockout, had an effect on 
the formation of MVBs or on inward vesiculation within MVBs. It is important to 
note that within this study only anti-EGFR-gold containing MVBs were counted in 
annexin 2 RNAi-treated HeLa cells. As EGF-stimulation increased both MVB 
formation and inward vesiculation within MVBs (Chapter 3), these studies show 
that annexin 2 is not involved in EGF-stimulated MVB formation and also, unlike 
annexin 1, annexin 2 is not involved in EGF-stimulated inward vesiculation.
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vFigure 4.11. Effect o f double annexin depletion on MVB morphology. HeLa cells 
were nucleofected with a combination of annexin 1 and 2 RNAi oligonucleotides. 
Cells were re-transfected after 24 hours and left for 48 hours. On day 3, cells were 
serum starved for 1 hour, stimulated with EGF (lOOng/ml), in the presence of anti- 
hEGFR-gold, for 1 hour and processed for TEM. The morphology of MVBs was 
observed and electron micrographs show typical anti-hEGFR-gold containing MVBs 
from double RNAi-treated cells only, which show the same morphology as those 
observed in annexin 1 RNAi-treated cells, i.e. they contain few internal vesicles.
Bar = 200nm.
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DT40 cells were not EGF-stimulated and, therefore, the data from these cells is not 
directly comparable with that of annexin 2 RNAi-treated HeLa cells. However, 
studies using DT40 annexin 2 -/- cells show that annexin 2 is not required for MVB 
formation in unstimulated cells. Interestingly, the number of MVBs per pm2 
cytoplasm in DT40 cells was surprisingly high given the lack of EGF stimulation. 
There are several possible explanations for this. The first, and most likely, is that 
DT40 cells and HeLa cells are different cell types derived from different species. 
Secondly, the DT40 cells were not serum starved (unlike unstimulated JACRO cells 
in Chapter 3) because of their susceptibility to spontaneous apoptosis (personal 
observations). This suggests the basal level of MVB formation is higher in non­
starved cells than in serum starved cells. Finally, DT40 cells have a different 
morphology to HeLa or JACRO cells, having very little cytoplasm surrounding the 
nucleus. This difference in morphology could affect comparisons of MVB numbers 
between cell lines.
The findings described above are inconsistent with those of Mayran et al. (2003). 
This group focussed initially on the influence of membrane cholesterol on the 
distribution of annexin 2, by studying cholesterol accumulation that occurs 
naturally in Niemann Pick C fibroblasts and through drug treatment in human skin 
fibroblasts. They reported that cholesterol accumulation in large swollen late 
endosomes and lysosomes caused a redistribution of annexin 2 to these structures, 
accompanied by an inhibition of transport from early to late endosomes, as 
observed by increased recycling of fluid phase markers. In the absence of 
cholesterol accumulation, annexin 2 was localised to the cytoplasm, the plasma 
membrane and early endosomes, in agreement with other published data (Harder 
and Gerke, 1993; Jost et a l , 1997).
Further investigation by Mayran et al. (2003) into the role of annexin 2 in 
endocytosis revealed that loss of annexin 2 inhibited early to late endosome 
transport of dextran and EGF. Dextran was recycled out of cells instead of being 
delivered to the lysosome, while EGF was retained in an enlarged EEA1 positive 
compartment. To determine whether the inhibition of transport from early to late 
endosomes was due to a failure of membrane fusion, an in vitro membrane fusion
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assay was used. Depletion of annexin 2 from membranes and cytosol reduced 
membrane fusion by 50% but this reduction was insufficient to cause the dramatic 
inhibition of transport observed. Subsequently, the loss of annexin 2 on the in vitro 
formation of endosomal carrier vesicles/MVBs was investigated. This assay used 
early endosomes depleted of annexin 2 by drug treatment, and showed that these 
failed to form ECV/MVBs. Similarly, antibodies against annexin 2 inhibited 
ECV/MVB formation from normal endosomes. Finally, ultrastructural analysis of 
control cells showed HRP within MVBs of control cells, but in RNAi-treated cells 
HRP-containing structures were described as ring-shaped or tubular. However, 
annexin 2 was not involved in inward vesiculation as HRP was often present in 
multivesicular areas attached to these ring-shaped structures (Mayran et al., 2003).
That annexin 2 is not involved in inward vesiculation is consistent with the data 
presented in this chapter. However, the ultrastructural analysis of MVB formation 
in HeLa cells depleted of annexin 2 performed here did not reveal any alteration in 
the morphology of MVBs compared to control cells. Normally inter-lab variations 
can be explained through the use of different cell lines or reagents. However, both 
sets of data used annexin 2 RNAi in HeLa cells. The studies in this chapter used a 
combination of two annexin 2 oligonucleotides, one of which is the published 
sequence from the work of Mayran et al. (2003). Having shown in the previous 
chapter that EGF-stimulation increases both MVB formation and inward 
vesiculation, it is possible that annexin 2 is involved in the formation of the non- 
EGFR containing sub-population of MVBs. Indeed the electron micrographs from 
Mayran et al. (2003) were from unstimulated cells, however, they also reported the 
inhibition of EGF transport to late endosomes. Therefore, it is unlikely that the 
work presented here and the work of Mayran et al. (2003) are looking at different 
populations of MVBs, as both sets of experiments used EGF stimulation. 
Additionally, the use of HRP, as a marker of fluid phase endocytosis, in 
unstimulated DT40 annexin 2 -/- cells failed to reveal any difference in MVB 
formation, when compared to wild type cells.
For ultrastructural analysis, Mayran et al. (2003) used nocodazole to depolymerise 
microtubules in HeLa cells before incubation with HRP. No reason was given for 
this treatment but it has commonly been used to accumulate MVBs by inhibiting
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their transport from early endosomes to late endosomes/lysosomes. In control cells, 
normal MVBs formed, containing HRP, and failed to fuse with lysosomes due to 
the lack of microtubules. However, in cells lacking annexin 2 HRP-containing 
structures were shown to be mis-formed. Annexin 2 is required for the proper 
localisation of early endosomes (Harder and Gerke, 1993), and microtubules are 
required for the distribution of late endosomes and to facilitate delivery to the 
degradative pathway (van Deurs et al., 1995; Durrbach et al., 1996). It is therefore 
possible that loss of both annexin 2 and microtubules, at the same time, disrupts the 
localisation of endosomes, and that this mis-localisation is linked to the improper 
formation of MVBs observed by Mayran et al. (2003). In support of this theory, 
careful examination of the electron micrographs from the work of Mayran et al. 
(2003) shows a difference in the localisation of HRP-containing structures. In 
control cells, MVBs were present throughout the cytoplasm, whereas in RNAi- 
treated cells structures were shown close to the cell surface. This difference in 
localisation was not mentioned in the accompanying text. Taken together, it may 
be that efficient MVB formation and positioning may require both annexin 2 and 
intact microtubules.
However, the hypothesis described above does not explain the major finding of 
Mayran et al. (2003) that loss of annexin 2 inhibits delivery of EGF to the 
lysosome. The data presented in this chapter showed that EGF (as EGF-HRP) is 
delivered to lysosomes in annexin 2 depleted cells. This finding is consistent with 
those of the Gerke group, who reported that loss of annexin 2 had no effect on the 
delivery of fluid phase markers, or LDL, to the lysosome (Zobiack et al., 2003).
The data presented in this chapter provides detailed quantitative measurement of 
the number and size of MVBs, and also the number of internal vesicles per MVB, 
from both EGF-stimulated HeLa cells depleted of annexin 2 and unstimulated 
annexin 2 -/- DT40 cells. In contrast, the finding of Mayran et al. (2003), that EGF 
transport to late endosomes is inhibited in cells depleted of annexin 2, was based on 
fluorescence images and no quantitation was performed. Quantitation of different 
HRP-containing structures was performed by Mayran et al. (2003), but only a small 
number of cells were observed to generate this data.
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4.3.2 Differences in the nomenclature o f  endocytic compartments
A crucial difference between the work presented in this chapter and that of the 
Gruenberg lab (Mayran et al., 2003) may stem from the definition of endocytic 
compartments. The definition of a MVB used here is a vacuole with a diameter > 
200nm and containing > 1 internal vesicle. Although Mayran et al. (2003) gave no 
definition of a MVB, it appears that only MVBs with many internal vesicles were 
counted, and those that contained few internal vesicles were counted under a 
separate category. The data presented in both this chapter, and the previous 
chapter, showed that within a single experiment there is a wide range of MVBs 
containing different numbers of internal vesicles.
In a recent review, Gruenberg and Stenmark (2004) proposed a scheme whereby 
MVBs, also called endosomal carrier vesicles (ECVs), are defined as vacuoles that 
transport material from early to late endosomes, are multivesicular and LBPA 
negative (Gruenberg and Stenmark, 2004). According to this scheme, late 
endosomes contain both multivesicular and multilamellar regions and are LBPA 
positive. However, much data exists to suggest that MVBs/ECVs are more than 
just transport vesicles and also perform an important sorting function. This is 
shown by the gradual accumulation of lysosomally directed proteins, e.g. EGF and 
LDL, the gradual accumulation of internal vesicles and the gradual removal of 
recycling proteins, e.g. TfR (Hopkins et al., 1990; van Deurs et al., 1993; Futter et 
al., 2001). Thus MVBs can be early and late; early MVBs have few internal 
vesicles and still contain recycling proteins, whereas late MVBs have many internal 
vesicles and lack recycling proteins. In conclusion, the differences in defining 
endocytic compartments need to be addressed, as the experiments in this chapter 
include a much wider variety of structure than those counted in the work of Mayran 
etal. (2003).
4.3.3 Annexin 2 is unable to functionally compensate for annexin 1
Annexins 2 and 6 are upregulated in JACRO annexin 1 -/- cells (Fig. 4.1) (Croxtall 
et al., 2003), and it has been suggested that closely related annexins may
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compensate for each other in various cellular function (Tomas et al., 2003). In the 
previous chapter, RNAi was used to deplete levels of annexin 1 in HeLa cells for 
two reasons, to be able to use a human cell line but also to avoid the upregulation of 
annexin 2. However, even after 3 days of RNAi treatment annexin 2 was slightly 
upregulated in these cells. In this chapter, depletion of annexin 2 had no effect on 
MVB formation or inward vesiculation but these cells expressed slightly higher 
levels of annexin 1. Therefore, it is possible that the upregulation of these closely 
related members of the annexin family may partially compensate for each other. 
Furthermore, this compensation could mask the phenotype caused by loss of a 
single annexin. To explore this further, both annexins were targeted using RNAi- 
induced protein depletion. However, the effect observed on the formation of 
internal vesicles within MVBs was no greater, or different, to that observed with 
annexin 1 depletion alone. These data confirm that annexin 2 does not play a role 
in MVB formation or inward vesiculation.
4.3.4 Possible role for annexin 2
These studies provide extensive evidence that annexin 2 is not required for MVB 
formation in either unstimulated or EGF-stimulated cells, nor is it required for 
inward vesiculation. That annexin 2 is not involved with any aspect of MVBs 
investigated here is not surprising, as the majority of work on annexin 2 has 
identified it as associated with earlier endosomal structures, especially with 
recycling endosomes. Fractionation studies in rat hepatocytes failed to identify any 
annexin 2 associated with MVBs (Pol et al., 1997). The apparent discrepancies 
between the data presented here and those of Mayran et al. (2003) could be due, in 
part, to the nomenclature used to describe endocytic compartments. Also, the lack 
of fusion activity in vitro does not always translate in vivo. It therefore seems more 
likely that annexin 2 is playing a role at a different stage of endocytosis, possibly 
within recycling endosomes (Zobiack et al., 2003).
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4.3.5 Summary o f findings
These data provide conclusive evidence that annexin 2 is not required for the proper 
formation of MVBs in unstimulated DT40 cells, nor in the formation of EGF- 
stimulated MVBs in HeLa cells. Furthermore, unlike annexin 1, annexin 2 is not 
required for the formation of internal vesicles in MVBs of EGF-stimulated cells. 
This latter finding is consistent with those of Mayran et al. (2003), although this 
group also report that annexin 2 depletion inhibits early to late endosomal transport 
through a failure of MVBs to bud off from endosomes.
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Chapter 5 -  Annexins and receptor trafficking
5.1 Introduction
As shown in the previous chapters, neither annexin 1 nor annexin 2 were required 
for basal or EGF-stimulated formation of MVBs. Internal vesicles could form 
within MVBs in the absence of either, or both, annexins. However, annexin 1, but 
not annexin 2, was required for the EGF-stimulated increase in inward vesiculation. 
The inhibitory effect observed on EGF-stimulated inward vesiculation led to the 
proposal that annexin 1 may be involved in EGF/EGFR trafficking. Although 
internal vesicles form in the absence of EGF-stimulation, a proposed role of 
internal vesicle formation is to remove EGFR from the recycling pathway. 
Therefore, an inhibition of inward vesiculation, as seen in annexin 1 -/- cells, would 
be expected to alter EGFR trafficking, by promoting receptor recycling and thus 
reducing EGF/EGFR degradation. However, it is likely that inward vesiculation 
plays more than one role. Receptor sorting within MVBs can be divided into cargo 
selection for inclusion on internal vesicles and formation of internal vesicles. 
These processes are believed to be coupled through the FYVE-domain containing 
protein Hrs, which recruits the ESCRT complexes (Urbe et a l , 2003). However, 
Futter et al (2001) showed that it was possible to uncouple receptor sorting from 
inward vesiculation, using wortmannin to inhibit PI3K dependent processes (Futter 
et a l , 2001). As seen with wortmannin treated cells, a small number of internal 
vesicles still form in MVBS from annexin 1 -/- cells and these often contained anti- 
hEGFR-gold, showing that EGFR could still be sorted onto internal vesicles. 
Quantification of EGFR sorting onto internal vesicles has proved difficult, as when 
internal vesicles are close to the perimeter membrane, it is not always clear whether 
the anti-hEGFR-gold is present on the limiting membrane or on the internal vesicle. 
Therefore, to obtain accurate quantitative measurements of the effect of loss of 
annexin 1 on receptor sorting in these studies, biochemical analysis of radio 
labelled EGF degradation and EGF/Tf recycling was performed.
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Despite the failure to observe an effect of annexin 2 depletion on any aspect of 
MVB biogenesis, the question of whether annexin 2 is involved in receptor sorting 
has been raised. The data presented in the previous chapter contradicted published 
work from Mayran et al. (2003) that stated annexin 2 is required for MVB 
biogenesis. Work from the same group also reported that annexin 2 depletion 
inhibited the transport of EGF from early to late endosomes, but did not affect Tf 
internalisation or trafficking (Mayran et al., 2003). However, these experiments 
were based on the use of fluorescent ligands and no quantitation was performed. 
The use of radio labelled EGF to measure degradation and recycling is very 
sensitive, even to small differences, and therefore was used in this chapter to 
compare EGF-trafficking in control and annexin 2 RNAi-treated cells.
The data presented in this chapter show that EGF degradation was unaffected by 
loss of either annexin, but that EGFR degradation was altered in cells lacking 
annexin 1, but not annexin 2. This delay in EGFR degradation, or inhibition of a 
small proportion of EGFR to become degraded, was accompanied by an 
enhancement of downstream phosphorylation i.e. signalling. Meanwhile, annexin 2 
depletion was shown to have no effect on any aspect of EGF/EGFR trafficking. 
Instead, annexin 2 appears to be involved in the positioning of Tf positive recycling 
endosomes.
5.2 Results
5.2.1 EGF degradation is not affected by loss o f annexin 1 or annexin 2 depletion
To measure the kinetics of EGF degradation in JACRO cells, both wild type and 
annexin 1 -/- cells were incubated with 1-125 labelled EGF (125I-EGF) for 10 
minutes at 37°C to allow internalisation. Surface bound EGF was stripped and 
internalised EGF chased through cells using warm serum-free medium. At each 
time point, medium was collected and counts per minute (cpm) measured using a 
gamma counter. Cells were solubilised using Triton X-100 (TxlOO) to release 
remaining EGF. Within the lysosome, EGF is degraded into single amino acids,
137
which releases the 125I labelled tyrosine. After EGF degradation, iodotyrosines are 
able to freely diffuse across membranes, and so are rapidly released into the
1 'yc
medium. At the same time recycled I-EGF will also be present in the media. To 
distinguish between degraded and recycled label, all media samples were incubated 
with trichloroacetic acid (TCA) for 1 hour at 4°C and centrifuged to form a pellet. 
Iodotyrosines, from the degraded EGF, are soluble in TCA and remain in the
19Ssupernatant, whereas I-EGF that has been recycled is TCA precipitatable. The 
percentage of internalised EGF degraded was calculated for each time point (see 
Materials & Methods section 2.8.4).
Despite the marked change in morphology of EGFR-containing MVBs observed in 
annexin 1 -/- cells, there was no difference in the kinetics of EGF degradation 
between JACRO cell lines (Fig. 5.1 A). After 1 hour, 20% EGF was degraded in 
both cell lines and the percentage of EGF degraded showed a linear increase up to 2 
hours (46% degraded) and reached a plateau at 3 hours (56% EGF was degraded in 
both cell lines).
While the majority of EGF and its receptor are degraded, a small amount is 
constitutively recycled back to the cell surface. In the experiments described 
above, the percentage of EGF recycled at each time point was also calculated. Wild 
type cells recycled 7% more EGF than annexin 1 -/- cells after 3 hours incubation 
(Fig. 5.IB). This small increase was statistically significant (p<0.05). At each time 
point, wild type cells consistently recycled slightly more EGF than annexin 1 -/- 
cells and this increase was statistically significant at each time point after 25 
minutes. As the percentage of EGF degraded was not increased in annexin -/- cells, 
the average percentage EGF remaining in the cell after 3 hours was calculated (Fig. 
5.2). After 3 hours, 9.8% of internalised EGF remained in wild type cells compared 
to 13.8% annexin 1 -/- cells, and this difference was statistically significant.
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Figure 5.1. Loss o f annexin 1 does not affect the kinetics o f EGF degradation. 
JACRO cells were serum starved and incubated with 125I-EGF for 10 minutes at 37°C. 
Surface bound EGF was stripped and cells were incubated with warm medium to chase 
EGF through the cell. Medium was collected at different time points and cpm 
measured. Each medium sample was TCA precipitated and the cpm in the TCA 
soluble supernatant measured. The percentage of EGF degraded (A) or recycled (B) 
was calculated (see Materials & Methods section 2.8.4). There was no difference 
between cell lines in the rate of EGF degradation, although loss of annexin 1 decreased 
the amount of EGF recycled. Graphs show mean ± SEM of three independent 
experiments. * p<0.05.
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Figure 5.2. Effect o f loss o f annexin 1 on EGF trafficking. From the experiments 
shown in Fig. 5.1 the percentage of EGF recycled, degraded, and remaining in the 
cell, after 3 hours was calculated. Graph shows the mean ± SEM of three 
independent experiments. * p <0.01, ns = non significant.
Ideally, to compare the effects of loss of annexin 1 and 2 on the kinetics of EGF 
degradation and recycling, an annexin 2 -/- cell line would be used. However, the 
DT40 annexin 2-1- cell line, used in the previous chapter, was unsuitable because 
these cells do not express EGFR. Therefore, control and annexin 2 RNAi-treated 
HeLa cells were serum starved and incubated with 125I-EGF (as described in 
Materials & Methods 2.8.2). Cells from the same RNAi experiment were also 
collected and lysates blotted for annexin 2, to check the efficiency of protein 
depletion (Fig. 5.3A). There was no difference in the kinetics of EGF degradation 
between control and annexin 2 RNAi-treated cells (Fig. 5.3A). After 4 hours, 
-70% EGF had been degraded in both control and RNAi treated cells. Similarly, 
there was no significant difference observed at any time point in the percentage of 
EGF recycled between cell types (Fig. 5.3B). After 4 hours, -16% EGF had been 
recycled out of control and annexin 2 RNAi-treated cells. Finally, there was no 
difference in the percentage of EGF remaining in cells after 4 hours. In both 
control and annexin 2 -/- cells, there was approximately 11% EGF remaining (Fig. 
5.3C), which was consistent with the percentage calculated in JACRO cells.
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Figure 5.3. Depletion o f annexin 2 has no effect on EGF degradation or recycling. 
HeLa cells were transfected with control (C) or annexin 2 RNAi (A2) for 3 days. 
Cell lysates were blotted with anti-tubulin (tub) and anti-annexin 2 (Anx2) to check 
efficiency of knockdown (A). Cells were serum starved before a 10 minute 
incubation with 125I-EGF at 37°C. Surface bound EGF was removed and internalised 
EGF was chased through cells. Media was collected at each time point and EGF 
remaining in cells was released using 1% TxlOO. All media samples were TCA 
precipitated to determine how much EGF was recycled or degraded at each time 
point. Graphs show percentage of EGF degraded (B), recycled (C) and a comparison 
of percentages (D). There was no difference between control and annexin 2 RNAi- 
treated cells in the kinetics of EGF degraded or recycled. Graphs show mean ± SEM 
of four independent experiments.
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5.2.2 Annexin 1 is not involved in T f recycling, but annexin 2 depletion alters 
intracellular T f distribution
Whilst investigating the effect of loss of annexin 1 on EGF degradation and 
recycling, a slight inhibition of EGF recycling was observed. To further explore 
the role of annexin 1 in receptor recycling, the effects of loss of annexin 1 on Tf 
recycling were investigated. JACRO cells were preloaded with 125I-Tf for 1 hour 
and then incubated with warm media to chase Tf through cells. Media was 
collected at each time point and cpm measured. The percentage of Tf recycled was 
calculated at each time point (described in Materials and Methods section 2.8.4). 
There was no difference in the kinetics of Tf recycling between wild type and 
annexin 1 -/- cells at any time point (Fig. 5.4). After 2 hours, 85% 125I-transferrin 
had been recycled in both cell lines. The lack of effect suggests that Tf recycling 
occurs independently of annexin 1.
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Figure 5.4. Loss o f annexin 1 has no effect on T f recycling. JACRO cells were 
preloaded with 125I-Tf for 1 hour and then incubated with warm medium to chase Tf 
through cells. Medium was collected at different time points and cpm measured. 
The cpm in each media sample represents the recycled Tf and this was expressed as 
a percentage of the total Tf internalised. There was no difference in the kinetics of 
Tf recycling between cell lines. Graph shows the mean ± SEM of three 
independent experiments.
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Recent studies have reported that annexin 2 depletion induced a relocalisation of 
Tf-positive recycling endosomes but had little effect on Tf recycling (Zobiack et 
al., 2003). Around the same time, a conflicting report stated that annexin 2 
depletion had no effect on Tf internalisation or the distribution of T f positive 
endosomes (Mayran et al., 2003). As the data presented in the previous chapter 
was inconsistent with the findings of Mayran et al. (2003), who also reported that 
annexin 2 depletion inhibited MVB biogenesis, these published experiments were 
repeated to determine the exact nature of the effect of annexin 2 depletion on the 
distribution of Tf-containing recycling endosomes. Therefore, HeLa cells treated 
with control or annexin 2 RNAi were serum starved, incubated with fluorescent Tf 
for 5 minutes followed by a 20 minutes chase with serum free media. Cells were 
fixed and processed for immunofluorescence (as described in Materials and 
Methods 2.10). Cells were labelled with an anti-annexin 2 antibody to identify 
successfully depleted cells (Fig. 5.5). Cells were also stained with phalloidin to 
label actin and to help visualise cells depleted of annexin 2. Control cells formed 
neat monolayers and actin staining was spread throughout the cell. Cells lacking 
annexin 2 did not grow as neat patches, instead they were mostly present as single 
cells with actin staining revealing the presence of more stress fibres than seen in 
control cells.
After the chase, there was very little Tf remaining in control cells, as the majority 
would have been recycled out of the cell (Fig. 5.5, upper panels). Annexin 2 
RNAi-treated cells were imaged under the same conditions and many cells still 
contained Tf, visible in a perinuclear cluster (Fig. 5.5, lower panels). This 
difference was observed in the majority of cells depleted of annexin 2 but not in 
wild type cells.
These finding were consistent with those of Zobiack et al. (2003), although the 
phenotype described above was less marked than that observed in the published 
study. These Tf-containing structures were studied further using TEM. Cells were 
incubated with Tf-HRP for 5 minutes followed by a 20 minute chase, as a repeat of 
the experiment performed using fluorescence, and embedded for TEM. However, 
analysis of both control and annexin 2 RNAi-treated cells failed to reveal any Tf- 
HRP-containing structures, as identified by the product of the HRP/DAB reaction.
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Figure 5.5. Annexin 2 depletion causes a redistribution o f T f positive endosomes. HeLa cells 
were treated with control or annexin 2 RNAi for 3 days. Cells were serum starved and 
incubated with Tf-AlexaFluor-555 (red) for 5 minutes at 37°C and then with media for 20 
minutes at 37°C. Cells were fixed, permeabilised and stained using an anti-annexin 2 
antibody (green) and phalloidin (blue), to label actin. Tf accumulated in cells depleted of 
annexin 2. Typical images are shown for each treatment (A - low magnification; B - higher 
magnification). Stars indicate some cells depleted of annexin 2. White arrows point to areas 
of concentrated Tf. Bars = 20pm.
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Figure 5.6. Localisation o f Tf-containing endocytic structures in annexin 2 RNAi- 
treated cells. HeLa cells were treated with control or annexin 2 RNAi for 3 days. Cells 
were serum starved and incubated with Tf-HRP for 1 hour before processing for TEM. 
Typical Tf-HRP containing structures are shown (A) and tubular structures (B). Non-Tf- 
HRP containing MVB (*). Bar = 200nm
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5.2.3 Loss o f  annexin 1, but not annexin 2, alters EGFR degradation
Loss of annexin 1 had no effect on the kinetics of EGF degradation, despite the 
inhibition of EGF-stimulated inward vesiculation. To investigate whether loss of 
annexin 1 had an effect on EGFR degradation, JACRO cells were serum starved 
and stimulated with EGF for up to 3 hours. At each time point cells were harvested 
and lysates blotted for EGFR and tubulin, as a loading control. Although EGF 
stimulated receptor degradation occurred in both cell lines, it was altered in annexin 
1 -/- cells, to the extent that from 45 minutes onwards there was more EGFR in -/- 
cells than in wild type cells (Fig. 5.7A). Although wild type cells have slightly 
more EGFR than annexin 1 -/- cells (Fig. 3. IB), most of the EGFR signal was gone 
by 3 hours. At this time point in annexin 1 -/- cells, there was more EGFR 
remaining than in wild type cells. These data indicate that loss of annexin 1 either 
causes a delay in EGFR degradation or inhibits the degradation of some receptors.
To confirm that the alteration observed in EGFR degradation was due to loss of 
annexin 1, control and annexin 1 RNAi-treated HeLa cells were serum starved and 
stimulated with EGF for up to 3 hours. Cell lysates were collected at the same time 
points as in the JACRO cell experiment, and blotted for EGFR, tubulin and annexin 
1, to check efficiency of knockdown (Fig. 5.7B). Western blot analysis indicated 
that annexin 1 was depleted in RNAi-treated cells, compared to control cells. In 
annexin 1 depleted cells, there was more EGFR remaining after 3 hours than in 
control cells, confirming that loss of annexin 1 alters receptor degradation.
To investigate the possibility that annexin 2 depletion would alter EGFR 
degradation, despite the lack of effect observed on EGF degradation, control and 
annexin 2 RNAi-treated HeLa cells were serum starved and EGF stimulated for up 
to 3 hours. Cell lysates were blotted for annexin 2 to check for efficiency of protein 
depletion (Fig. 5.7C). Lysates were also blotted with an anti-tubulin antibody, to 
ensure equal protein loading, and anti-EGFR, to analyse EGFR degradation. As 
expected, there was no difference in EGFR degradation between control and 
annexin 2 RNAi-treated HeLa cells. In both cell lines significant EGFR 
degradation had occurred by 90 minutes. By 180 minutes there was very little 
EGFR remaining in either cell line.
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Figure 5.7. Loss o f annexin 1, but not annexin 2, alters EGFR degradation. 
JACRO cells (A), annexin 1 RNAi-treated (B) or annexin 2 RNAi-treated HeLa 
cells (C) were serum starved, incubated with EGF and cell lysates collected at 
different time points of EGF stimulation. JACRO cell lysates were blotted with 
anti-EGFR and anti-tubulin. EGFR degradation was altered in annexin 1 -/- cells 
compared to wild type cells, as more remained undegraded in -/- cells after 3 hours. 
RNAi-treated cell lysates were blotted for EGFR, tubulin and annexin 1 (B) or 
annexin 2 (C), to check for efficient protein depletion. Annexin 1 depletion 
resulted in altered EGFR degradation, but depletion of annexin 2 had no effect.
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Control Anxl RNAi
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The above data show that loss of annexin 1, but not annexin 2, alters the amount of 
EGFR degraded over 3 hours. As the effect observed on EGFR degradation was 
quite subtle, a further assay of the efficiency with which EGFR reach the lysosome 
was used. Anti-hEGFR-gold is a commonly used marker to follow EGFR 
endocytosis and, in the previous chapters, it was used to observe EGF-stimulated 
MVB formation. Using anti-hEGFR-gold, the distribution of EGFR after 1 hour of 
EGF stimulation was observed in RNAi-treated HeLa cells. HeLa cells were 
treated with control or annexin 1 RNAi, serum starved for 1 hour, then stimulated 
with EGF, in the presence of anti-hEGFR-gold, for a further hour. The intracellular 
distribution of anti-hEGFR-gold was analysed using TEM. When EGFR are 
degraded in the lysosome, the antibody that stabilises the gold particles is also 
degraded but the gold particles remain behind and form clusters. Therefore, gold 
particles were counted and recorded as monodisperse (single gold particles) or 
aggregated (two or more particles touching), where aggregated gold indicated 
degraded EGFR (Fig. 5.8). The number of monodisperse or aggregated gold 
particles was recorded as a percentage of the total number of particles. Cells 
depleted of annexin 1 contained a higher percentage of monodisperse anti-EGFR- 
gold compared with control cells (36.6% ± 3.6 compared to 25.8% ± 2.7). This 
suggests that in cells lacking annexin 1 there is an alteration in the amount of EGFR 
degraded after 1 hour of EGF stimulation. The anti-hEGFR antibody was raised 
against the extracellular domain of the receptor (Bellot et al., 1990). Therefore, it 
would be present in the lumen of MVBs and should be expected to behave as EGF 
ligand i.e. degraded efficiently regardless of annexin 1. However, it is possible that 
EGF ligand and EGFR are degraded with different kinetics, which would explain 
the above result.
The previous chapters focused on the quantitation of MVBs following EGF 
stimulation. The biochemical experiments described above indicate that annexin 2 
depletion had no effect on the kinetics of EGF/EGFR degradation. Nevertheless, 
annexin 2 has been proposed to play a role in maintaining the distribution of 
endosomes (Harder and Gerke, 1993) and so to investigate whether the loss of 
annexin 2 affected any part of the endocytic pathway, annexin 2 RNAi-treated 
HeLa cells were stimulated with EGF, in the presence of anti-hEGFR-gold, for 
different time periods and ultimately processed for TEM. The electron micrographs
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in Figure 5.9 show typical anti-hEGFR-gold containing structures in both control 
and annexin 2 RNAi treated cells. No difference was observed in the distribution 
of anti-hEGFR-gold at any time point. After 10 minutes EGF stimulation, most 
anti-hEGFR-gold was near the cell surface, either in CCPs or in early endosomes 
(Fig. 5.9a). After 30 minutes EGF stimulation, there was more anti-hEGFR-gold 
present in both cell types and the majority was found in both immature (few 
vesicles) and mature (many vesicles) MVBs (Fig. 5.9b). Previous experiments 
have shown that after 1 hour of EGF stimulation mature, anti-hEGFR-gold 
containing MVBs were present in both control and annexin 2 RNAi treated cells 
(see Chapter 5). After 1 hour, a significant proportion of anti-hEGFR-gold was 
also found in lysosomes (Fig. 5.9c).
The percentage of monodisperse anti-hEGFR-gold compared to aggregated gold 
was calculated for annexin 2 RNAi treated cells, as described previously for 
annexin 1 RNAi treated cells (Fig. 5.8). There was no difference in the percentage 
of monodisperse anti-hEGFR-gold between annexin 2 RNAi-treated and control 
cells, indicating that annexin 2 is not involved in EGFR degradation.
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Figure 5.8. RNAi induced depletion o f annexin 1 delays EGFR degradation. HeLa 
cells were treated with control, annexin 1 or annexin 2 RNAi for 3 days. Cells were 
serum starved before stimulation with EGF and anti-EGFR-gold for 1 hour. Cells 
were processed for TEM and the distribution of EGFR-gold was analysed. Gold 
particles were counted in a number of cells and recorded as monodisperse or 
aggregated (2 or more gold particles touching). Cells treated with annexin 1 RNAi 
showed a slight decrease in aggregated gold, compared to control or annexin 2 RNAi 
treated cells. Graphs show mean ± SEM of three independent experiments. In total, 
10911 gold particles were counted. * p<0.05.
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Figure 5.9. Annexin 2 depletion does not affect lysosomal delivery o f EGFR. HeLa cells 
were treated with control or annexin 2 RNAi for 3 days. Cells were serum starved before 
stimulation with EGF (lOOng/ml), in the presence of anti-hEGFR-gold, for 10, 30 or 60 
minutes. Cells were processed for TEM and the distribution of anti-hEGFR-gold 
analysed. Electron micrographs show the location of anti-hEGFR-gold at each time point. 
There was no difference observed in the distribution of anti-hEGFR-gold between control 
and annexin 2 RNAi-treated cells. Bars = 200nm.
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Having established that the effect of loss of annexin 1 induces an EGF-specific 
phenotype, but that annexin 2 depletion does not, it was necessary to investigate 
whether the loss of annexin 2 affected delivery of fluid phase markers to the 
lysosome. To compare the experiments performed here with published studies, 
HRP was used as a marker of fluid phase endocytosis (Mayran et a l, 2003). DT40 
wild type and annexin 2 -/- cells were incubated with HRP for 4 hours. Cells were 
embedded for TEM analysis and the morphology of structures containing HRP 
observed. HRP was previously shown to be present in mature MVBs in both cell 
types (Fig. 4.5). In these experiments, HRP was also present in various lysosomal 
structures (Fig. 5.10A). HRP, visible as the dark HRP/DAB reaction product, was 
present in MVBs fused with the lysosome, and also in multilamellar lysosomes that 
do not contain multivesicular regions. For further confirmation that loss of annexin 
2 does not affect delivery of fluid phase markers to the lysosome, DT40 cells were 
incubated with BSA-gold, which is also taken up by fluid phase endocytosis. Cells 
were incubated with BSA-gold for 4 hours and then incubated with medium or 20 
hours, to chase BSA-gold through cells, in order to study delivery to the lysosome 
(Wettey et a l, 2002). As seen with anti-hEGFR-gold, as BSA-gold reaches the 
lysosome, BSA is degraded but the gold particle is not. Therefore, the presence of 
gold aggregates identifies the degradative compartment. Figure 5.10B shows 
typical lysosomes containing BSA-gold in both cell lines. Under these conditions, 
all BSA-gold was observed within multilamellar lysosomes in both cellslines. 
These data show that fluid phase endocytosis and delivery to the lysosome are 
unaffected in cells lacking annexin 2.
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Figure 5.10. Toss o / annexin 2 does not affect delivery o f fluid phase markers to the 
lysosome. DT40 wild type and annexin 2 -/- cells were incubated with fluid phase HRP 
for 4 hours (A) or with BSA coupled to lOnm gold for 4 hours followed by a 20 hour 
incubation with normal DT40 cell medium (B). Cells were processed for TEM and the 
presence of these markers in lysosomes observed, as dark DAB reaction in A, or gold 
clusters in B. HRP and BSA-gold were observed in MVBs and lysosomes of both cell 
lines, and no difference in morphology was observed. Bars = 200nm.
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5.2.4 Loss o f  annexin 1 prolongs MAPK signalling
Improper EGFR downregulation can result in the alteration of downstream 
signalling pathways. The ERK1/2 MAPK pathway is just one of many initiated by 
ligand-induced EGFR activation. This pathway has been well studied and it has 
been reported that EGFR endocytosis may be required for maximal activation of 
certain components of this pathway. Although EGFR initiates many signalling 
pathways, not all require receptor endocytosis. The well-characterised ERK1/2 
MAPK pathway was chosen to study the effect of loss of annexin 1 on downstream 
signalling. JACRO cell lysates, collected for analysis of EGFR degradation, were 
blotted with antibodies against total MEK 1/2 and phospho-MEK 1/2 (Fig. 5.11). 
There was no difference in the total amount of MEK1/2 between cell types. 
However, in annexin 1 -/- cells levels of phospho-MEK 1/2 were greatly increased 
compared to wild type cells. Phosphorylation of MEK occurred rapidly (within 5 
minutes) in both wild type and annexin 1 -/- cells. The amount of phosphorylated 
MEK remained constant for 2 hours and then levels decreased significantly in both 
cell types. In wild type cells there was almost no phospho-MEK 1/2 remaining at 3 
hours. In annexin 1 -/- cells there was a small amount of phospho-MEK 1/2 
remaining, but significantly less than at 2 hours. JACRO and annexin 1 or control 
RNAi-treated HeLa cell lysates were also blotted for ERK1/2 (p44/42 MAPK) and 
phospho ERK1/2 (phospho-p44/42). Again, there was no difference observed in 
the total cellular levels of the unphosphorylated protein between cell lines. Like 
MEK 1/2, phosphorylation of ERK1/2 occurred rapidly, within 5 minutes, in all cell 
types. Unlike phospho-MEK 1/2, phospho-ERKl/2 started to be dephosphorylated 
after 45 minutes in JACRO cells, and between 5 and 45 minutes in HeLa cells. In 
wild type JACRO cells and control HeLa cells, there was very little phospho- 
ERK1/2 remaining after 3 hours. However, in JACRO annexin 1 -/- cells and 
annexin 1 RNAi-treated HeLa cells there was significantly more phosphorylated 
protein remaining after 3 hours, especially in annexin 1 -/- cells. These data 
indicate that loss of annexin 1 prolongs signalling through the MAPK pathway.
The finding that loss of annexin 1 altered the amount or kinetics of EGFR 
degradation is novel, but that delayed receptor degradation resulted in prolonged
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signalling has previously been reported (Babst et al., 2000). Activated EGFR can 
signal, through tyrosine phosphorylation, to a wide range of downstream proteins, 
including the MAPK pathway. To investigate further the effect of loss of annexin 1 
on EGFR tyrosine kinase activity, JACRO cell lysates from the above experiment 
were blotted with an anti-phosphotyrosine antibody (Fig. 5.12).
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p-MEK
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p-p44/42 
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Figure 5.11. Loss o f annexin 1 prolongs MAPK signaling. JACRO cells (A) or 
HeLa cells treated with control or annexin 1 RNAi (B) were serum starved, 
incubated with EGF and cell lysates collected at different time points of EGF 
stimulation. Lysates were blotted with anti-phospho (p) MEK, anti-MEK, anti- 
phospho p44/42 and anti-p44/42. Levels of phospho-MEK were increased in 
annexin 1 -/- cells and dephosphorylation of MEK and p44/42 was delayed.
EGFR is a major substrate of its own tyrosine kinase and phosphorylated EGFR 
was clearly visible as a large band near the top of the blot in both cells lines. There 
was more tyrosine phosphorylation following EGF stimulation in annexin 1 -/- 
cells, especially of larger proteins. In both cell lines, many proteins were rapidly
Control Anxl RNAi
Wild type Anxl
0 5 45 90 120 180 0 5 45 90 120 180
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phosphorylated (within 1 minute) in response to EGF stimulation. There were also 
a number of proteins that are constitutively phosphorylated. In annexin 1 -/- cells 
there was one protein (46kDa) that was phosphorylated in response to EGF in wild 
type cells, but not detectable in annexin 1 -/- cells. The size of this protein 
corresponds to the size of annexin 1 (37kDa) plus S100A11 (lOkDa), however 
there is no evidence that this dimer exists. Interestingly, the presence of phospho- 
annexin 1 in wild type cells is not evident, as compared with annexin 1 -/- cells, but 
this is likely because anti-phosphotyrosine antibodies tend not to efficiently bind 
annexin 1 in western blots (personal communication - Steve Moss). Additionally, 
there was another smaller protein (27kDa) that was constitutively phosphorylated in 
wild type cells but not in annexin 1 -/- cells.
Wild type Anxl -/-
EGF(mins) 0 1 5 15 45 90 120 180 0 1 5 15 45 90 120 180
180 kDa
46kDa
27kDa
Figure 5.12. Effect o f loss o f  annexin 1 on EGF-stimulated tyrosine phosphorylation. 
JACRO cells were serum starved before EGF stimulation. Cell lysates were collected 
at different time points of EGF stimulation and blotted with anti-phosphotyrosine. 
Phospho-EGFR is visible as a very large band (180kDa) near the top of the blot. 
There is a band at approximately 46kDa that is only phosphorylated in wild type cells.
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5.3 Discussion
5.3.1 Loss o f  annexin 1 alters EGFR degradation and prolongs signalling
Despite the inhibition of EGF-stimulated inward vesiculation observed in MVBs 
from annexin 1 -/- cells (Chapter 3), there was no effect on the kinetics of EGF 
degradation in these cells when compared with wild type cells. These findings 
indicate that annexin 1 is not required for efficient EGF degradation. However, the 
kinetics, or amount, of EGFR degradation in these cells and also in HeLa cells 
depleted of annexin 1, but not annexin 2, was altered. Previous data, reported here, 
showed that in the absence of annexin 1 anti-hEGFR-gold was still present in 
MVBs, although the number of internal vesicles per MVB was significantly 
reduced. When internal vesicles formed, they frequently contained anti-hEGFR- 
gold and this, coupled with the lack of an increase in EGF recycling, indicates that 
annexin 1 is not involved in receptor sorting. A possible explanation for the 
alteration in EGFR degradation observed in annexin 1 -/- cells could be due to the 
fact that in MVBs lacking internal vesicles, EGFR are retained on the perimeter 
membrane and delivery to the degradative enzymes, within the lysosome, from here 
may be less efficient than delivery from the lumen. That there was more 
monodisperse anti-hEGFR-gold in annexin 1 -/- cells than wild type cells, suggests 
that there is a small reduction in the amount of EGFR degraded in the lysosome. 
Although anti-hEGFR-gold labels the extracellular domain of the hEGFR and 
should therefore behave as EGF, there is published evidence to suggest that EGF 
ligand dissociates from its receptor prior to degradation (Burke et al., 2001). This 
dissociation could explain the difference in the kinetics of degradation of ligand and 
receptor observed. The finding that EGF degradation is unaffected and that EGFR 
degradation still occurs in cells lacking annexin 1, albeit with a delay or slight 
reduction, suggests that delivery of EGFR onto internal vesicles is not essential for 
lysosomal degradation.
These findings are similar to those of Futter et al. (2001) who reported that 
wortmannin treatment of cells resulted in formation of enlarged anti-hEGFR-gold 
containing vacuoles with few internal vesicles (Futter et al., 2001). In these cells,
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there was no difference in the kinetics or magnitude of EGF degradation. Further 
investigation revealed that retention of EGFR on the perimeter membrane, due to 
lack of inward vesiculation, resulted in an increased amount of tyrosine- 
phosphoiylated proteins (Futter et al., 2001). In this chapter, annexin 1 -/- cells 
exhibited enhanced and prolonged phosphorylation of MEK 1/2 compared to wild 
type cells, and phosphorylation of its downstream effector ERK1/2 was also 
prolonged in -/- cells. The overall level of tyrosine phosphorylated proteins in 
annexin 1 -/- cells was increased, supporting the hypothesis that sequestration of 
activated EGFR onto internal vesicles of MVBs is required to attenuate signalling. 
These data also provide evidence that annexin 1 may participate in the 
downregulation of EGFR signalling, through the formation of internal vesicles.
5.3.2 Loss o f annexin 2 does not affect lysosomal delivery o f EGF or EGFR
That annexin 2 depletion had no effect on delivery of EGF, or its receptor, to the 
lysosome was to be expected given that no effect had previously been observed on 
MVB formation in these studies (Chapter 4). However, these data contradict recent 
published findings, in which an inhibition of early to late endosomal transport in 
annexin 2 RNAi treated cells was reported (Mayran et al., 2003). Mayran et al. 
(2003) found that fluorescent EGF was degraded after a 5 minute pulse followed by 
a 60 minute chase in control cells, but was still visible after the chase in enlarged 
EEA1 positive structures in annexin 2 RNAi-treated cells. However, these findings 
were not explored further using more detailed analysis and no quantitation of the 
inhibitory effect on lysosomal delivery was performed (Mayran et al., 2003). The 
data presented in this chapter are more consistent with recent work from Zobiack et 
al. (2003), who reported that annexin 2 depletion had no effect on LDL delivery to 
the lysosome, although this group did not specifically investigate EGFR trafficking 
(Zobiack et al., 2003). Additional studies of rat hepatocytes by Pol et al. (1997), 
using cellular fractionation techniques, demonstrated that while a significant 
amount of annexin 2 was present in fractions containing recycling endosomes, none 
was detected in the MVB fraction (Pol et al., 1997). The findings presented in this 
chapter, taken together with data from previous chapters, show that annexins 1 and 
2 do not functionally compensate each other, in terms of internal vesicle formation
158
and EGFR trafficking. Although annexin 2 is upregulated in annexin 1 -/- cells 
(Croxtall et al., 2003), its loss had no effect on MVB formation or delivery of 
EGFR to the lysosome.
5.3.3 Annexin 1 and signalling
The finding in this chapter that loss of annexin 1 has a positive effect on EGFR 
signalling is consistent with a negative role of annexin 1 in this process. Loss of 
annexin 1 could alter signalling directly through its effect on EGF-stimulated 
inward vesiculation and, thus, dowregulation of EGFR signalling. However, it is 
possible that the prolonged MAPK signalling in annexin 1 -/- cells could occur 
independently of the effects observed on membrane traffic. Grb2 is a central 
molecule in EGFR internalisation and interacts with both c-Cbl and EGFR at the 
plasma membrane, and also within endosomes. Grb2 is recruited to the plasma 
membrane after ligand-induced receptor activation and is thought to be involved in 
anchoring receptors to the Epsl5 complex, prior to CCV formation. Additionally, 
Grb2 is constitutively associated with SOS, which is part of the Ras signalling 
pathway. The N-terminal domain of annexin 1 contains a region, with sequence 
homology to SH2 recognition domains, that can bind Grb2 (Alldridge et al., 1999; 
Croxtall et al., 2000). Annexin 1 is believed to compete with Grb2 for binding to 
EGFR and inhibit the recruitment of further signalling factors (Croxtall et al., 
2000).
The role of annexin 1 in MAPK signalling also been investigated by groups 
working on LPS stimulation of macrophages (Alldridge and Bryant, 2003). In 
RAW macrophages overexpressing annexin 1, constitutive activation of ERK1/2 
was observed, and resulted in decreased cell proliferation (Alldridge and Bryant, 
2003). Although these findings are inconsistent with the work presented in this 
chapter and those of Croxtall et al. (2000), the effect of constitutive or enhanced 
signalling appears to be cell type specific, as ERK1/2 overexpression has been 
reported in transformed cells and allows translocation of phospho-proteins to the 
nucleus and subsequent phosphorylation of transcription factors (Marshall, 1995).
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That annexin 1 plays a role in the regulation of EGFR signalling has previously 
been reported (Croxtall et al., 2000), and the data presented here is consistent with 
a negative role for annexin 1 on EGF-stimulated signalling through the MAPK 
pathway. Efficient ERK1/2 signalling requires the formation of a scaffold complex 
on endosomes (Teis et al., 2002). Given the membrane and actin binding properties 
of annexin 1, it is entirely possible that annexin 1 may play a scaffold or adaptor 
role to control the formation of signalling complexes, although no evidence exists 
to support this hypothesis.
5.3.4 Annexin 2 and Tf recycling
The majority of Tf is reported to recycle through the fast pathway from endosomes, 
and although some is retained on the perimeter membrane of MVBs and sorted to 
Rab 11 positive recycling endosomes (Ullrich et a l, 1996; Green et al., 1997), 
these structures are not essential for Tf recycling (Sheff et al., 2002). However, 
annexin 2 has been identified on both endosomes and recycling endosomes (Emans 
et al., 1993; Harder and Gerke, 1993; Jost et al., 1997; Zeuschner et al., 2001; 
Zobiack et al., 2003). Recently it was shown that depletion of annexin 2 caused a 
relocalisation of Tf positive recycling endosomes, although this had little effect on 
the kinetics of Tf recycling (Zobiack et al., 2003). The data presented in this 
chapter is consistent with a role for annexin 2 in the proper positioning of recycling 
endosomes, although further work needs to be carried out to determine the 
ultrastructural nature and exact location of these organelles.
5.3.5 Summary o f findings
The data presented in this chapter is consistent with previous chapters investigating 
the roles of annexins 1 and 2 in MVB formation and inward vesiculation. While 
annexin 2 is not involved in MVB biogenesis, annexin 1 is required for EGF- 
stimulated formation of internal vesicles within MVBs. The loss of annexin 1, 
therefore, not only inhibits this process, but is also accompanied by a delay in, or 
slight inhibition of, EGFR degradation. Subsequent downstream signalling events,
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through tyrosine phosphorylation, are prolonged and this is consistent with 
published work that reports inward vesiculation is required to attenuate receptor 
signalling (Futter et a l, 2001). Meanwhile, loss of annexin 2 has no effect on these 
processes and instead is involved with the proper positioning of recycling 
endosomes, as reported by Zobiack et a l (2003).
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Chapter 6 -  Localisation of annexins in the endocytic pathway
6.1 Introduction
The data presented in the previous chapters demonstrates a role for annexin 1 
within MVBs of EGF-stimulated cells. In contrast, no role for annexin 2 was 
identified in MVB formation or sorting within MVBs, regardless of whether or not 
cells were stimulated with EGF. Consistent with these findings, annexin 1 has been 
localised to MVBs (Futter et al., 1993; Pol et al., 1997) but annexin 2 was only 
reported to be found in MVBs in cells induced to accumulate cholesterol (Mayran 
et a l , 2003). The localisation of annexin 1 to MVBs used fractionation techniques, 
but more recently annexin 1-GFP was used to examine the subcellular distribution 
of annexin 1 in living cells. In these studies, using unstimulated HeLa cells, 
annexin 1-GFP was localised to Tf positive endosomes and only localised to 
fluorescent dextran-containing late endosomes as a N-terminally truncated 
construct (Rescher et al., 2000). Annexin 2 has been localised to endosomes, both 
early and recycling, and this association is reportedly cholesterol dependent (Harder 
et al., 1997; Zeuschner et al., 2001; Mayran et al., 2003; Zobiack et al., 2003).
The effect of loss of annexin 1 on inward vesiculation suggests that annexin 1 is 
present on MVBs. Although the localisation of annexin 1 has been studied, 
whether it localises to internal vesicles or remains on the perimeter membrane 
remains unresolved. The finding that loss of annexin 2 had no effect on MVB 
formation or inward vesiculation within MVBs, taken together with the studies 
described above, suggests that annexin 2 is not part of the complex group of 
proteins that work within MVBs. However, this does not rule out the possibility 
that annexin 2 is present in MVBs, as a consequence of its localisation to early 
endosomes, which mature into MVBs.
A combination of fluorescence studies in living cells and cryo-immuno electron 
microscopy were used to investigate the intracellular locations of annexins 1 and 2. 
Given the EGF-stimulated effect mediated by annexin 1, it was important to also 
investigate whether EGF-stimulation altered the localisations of annexins 1 and 2. 
The main aim was to confirm the presence of annexin 1 in MVBs and to determine
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whether it was found on the perimeter membrane of MVBs or on internal vesicles. 
The data presented in this chapter show that annexin 1 and annexin 1-GFP were 
both present on the perimeter membranes of MVBs, but also on EGFR-positive 
internal vesicles. The absence of a significant amount of annexin 2 in MVBs 
confirmed the specificity of labelling. In EGF stimulated cells, annexin 1 
associated with EGFR-positive endosomes and remained associated with EGFR- 
positive structures until lysosomal degradation. As expected the localisation of 
annexin 2 did not alter upon EGF stimulation, and annexin 2 remained associated 
with a large number of TfR-positive membrane bound structures.
6.2 Results
6.2.1 Creating an annexin 1-GFP stable cell line to investigate the intracellular 
localisation o f annexin 1
Annexin 1 has previously been localised to early endosomes containing fluorescent 
Tf (Seemann et al., 1997; Rescher et al., 2000). Annexin 1 is an abundant protein 
and conventional use of immunofluorescence to label endogenous annexin 1 proved 
inadequate to localise the protein to any particular intracellular structure, as annexin 
1 is present throughout the cytoplasm and also in the nucleus (Fig. 6.1). Therefore, 
to overcome this problem an annexin 1-GFP chimera was expressed at low levels in 
HEp2 cells, and used to investigate the localisation of annexin 1 with Tf and EGF 
(see Materials & Methods section 2.2.1).
To test the expression of annexin 1-GFP, HEp2 cells were transiently transfected 
with the construct. Figure 6.2 shows HEp2 cells expressing annexin 1-GFP (left) or 
pGFP (right). Annexin 1-GFP was evident predominantly in the cytoplasm but a 
small amount was visible in the nucleus. It was also present as punctate regions 
throughout the cytoplasm. Cells transfected with pGFP showed diffuse GFP 
expression throughout the cytoplasm and high levels of expression in the nucleus. 
To create a stable cell line, HEp2 cells were transfected with annexin 1-GFP using 
the calcium phosphate transfection method (see Materials and Methods section 
2.3.2). Medium was removed, 48 hours post-transfection, and replaced with 
selection medium containing G418. Over 2 weeks, cells that did not contain 
annexin 1-GFP, and therefore the antibiotic resistance gene, died and colonies
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Figure 6.1. Immunofluorescence staining o f endogenous annexin 1. HEp2 cells were 
fixed using 3% PFA and processed for immunofluorescence. Cells were labelled 
with anti-annexin 1 antibody (green) and phalloidin-AlexaFluor-547 (red) to label 
actin. Images show diffuse cytoplasmic annexin 1 staining with little intracellular 
detail and some nuclear staining. Bar = 20pm.
Figure 6.2. HEp2 cells transiently expressing annexin 1-GFP. HEp2 cells were 
transiently transfected with annexin 1 -GFP (left), or pGFP-N 1 (right), for 24 hours. Cells 
were imaged using confocal microscopy. Images shown are combined images, from 6 
images taken in a Z-stack through the cell, and show that annexin 1-GFP expression is 
very different from GFP expression. Bar = 20pm.
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formed from single cells that contained the plasmid. Colonies were picked and 
annexin 1-GFP expression observed using confocal microscopy. Cells derived 
from a single colony showed uniform expression of annexin 1-GFP (Fig. 6.3). One 
colony was chosen due to its low level expression, as it was difficult to identify 
intracellular structures in cells overexpressing annexin 1-GFP. Also, HEp2 cells 
express high levels of endogenous annexin 1 so overexpression of annexin 1-GFP 
could result in mislocalisation of the protein and/or an alteration in function.
Although the sequence of the annexin 1-GFP construct was correct (see Appendix 
1, Fig. S.3) and its expression in cells in agreement with published data, a western 
blot was performed to further confirm the expression of annexin 1-GFP. HEp2 
cells and cells from the stable cell line were harvested, and cell lysates blotted with 
anti-tubulin (loading control), anti-annexin 1 or anti-GFP antibodies (Fig. 6.4). In 
stably expressing cells blotted for annexin 1, there was an extra band of ~62 kDa 
visible that was not seen in control cells. This band corresponds to the size of 
annexin 1 (35kDa) plus GFP (27kDa). The levels of annexin 1-GFP expressed in 
these cells are much lower than that of endogenous annexin 1.
6.2.2 Annexin 1 colocalises with Tfin unstimulated cells
In live unstimulated cells annexin 1-GFP staining was visible as punctae throughout 
the cytoplasm, with some diffuse staining (Fig. 6.5). These cells express annexin 1- 
GFP at low levels and consequently little staining was visible in the nucleus. To 
identify the nature of the punctate annexin 1-GFP structures observed, cells were 
incubated with AlexaFluor555-labelled Tf for 10 or 60 minutes (Fig. 6.6). After 10 
minutes, there was significant colocalisation between annexin 1-GFP and Tf in 
punctae around the cell periphery. There were also a number of structures that 
labelled for either Tf or annexin 1-GFP, but not both. After 60 minutes, the Tf- 
positive labelling had spread inwards from the cell periphery and some 
colocalisation with annexin 1-GFP occurred on large perinuclear structures, 
possibly MVBs before Tf has been sorted to the recycling pathway. However, 
there were also many single-labelled structures present around the nucleus.
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Figure 6.3. Selection o f stable cell line expressing annexin 1-GFP. HEp2 cells were 
transfected with annexin 1-GFP, using calcium phosphate treatment, for 48 hours. 
Medium was replaced with selection medium containing 0.5mg/ml G418 for 10-14 
days. Colonies were picked and annexin 1 -GFP expression observed. Some colonies 
expressed low uniform annexin 1-GFP expression (left), whilst others were clearly 
derived from mixed colonies (right), showing different levels of expression.
Bar = 20pm.
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Figure 6.4. Annexin 1-GFP expression in HEp2 cells. HEp2 cells, stably expressing 
annexin 1-GFP (+), and control HEp2 cells (-) were collected for western blotting. 
Cell lysates were blotted for annexin 1 and tubulin (A) or GFP and tubulin (B). In 
transfected cells, there was an extra band visible of approximately 62kDa, which is 
around the correct size for annexin 1-GFP (35 + 27).
Interestingly, after 60 minutes incubation with labelled Tf, there was a significant 
number of Tf-positive vesicles just under the plasma membrane that did not 
colocalise with annexin 1-GFP, suggesting that annexin 1 is not involved in Tf 
internalisation. The small structures that only label for Tf could be endosomes 
returning Tf to the plasma membrane, via the fast recycling route. At later stages of 
Tf incubation, these single labelled structures were predominantly in a perinuclear 
distribution and it is likely that these are recycling endosomes. As this work was 
carried out in living cells, early or recycling endosomal markers, such as Rab5, 
EEA1 or Rabl 1, could not be used.
To further investigate the colocalisation of annexin 1-GFP and Tf, unstimulated 
HEp2 cells stably expressing annexin 1-GFP were fixed and processed for immuno- 
EM (see Materials & Methods section 2.11). Sections were labelled with anti-GFP 
and anti-TfR antibodies, followed by lOnm or 15nm Protein A Gold (PAG), 
respectively (Fig. 6.7). Sections from the same cells were also labelled with anti- 
GFP (lOnm gold) and anti-EGFR (15nm gold) to further investigate the localisation 
of annexin 1 in the absence of EGF stimulation (Fig. 6.8).
In unstimulated cells, anti-GFP staining was observed in the cytoplasm, in small 
vesicles near the plasma membrane, and on endocytic structures. TfR and GFP co­
labelled a number of small endocytic structures. The TfR antibody was raised 
against the extracellular domain of the receptor and should, therefore, label the 
lumen of intracellular vesicles. Indeed, TfR was observed within CCVs that did not 
label for annexin 1-GFP.
These sections, from unstimulated cells, contained few MVBs, which is consistent 
with data describing the EGF-stimulation of MVB formation in Chapter 3. 
However, a small number of MVBs were observed and many of these contained 
annexin 1-GFP labelling on internal vesicles (Fig. 6.7 & 6.8). Annexin 1-GFP was 
also present at the perimeter membrane of MVBs with TfR and on small vesicles 
near MVBs, which could be approaching endosomes ready to fuse with MVBs or 
recycling endosomes leaving the perimeter membrane. However, not all MVBs 
labelled for annexin 1-GFP. There was little EGFR labelling in MVBs in 
unstimulated cells.
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Figure 6.5. Localisation o f annexin 1-GFP in unstimulated cells. HEp2 cells stably 
expressing annexin 1-GFP were serum starved for 1 hour and imaged using BioRad 
confocal microscope. Annexin 1-GFP was visible throughout the cytoplasm and as 
punctae especially near the nucleus (inset shows 2x magnification). Bar = 20pm.
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Figure 6.6. Annexin 1-GFP colocalises with Tf in unstimulated cells. Live unstimulated 
HEp2 cells, stably expressing annexin 1-GFP, were incubated with Tf-AlexaFluor 555 
for 10 minutes or 60 minutes. Annexin 1-GFP colocalised with Tf in punctate structures, 
especially near the cell surface (arrows). Inset (2x magnification) shows that not all Tf 
and annexin 1-GFP are in the same punctae. Block arrowheads show Tf only positive 
structure near the membrane. Open arrowheads shown annexin 1-GFP only structures. 
Bars = 20pm.
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Figure 6.7. Ultrastructural localisation o f annexin 1-GFP and TfR in unstimulated 
cells. HEp2 cells, stably expressing annexin 1-GFP, were serum starved and 
processed for immuno-EM. Sections were labelled with anti-GFP (lOnm gold, 
block arrowheads) and anti-TfR (15nm gold, open arrows) antibodies. TflR. 
labelling was found at the plasma membrane (pm), in CCVs (c) and within 
endosomes. Annexin 1-GFP labelled TfR positive structures and was found in the 
cytoplasm. Annexin 1-GFP also labelled most MVBs, but some MVBs contained 
no label (*). TfR labelling was not found within MVBs, but at the perimeter 
membrane with annexin 1-GFP, or in small vesicles nearby with annexin 1-GFP. 
Bar = 200nm.
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Figure 6.8. Annexin 1-GFP and EGFR localisation in unstimulated cells. HEp2 cells, 
stably expressing annexin 1-GFP, were serum starved and processed for immuno-EM. 
Sections were labelled with anti-GFP (lOnm gold, block arrowheads) and anti-EGFR 
(15nm gold) antibodies. Annexin 1-GFP labelling was observed at the plasma 
membrane (pm) and on a number of small vesicles. Annexin 1-GFP also labelled the 
internal vesicles of some MVBs. There was little EGFR labelling of MVBs in 
unstimulated cells. Bar = 200nm.
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To investigate whether EGF-stimulation had an effect on the colocalisation of 
annexin 1-GFP and Tf, sections from EGF-stimulated HEp2 cells, stably expressing 
annexin 1-GFP, were labelled with anti-GFP (lOnm gold) and anti-TfR (15nm 
gold) antibodies and PAG (Fig. 6.9). After 30 minutes of EGF stimulation, the 
location of TfR staining was not markedly different to that seen in unstimulated 
cells, although more CCVs were observed with TfR labelling within. The 
formation of more CCVs is probably due to EGF stimulation, as it is known that 
EGF stimulation increases the density of CCPs at the cell surface (Connolly et al., 
1984). TfR labelling was observed at the plasma membrane, within CCVs, 
endosomes and on the perimeter membrane of MVBs. After EGF stimulation, 
more annexin 1-GFP labelled the internal vesicles of MVBs and was also present 
within lysosomes. These studies show that annexin 1-GFP is associated with TfR 
positive structures in unstimulated cells and that after EGF stimulation annexin 1- 
GFP is also associated with EGFR positive structures. EGF-stimulation induces the 
formation of MVBs, and the finding that annexin 1-GFP labelling was observed on 
many MVBs indicates that EGF-stimulation also alters the localisation of annexin 1 
within cells.
6.2.3 Annexin 1 colocalises with EGFR after EGF stimulation
Following EGF stimulation, the localisation of TfR was unaffected but increased 
annexin 1-GFP labelling o f internal vesicles of MVBs was observed. To 
investigate the exact nature o f this EGF-stimulated effect, live HEp2 cells stably 
expressing annexin 1-GFP were stimulated with EGF and the localisation of 
annexin 1-GFP observed. After 10 minutes EGF stimulation, annexin 1-GFP and 
fluorescent EGF were present together in a number of peripheral structures (Fig. 
6.10). EGF was also visible in annexin 1-GFP negative punctae. Annexin 1-GFP 
staining was visible throughout the cytoplasm, as described previously, and also in 
EGF negative vesicles distributed in a perinuclear location.
After 30 minutes of EGF stimulation, there was more colocalisation of annexin 1- 
GFP and EGF in larger structures throughout the cytoplasm (Fig. 6.11). There were 
also some single labelled vesicles, as observed after 10 minutes.
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Figure 6.9. Annexin 1-GFP and TfR localisation in EGF-stimulated cells. HEp2 
cells, stably expressing annexin 1-GFP, were serum starved, EGF stimulated for 30 
minutes and processed for immuno-EM. Sections were labelled with anti-GFP (lOnm 
gold, block arrowheads) and anti-TfR (15nm gold, open arrows) antibodies, to 
examine the localisation of annexin 1-GFP and TfR in EGF-stimulated cells. The 
localisation of TfR after EGF stimulation was not markedly different. TfR labelling 
was observed at the plasma membrane (pm), in CCVs (c) and in endosomes. TfR 
also labelled the perimeter membrane of some MVBs. Annexin 1-GFP labelling of 
internal vesicles of MVBs was significantly increased, compared to unstimulated 
cells. Annexin 1-GFP labelling was also observed in MVB/lysosomes (L). Bar = 
200nm.
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Figure 6.10. Annexin 1-GFP colocalises with EGF in early endosomes. Live HEp2 
cells, stably expressing annexin 1-GFP, were serum starved for 1 hour, incubated with 
EGF-Alexafluor555 for 10 minutes and imaged using confocal microscopy. Images 
show typical annexin 1-GFP and EGF staining after 10 minutes of EGF stimulation. 
White arrows show areas of colocalisation, open arrows show structures positive for 
annexin 1-GFP alone, and block arrowheads structures positive for EGF alone. Inset = 
2x magnification. Bars = 20pm.
Figure 6.11. Annexin 1 colocalises with EGF in later endocytic structures. Living HEp2 
cells, stably expressing annexin 1-GFP, were serum starved and incubated with EGF- 
Alexafluor555 for 30 minutes. There was significant colocalisation in punctae in a 
perinuclear distribution (white arrows). Open arrows show structures positive for 
annexin 1-GFP alone and block arrowheads structures positive for EGF alone Inset = 2x 
magnification. Bars = 20pm.
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To observe the intracellular location of annexin 1-GFP with greater resolution, 
cryo-sections from EGF-stimulated HEp2 cells, stably expressing annexin 1-GFP, 
were labelled with anti-GFP (lOnm gold) and anti-EGFR (15nm gold) antibodies 
(Fig. 6.12). After 30 minutes of EGF stimulation, EGFR labelling was observed on 
small endocytic structures and MVBs (Fig. 6.12). The anti-EGFR antibody was 
raised against the cytoplasmic domain of the receptor and, therefore, labelled the 
cytoplasmic side of the endosomal and MVB membranes, and the inside of internal 
vesicles. After 30 minutes, approximately equal amounts of EGFR labelled the 
perimeter membrane of MVBs and internal vesicles. Annexin 1-GFP also labelled 
EGFR-containing structures and was present on the same internal vesicles as 
EGFR.
Annexin 1-GFP showed extensive colocalisation with EGFR after EGF stimulation. 
To further confirm this finding, sections from EGF-stimulated HEp2 cells and 
HEp2 cells expressing annexin 1-GFP were labelled with anti-annexin 1 (lOnm 
gold), to label endogenous annexin 1, and anti-EGFR (15nm gold) antibodies (Fig.
6.13). The anti-annexin 1 antibody would also be expected to recognise annexin 1- 
GFP but, as levels of endogenous annexin 1 are far higher (Fig. 6.4), the antibody 
should label predominantly the endogenous protein. In both wild type and annexin 
1-GFP expressing HEp2 cells, anti-annexin 1 labelling was present throughout the 
cytoplasm, as well as on membranes. Furthermore, anti-annexin 1 labelling, like 
anti-GFP labelling, was also observed on EGFR-containing internal vesicles of 
MVBs and at the perimeter membrane of MVBs with EGFR.
As observed in unstimulated cells, there were a number of MVBs that did not label 
for either annexin 1, annexin 1-GFP or EGFR, and this provides further evidence of 
different sub-populations of MVBs. With both anti-GFP and anti-annexin 1 
labelling, there were a number of structures that only labelled for annexin 1 or 
EGFR. This is consistent with fluorescence experiments that showed extensive, but 
not total, colocalisation of annexin 1-GFP and EGF. From these findings, it 
appears that annexin 1 is able to move with EGF and its receptor through the 
endocytic pathway. To investigate whether annexin 1 remains associated with 
EGFR until degradation in the lysosome, longer time points of EGF stimulation 
were examined.
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Figure 6.12. Annexin 1 is present on EGFR positive internal vesicles. HEp2 cells, 
stably expressing annexin 1-GFP, were serum starved, stimulated with EGF 
(lOOng/ml) for 30 minutes and processed for immuno-EM. Sections were labelled 
with anti-GFP (lOnm gold, block arrowheads) and anti-EGFR (15nm gold, open 
arrows) antibodies. EGFR labelling was observed on small vesicles, on the 
perimeter membrane of MVBs and also on internal vesicles. The majority of 
annexin 1-GFP labelling was on EGFR positive structures and annexin 1-GFP co­
labels the same internal vesicles that contain EGFR. Unlabelled MVB is marked 
with a star. Bar = 200nm.
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Figure 6.13. Colocalisation o f  endogenous annexin 1 and EGFR. HEp2 cells, stably 
expressing annexin 1-GFP (A) or wild type (B), were serum starved, stimulated with 
EGF (lOOng/ml) for 30 minutes and processed for immuno-EM. Sections were 
labelled with anti-annexin (74/3) (lOnm gold, block arrowheads) and anti-EGFR 
(15nm gold, open arrows) antibodies. EGFR labelling small endocytic vesicles and 
MVBs, as shown in Fig. 7.12. Endogenous annexin 1 labelling was observed in the 
cytoplasm, on endocytic vesicles, and with EGFR, both within MVBs and at the 
perimeter membrane. Bars = 200nm.
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After 60 minutes EGF stimulation, annexin 1-GFP still colocalised with fluorescent 
EGF in living cells, although there was a significant number of structures that only 
labelled for either EGF or annexin 1-GFP (Fig. 6.14A). Colocalisation occurred in 
larger structures around the nucleus, likely to be MVBs. After 90 minutes of EGF 
stimulation, there was less fluorescent EGF present within cells, indicating that 
EGF degradation had occurred. Colocalisation of annexin 1-GFP and EGF was 
visible in larger, perinuclear structures similar to those seen after 60 minutes. 
Ultrastructural analysis revealed that annexin 1-GFP labels EGFR-positive mature 
MVBs and also lysosomal structures, as identified by the presence of multilamellar 
regions (Fig. 6.15). Although there was less EGFR staining after 60 minutes, due 
to receptor degradation, the majority of EGFR labelling was observed on internal 
vesicles of MVBs, compared to 30 minutes EGF stimulation where a significant 
proportion of EGFR was also present on the perimeter membrane of MVBs. These 
data show that annexin 1 remains with EGFR until lysosomal degradation.
6.2.4 Effect o f loss o f EGFR phosphorylation on annexin 1 localisation
After EGF stimulation a significant amount of annexin 1 was observed on MVBs, 
and on lysosomes after longer incubations. As little annexin 1 was observed on 
MVBs in unstimulated cells, it is possible that annexin 1 relocates from the 
cytoplasm to MVBs after EGF stimulation. It has been previously reported that an 
N-terminally truncated annexin 1-GFP construct localised to late endosomes, 
whereas the full length construct localised to early endosomes (Rescher et al., 
2000). Phosphorylation o f annexin 1 increases its susceptibility to N-terminal 
proteolysis (Haigler et al., 1987), although whether this occurs in vivo is still 
uncertain. The observation that annexin 1 is only phosphorylated by EGFR within 
MVBs led to the proposal that EGF-mediated phosphorylation of annexin 1 
controls annexin 1 function (Futter et al., 1993). Therefore, to investigate whether 
EGF-stimulated annexin 1 phosphorylation is required for the association of 
annexin 1 with later EGF-containing endocytic structures, an annexin 1-GFP 
mutant containing an amino acid substitution at the site of EGFR tyrosine 
phosphorylation (Y21F) was constructed (see Materials and Methods section 2.2.2). 
Y21F annexin 1-GFP was sequenced to confirm the presence of the mutation (see 
Appendix 1, Fig. S.4).
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Figure 6.14. Annexin 1-GFP moves with EGF to the lysosome. Living HEp2 cells, 
stably expressing annexin 1-GFP, were serum starved and incubated with EGF- 
Alexafluor555 for 60 minutes or 90 minutes. There was significant colocalisation in 
juxtanuclear punctae (arrows), but also some structures that were only positive for 
annexin 1-GFP (open arrows) or EGF (block arrowheads). Insets = 2x magnification. 
Bars = 20pm.
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Figure 6.15. Annexin 1-GFP remains associated with EGFR until the lysosome. HEp2 
cells, stably expressing annexin 1-GFP, were serum starved, stimulated with EGF 
(lOOng/ml) for 60 minutes and processed for immuno-EM. Sections were labelled with 
anti-GFP (lOnm gold, block arrowheads) and anti-EGFR (15nm gold, open arrows) 
antibodies. EGFR labelling of MVBs was primarily on internal vesicles, which also 
label for annexin 1-GFP. There was less EGFR labelling visible after 60 minutes, due 
to lysosomal degradation. Annexin 1-GFP and EGFR co-label both MVBs and 
lysosomes (L). G = Golgi apparatus. Bar = 200nm.
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To test the expression of Y21F annexin 1-GFP, HEp2 cells were transiently 
transfected with the construct and its localisation observed after 24 hours. Y21F 
annexin 1-GFP (Y21F) was observed as diffused cytoplasmic staining with some 
areas of punctate staining in unstimulated cells (Fig. 6.16), and this localisation was 
similar to that of wild type annexin 1-GFP (Fig. 6.5). To examine whether loss of 
EGFR phosphorylation alters the localisation of annexin 1, cells were serum starved 
and observed after 10 minutes stimulation with fluorescent EGF (Fig. 6.17). The 
localisation of Y21F was not markedly altered after this short period of EGF 
stimulation. It was visible throughout the cytoplasm and also in a number of EGF- 
positive punctae, similar to those observed with wild type annexin 1-GFP, although 
there appeared to be less colocalisation in cells expressing Y21F. After 30 minutes 
of EGF stimulation, there was some colocalisation of Y21F and EGF, but a number 
of EGF positive vesicles were also visible (Fig. 6.18).
By 60 minutes, much EGF appeared to have been degraded. However, some 
colocalisation was still visible in a perinuclear distribution. The localisation of 
Y21F after EGF stimulation was not obviously different to that of wild type 
annexin 1-GFP, suggesting that EGFR phosphorylation of annexin 1 is not essential 
for its localisation.
6.2.5 Annexin 2 colocalises with TfR but not EGFR
The intracellular localisation of annexin 2 was examined to explore whether 
annexin 2 was present in MVBs despite its apparent lack of function in these 
structures. Previous immunofluorescence experiments (Chapter 5) revealed that 
annexin 2 was present throughout the cytoplasm, concentrating near the plasma 
membrane, and also on punctate structures throughout the cytoplasm.
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Figure 6.16. Localisation o f Y2IF annexin 1-GFP in unstimulated cells. HEp2 cells 
were transiently transfected with Y21F annexin 1-GFP for 24 hours. Fiving cells 
were serum starved for 1 hour and imaged using confocal microscopy. Y21F annexin 
1 -GFP was present throughout the cytoplasm and as punctae. Bars = 20pm
Y21F
Figure 6.17. Y21F annexin 1-GFP partially colocalises with EGF in early endosomes. 
HEp2 cells were transiently transfected with Y21F annexin 1-GFP for 24 hours before 
serum starving for 1 hour. Cells were incubated with EGF-AlexaFluor555 for 10 minutes 
and imaged using confocal microscopy. Inset (2x magnification) shows areas of 
colocalisation between Y21F and EGF in peripheral punctae. Arrows point to punctae 
positive for Y21F and EGF, open arrows point to EGF-only positive structures.
Bar = 20pm.
Figure 6.18. Y2IF  annexin 1-GFP localisation in EG F stimulated cells. HEp2 cells 
were transiently transfected with Y21F annexin 1-GFP for 24 hours before serum 
starving for 1 hour. Cells were incubated with EGF-AlexaFluor555 for 30 or 60 minutes 
and imaged using confocal microscopy. After 30 minutes there was some colocalisation, 
but many EGF-positive structures did not contain Y21F. After 60 minutes there was less 
EGF staining but still some colocalisation. Arrows point to punctae positive for Y21F 
and EGF, open arrows point to EGF-only positive structures. Insets = 2x magnification. 
Bars = 20pm.
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To examine the localisation of annexin 2 in more detail, cryo-sections from 
unstimulated annexin 1-GFP expressing HEp2 cells were labelled with anti-annexin 
2 (lOnm gold) and anti-TfR (15nm gold) antibodies to identify whether annexin 2 
localised to TfR positive structures (Fig. 6.19). Annexin 2 labelling was observed 
just underneath the plasma membrane, throughout the cytoplasm and on small 
membrane-bound vesicles, many of which co-labelled for TfR. Some structures 
that co-labelled were vesicular, whereas others were more tubular in shape, 
although the shape of the structure depends on the plane of sectioning. Although 
many structures labelled for both annexin 2 and TfR, some labelled only for 
annexin 2, especially in the cytoplasm.
As EGF stimulation appeared to increase annexin 1 labelling of MVBs, the effect of 
EGF stimulation on the localisation of annexin 2 was examined. Sections from 
EGF-stimulated cells were labelled with anti-annexin 2 and anti-TfR antibodies 
(Fig. 6.20). Previous work localising TfR showed that EGF stimulation had no 
effect on its localisation (Fig. 6.9). The data here show that EGF stimulation does 
not alter the localisation of annexin 2, as annexin 2 labelling was again observed on 
the membrane of TfR positive vesicles and tubular structures. Annexin 2 also co­
labelled vesicles with TfR near unlabelled MVBs.
Having shown that EGF stimulation did not affect the localisation of annexin 2, it 
was necessary to investigate whether annexin 2 labelled any EGFR-positive 
structures. From published work, it was predicted that annexin 2 would label early 
endosomes containing EGFR, but whether annexin 2 is in EGFR-containing MVBs 
had not been investigated. Sections from EGF-stimulated cells were labelled with 
anti-annexin 2 (lOnm gold) and anti-EGFR antibodies (15nm gold) (Fig. 6.21). As 
observed when investigating annexin 1 localisation, after 30 minutes of EGF 
stimulation much EGFR labelling was present on both the perimeter membrane and 
on the internal vesicles of MVBs. Unlike annexin 1, little annexin 2 labelling was 
observed on the internal vesicles of EGFR-positive MVBs. However, some 
annexin 2 labelling was observed on the perimeter membrane of a small number of 
MVBs.
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Figure 6.19. Annexin 2 localises to TfR positive vesicles. HEp2 cells, stably 
expressing annexin 1-GFP, were serum starved and processed for immuno-EM. 
Sections were labelled with anti-annexin 2 (HH7) (lOnm gold, block arrowheads) and 
anti-TfR (15nm gold, open arrows) antibodies. Some annexin 2 labelling was 
observed just underneath the plasma membrane (pm). TfR labelled membrane bound 
vesicles and these co-labelled for annexin 2. Bar = 200nm.
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Figure 6.20. Annexin 2 localisation in EGF-stimulated cells. HEp2 cells, stably 
expressing annexin 1-GFP, were serum starved, EGF stimulated for 30 minutes and 
processed for immunoEM. Sections were labelled with anti-annexin 2 (HH7) (lOnm 
gold, block arrowheads) and anti-TfR (15nm gold, open arrows) antibodies. Annexin 
2 and TfR co-label many small endocytic structures, with TfR typically in the lumen 
of the vesicle or tubule, and annexin 2 on the membrane. Annexin 2 co-labels TfR 
positive vesicles that are close to MVBs, possibly recycling endosomes. Unlabelled 
MVBs are marked with a star. Bar = 200nm.
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Figure 6.21. Annexin 2 does not localise with EGFR in MVBs. HEp2 cells, stably 
expressing annexin 1-GFP, were serum starved, EGF stimulated for 30 minutes and 
processed for immunoEM. Sections were labelled with anti-annexin 2 (lOnm gold, 
block arrowheads) and anti-EGFR (15nm gold, open arrows) antibodies. EGFR 
labelling was observed in MVBs, both on the perimeter membrane (see MVB in 
upper right picture) and on internal vesicles. There was little annexin 2 labelling of 
these structures, although a small amount was observed on the perimeter membrane. 
Annexin 2 labelled small vesicles and near the plasma membrane (pm). Unlabelled 
MVB marked with a star. Bar = 200nm.
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Thus far the functions described for annexin 1 do not apply to annexin 2. Annexin 
1 has previously been localised to early endosomes and late endosomes after N- 
terminal proteolysis. Data shown here, for the first time, localised annexin 1 to the 
same internal vesicles as EGFR in MVBs of EGF stimulated cells, providing 
further evidence for its role in EGF-stimulated inward vesiculation in a 
subpopulation of MVBs. Annexin 2 did not label these structures to the same 
extent and instead colocalised extensively with TfR positive structures. Therefore, 
to further confirm that annexins 1 and 2 exhibit distinct cellular localisations, 
sections from EGF-stimulated cells were labelled with anti-GFP (15nm gold) and 
anti-annexin 2 (lOnm gold) (Fig. 6.22). Both labelled the plasma membrane and 
throughout the cytoplasm. Annexin 1-GFP labelled the internal vesicles and 
perimeter membrane of MVBs, yet little annexin 2 labelling was observed on these 
structures. These data are consistent with those described above (Fig. 6.12 and 
6.21), showing that annexin 1, not annexin 2, is involved in EGF-stimulated 
formation o f internal vesicles.
6.3 Discussion
6.3.1 EGF stimulation alters the distribution o f annexin 1
One of the aims o f this study was to investigate the effect of EGF on the 
localisation of annexin 1. These data show, through a combination of fluorescence 
and cryo-immuno EM, that the localisation of annexin 1, as annexin 1-GFP, but not 
annexin 2, is altered after EGF stimulation. In unstimulated cells, annexin 1 is 
present both in the cytoplasm and on small vesicles near the plasma membrane, and 
on Tf/TfR positive early endosomes, consistent with published data (Seemann et 
al., 1997; Rescher et al., 2000). Following EGF stimulation, annexin 1-GFP co­
labels small EGF positive endosomes and, after longer incubations, larger EGF 
positive structures distributed in a juxtanuclear position, which correspond to the 
usual location of MVBs. Immunolabelling of cryosections showed that these 
structures are EGFR-positive MVBs and that annexin 1 remains associated with 
EGF/EGFR positive structures until reaching the lysosome. This is the first report 
that annexin 1 is associated with EGFR containing endocytic structures until 
lysosomal degradation.
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Figure 6.22. Localisation o f  annexins 1 & 2 in EGF stimulated cells. HEp2 cells, 
stably expressing annexin 1-GFP, were serum starved, EGF stimulated for 30 
minutes and processed for immunoEM. Sections were labelled with anti-annexin 2 
(HH7) (lOnm gold, block arrowheads) and anti-GFP (15nm gold, open arrows) 
antibodies. Both annexins 1 and 2 labelled near, or just underneath, the plasma 
membrane (pm). The majority of annexin 1-GFP labelling was observed within 
MVBs. Unlabelled MVBs are marked (*). Annexin 2 preferentially labelled small 
vesicles throughout the cytoplasm, near MVBs and on the perimeter membrane of 
MVBs. G = Golgi apparatus. Bar = 200nm.
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The finding that a mutant annexin 1 lacking the EGFR phosphorylation site still 
colocalised with fluorescent EGF indicates that EGF-stimulated phosphorylation of 
annexin 1 is not required for the initial association of the protein with EGF- 
containing endosomes, consistent with the findings of Seemann et al. (Seemann et 
a l , 1996). This mutant annexin 1-GFP construct still localised to EGF-positive 
structures after longer incubations with EGF. That the localisation of this mutant 
annexin 1 was not markedly different from that of wild type annexin 1-GFP could 
be explained by the fact that phosphorylation of annexin 1 does not occur until after 
annexin 1 has associated with EGF-positive endosomes. As endosomes mature to 
form MVBs, annexin 1 remains associated and it is within the MVB that annexin 1 
performs its role in inward vesiculation, although the exact mechanism remains 
unclear. Therefore, even the mutant form of annexin 1-GFP, unable to be 
phosphorylated by EGFR, would be present on MVBs. It has been suggested that 
EGFR-mediated phosphorylation of annexin 1 is required for release of newly 
formed internal vesicles and so the effects of a phosphorylation mutant would not 
be observed until later stages of EGFR trafficking. As HEp2 cells express 
endogenous annexin 1, little functional evidence can be collected from these 
experiments as to the exact nature of the effect of loss of phosphorylation of 
annexin 1 on inward vesiculation.
These findings differ slightly from published work that reported the localisation of 
annexin 1-GFP in living cells for the first time (Rescher et al., 2000). Rescher et al. 
(2000) showed that in unstimulated cells annexin 1-GFP localised to Tf-positive 
endosomes, which is consistent with the data presented in this chapter. However, 
these published experiments failed to localise annexin 1-GFP to late endosomes, 
marked by a pulse of fluorescent HRP (Rescher et al., 2000). Only a N-terminally 
truncated annexin 1-GFP construct was found to label late endosomes (Rescher et 
al., 2000). The data presented in this chapter can be reconciled with these published 
findings on the basis that annexin 1 plays a specific role within EGF stimulated 
cells. The experiments performed and described in this chapter show that annexin 
1-GFP colocalises with EGF/EGFR in MVBs and lysosomes. In unstimulated cells 
there are fewer MVBs and these do not label as heavily for annexin 1-GFP. That 
some annexin 1-GFP was localised to MVBs in unstimulated cells, in this chapter, 
could be accounted for by the enhanced sensitivity of immuno EM compared with
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immunofluorescence. Increased annexin 1 labelling of MVBs after EGF 
stimulation may be due, in part, to the increased number of MVBs. Therefore, the 
work of Rescher et al. (2000) in unstimulated cells provides further evidence that 
EGF-stimulation may alter the localisation of annexin 1, by promoting its 
association with endosomes and thus MVBs. The fact that only the core domain of 
annexin 1 localised to late endosomes (Rescher et al., 2000) is consistent with the 
theory that phosphorylation induced N-terminal proteolysis of annexin 1 occurs, 
and that this process is coupled to inward vesiculation. However, the finding that 
annexin 1 lacking the EGFR phosphorylation site still localised to EGF-positive 
MVBs/late endosomes is inconsistent with the published work. One possible 
explanation could be that EGF stimulation induces the recruitment of annexin 1 to 
MVBs independently of annexin 1 phosphorylation, and that phosphorylation is 
only required for the release of internal vesicles within MVBs.
6.3.2 Annexin 1 is recruited onto internal vesicles o f MVBs with EGFR
The finding that annexin 1 is associated with EGFR-positive MVBs confirms 
previously published fractionation studies (Futter et a l, 1993; Pol et al., 1997). 
Furthermore, these experiments allowed the exact ultrastructural localisation to be 
examined, with regard receptor trafficking. The data presented here shows that not 
only is annexin 1 present within EGFR-positive MVBs, but that it labels the same 
internal vesicles as EGFR. While the EGFR antibody labelled the receptor 
cytoplasmic domain within the internal vesicles, it was not clear which side of the 
internal vesicle membrane annexin 1 labelled, partly due to the use of bridging 
antibodies. However, its localisation on internal vesicles is in keeping with a role 
for annexin 1 in allowing fission of newly formed vesicles into the lumen of the 
MVB. Some annexin 1 labelling was also found at the perimeter membrane and, 
although these experiments do not investigate it directly, this finding is consistent 
with the hypothesis that annexin 1 is phosphorylated by EGFR at the perimeter 
membrane, in order to induce N-terminal proteolysis of annexin 1, thus releasing 
the newly formed internal vesicle into the lumen of the MVB. These data also 
show that little annexin 2 was found within MVBs, although a small amount of 
labelling was observed, the majority of which was on the perimeter membrane.
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This finding is in agreement with work suggesting a role for annexin 2 in TfR 
recycling, which also reports that loss of annexin 2 had no effect on delivery to the 
late endosome/lysosome (Zobiack et al., 2003).
6.3.3 Further evidence for subpopulations o f MVBs
In unstimulated cells there were fewer MVBs observed, consistent with the data 
shown in Chapter 3, and following EGF stimulation the number of MVBs was 
greatly increased. Annexin 1 and EGFR co-labelled the majority of MVBs 
observed. After 30 minutes of EGF stimulation, labelling was divided between the 
perimeter membrane and internal vesicles, whereas after longer incubations 
labelling was predominantly on internal vesicles. However, even after EGF 
stimulation, not all MVBs labelled for annexin 1 and EGFR. Those MVBs that did 
not label for EGFR did not label for annexin 1 either and are shown in Figures 6.7, 
6.12 and 6.22. Taken together with previous findings (Chapter 3) showing that loss 
of annexin 1 did not affect the formation of all MVBs, these data provide further 
evidence for the existence of different sub-populations of MVBs.
Annexin 1-GFP labelled the majority of EGFR-positive MVBs, although some 
multivesicular structures labelled only for EGFR. This finding could be due to the 
fact that cells express far higher levels of endogenous annexin 1 than annexin 1- 
GFP, and that while endogenous annexin 1 may be present within MVBs, it was not 
recognised by the anti-GFP antibody. Within EGFR-positive MVBs, annexin 1- 
GFP only labelled certain internal vesicles, mostly those containing EGFR. 
Labelling of cryosections with an anti-annexin 1 antibody confirmed this finding 
and indicates that within MVBs there are at least two types of internal vesicle, those 
that label for annexin 1 and those that do not. Fractionation studies of late 
endosomal membranes separated MVB internal membranes into at least 2 
populations, both of which contained the tetraspanin CD63. One of these 
populations contained the majority of cellular LBPA, while the other was enriched 
in phosphatidylcholine (Kobayashi et al., 2002). However, from these experiments 
it was unclear whether there were two distinct populations of MVBs or two 
populations of internal vesicles within MVBs.
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Unpublished data also identified the presence of at least two subpopulations of 
MVB (White et al., under review), consistent with the data presented in this 
chapter. This work identified many EGFR-containing MVBs and a smaller 
number of morphologically similar MVBs that did not contain EGFR, but labelled 
for LBPA. The data from this chapter confirm the presence of two sub-populations 
of MVB, and also show that EGFR-containing MVBs label for annexin 1. Annexin 
1 mediates the EGF-stimulated increase in inward vesiculation within MVBs, but 
only within those containing EGFR. Coupled with its localisation on EGFR- 
positive internal vesicles, it seems likely that annexin 1 is only present on one 
population of MVB and perhaps only one type of internal vesicle.
6.3.4 Annexin 2 and TfR
The majority of data discussed so far have concerned annexin 1 and its EGF- 
stimulated functions. That annexin 2 does not mediate any EGF-specific effect on 
MVB formation, or internal vesicle formation within MVBs, is not surprising, 
given that it is a poor substrate for the EGFR tyrosine kinase, unlike annexin 1. 
The data presented in this chapter confirm published studies that showed 
colocalisation of annexin 2 and early endosomes (Emans et al., 1993). In the 
current study, the majority of annexin 2 labelling was observed on small membrane 
bound vesicles and a large amount was closely associated with TfR-positive 
structures. Although EGF stimulation did not markedly alter either annexin 2 or 
TfR localisation, in EGF stimulated cells annexin 2 and TfR co-labelled a number 
of vesicles near mature MVBs, possibly recycling endosomes.
These data support the evidence presented in the previous chapters that argue 
against a role for annexin 2 in MVB formation, but point towards a role in TfR 
trafficking, possibly in recycling. Annexin 2 is recruited to sites of actin 
polymerisation at both the plasma membrane and endosomes (Rescher et al., 2004). 
Actin is known to be involved in TfR recycling and this provides another clue to 
the action of annexin 2 (Durrbach et al., 1996).
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6.3.5 Summary o f findings
These data show, though a combination of fluorescence and immuno EM, that 
annexin 1 colocalises with EGF in early endosomes, but also in MVBs and 
lysosomes. That annexin 1 is present in early endosomes has been previously 
reported (Seemann et al., 1997; Diakonova et al., 1997; Rescher et al., 2000), but 
the ultrastructural location of annexin 1 to MVBs is shown here for the first time. 
The finding that annexin 1 is present on the same internal vesicles as EGFR after 
EGF stimulation provides further evidence for its role in formation of EGF- 
stimulated internal vesicles. The absence of annexin 2 from MVBs and lysosomes, 
both in unstimulated and EGF-stimulated cells, supports previous findings that loss 
of annexin 2 does not affect MVB formation (Chapter 4) or lysosomal delivery 
(Chapter 5), and is consistent with published fractionation studies, in which no 
annexin 2 was associated with MVBs (Pol et al., 1997). Instead, annexin 2 is 
closely associated with structures that also label for Tf/TfR. The localisation of 
annexin 2 does not alter after EGF stimulation, which is unsurprising as it is a poor 
substrate for the EGFR tyrosine kinase. Finally, detailed analysis of the 
intracellular locations of annexins 1 and 2 revealed that, although they are both 
present at the plasma membrane and throughout the cytoplasm, their localisations 
are very different and this could account for their distinct roles within EGFR 
trafficking.
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Chapter 7 -  A role for annexin 1 in the regulation of cell shape and 
motility
7.1 Introduction
JACRO annexin 1 -/- cells were studied in detail to investigate the effect of loss of 
annexin 1 on MVB formation and inward vesiculation (Chapter 3). Whilst using 
these cells, and the wild type cell line, a difference in cell size and shape was 
observed between cell lines. Croxtall et al. (2003) reported that annexin 1 -/- cells 
had more spindle-like appearance but did not investigate this further (Croxtall et al., 
2003). That annexin 1 may be involved in regulation of cell shape is consistent 
with its membrane- and actin-binding properties (Glenney, Jr. et al., 1987). 
Regulation of the actin cytoskeleton is important for maintaining cell size and 
shape, and also in the regulation of cell motility. Additionally, annexin 1 is able to 
bind the actin-modifying protein, profilin (Alvarez-Martinez et al., 1996; Alvarez- 
Martinez et al., 1997).
The effects of growth factor stimulation on fibroblast motility have been widely 
investigated, in particular those of EGF (O'Neill et al., 1985; Lin and Bertics, 1995; 
Xie et a l , 1998; Ware et a l , 1998; Wells et a l , 1999b) and fibroblast growth factor 
(FGF) (Taylor et a l , 1993; Ding et a l , 2000). EGF induces both mitogenic and 
motogenic responses in a variety of cell types, including fibroblasts (Chen et a l , 
1994a&b). Fibroblast migration is stimulated by EGF receptor activation, in a 
process involving PLCy mediated PIP2 hydrolysis at the leading edge of cells and 
the localised release o f the actin-modifying proteins, profilin and gelsolin 
(Goldschmidt-Clermont et a l , 1991; Banno et a l , 1992; Chen et a l , 1996a; Chou 
et a l , 2003). Annexins have also been implicated in cell migration although, in the 
case of annexin 1, the inhibition of the transendothelial migration of leukocytes by 
annexin 1 and N-terminal annexin 1 peptides is mediated by extracellular binding to 
members of the formyl peptide receptor family, rather than by direct interaction of 
annexin 1 intracellularly with the actin cytoskeleton (Walther et a l, 2000; Rescher 
et a l, 2002; Ernst et a l, 2004). The role of annexin 1 in EGF-stimulated cell 
motility has not yet been investigated. However, annexin 1 is phosphorylated by 
the EGFR tyrosine kinase and phosphorylation modifies the Ca2+ dependency of
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membrane association and increases the susceptibility of annexin 1 to N-terminal 
proteolysis (Haigler et a l, 1987; Chuah and Pallen, 1989; Ando et a l, 1989; Futter 
et al, 1993). The effect of tyrosine phosphorylation on actin binding and bundling 
activity has not been investigated directly, but EGF stimulation has been reported to 
induce colocalisation of annexin 1 with F-actin on membrane ruffles (Campos- 
Gonzalez et a l, 1990).
The initial aim of this study was to investigate the effect of loss of annexin 1 on the 
size and shape of mouse lung fibroblasts, using the JACRO cell lines. Cells lacking 
annexin 1 were slightly larger than wild type cells, but significantly flatter, as 
shown by an increased average area and confirmed using scanning electron 
microscopy. This increase in cell area was reversed by expressing annexin 1 in 
annexin 1 -/- cells. As annexin 1 plays a specific role in EGF-stimulated inward 
vesiculation, the effect of EGF was investigated and found that, although EGF- 
stimulation induced a change in cell shape, consistent with published data (Wells et 
al, 1999a), no significant effect was observed in annexin 1 -/- cells compared with 
wild type cells. However, the use of EGF in these studies led to the observation 
that annexin 1 -/- cells appeared to move more in response to EGF stimulation.
The studies presented here show that EGF-stimulation enhanced cell motility in 
both cell lines, although the mean distance moved by annexin 1 -/- cells was 
markedly increased compared to that of wild type cells. This increase was reversed 
by re-expression of annexin 1, but not by expression of a mutant annexin 1 lacking 
the EGFR phosphorylation site. These data show that annexin 1 inhibits EGF- 
stimulated fibroblast motility, a process that requires EGFR-mediated annexin 1 
phosphorylation.
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7.2 Results
7.2.1 Loss o f  annexin 1 alters the morphology o f  JACRO cells
Both JACRO cell lines formed adherent confluent monolayers. Proliferation of 
annexin 1 -/- cells was slightly reduced compared to wild type cells (Croxtall et al., 
2003). To confirm the absence of annexin 1 in the -/- cells, JACRO cell lysates 
were collected and blotted for annexin 1 (Fig. 7.1 A). The morphology of JACRO 
cells was observed using light microscopy, where JACRO annexin 1 -/- cells 
looked larger than wild type cells under sub-confluent conditions (Fig. 7.IB). The 
difference in cell morphology has already been reported, but focused on the more 
spindle-like appearance in the annexin 1 -/- cells compared to wild type cells 
(Croxtall et al., 2003).
Annexin 1 -/■
Figure 7.1. Loss o f annexin 1 alters morphology o f JACRO cells. (A) JACRO wild 
type (WT) and annexin 1 -/- cell lysates were blotted for annexin 1 and tubulin. (B) 
Wild type and annexin 1 -/- cells were imaged at subconfluency (top) or confluency 
(lower). Cells lacking annexin 1 have a more spindle-like, elongated shape.
Bars = 10pm.
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To further analyse the difference in cell morphology, phase images were taken of 
each cell line and the area of cells measured (see Materials and Methods section 
2.9.2) (Fig. 7.2). JACRO annexin 1 -/- cells had a larger area than wild type cells 
(2.8-fold increase). These cells also had a greater cell perimeter than wild type 
cells under the same conditions, but the difference was not as great (1.4-fold).
The fact that there was a large difference in the area of JACRO cells was not 
surprising, having observed both cell lines in culture. However, when cells were 
trypsinised, for passaging or cell counting, the difference in size of rounded-up cells 
was not noticeably different. To compare the actual sizes of wild type and annexin 
1 -/- JACRO cells, flow assisted cell sorting (FACS) analysis was used. To 
compare cell size, forward scatter was plotted on the X axis against side scatter on 
the Y axis. Comparing the data from wild type cells with annexin 1 -/- cells, a 
small but distinct shift in forward scatter was observed (Fig. 7.3A). The average 
(relative) value for wild type cell size was 417.6 compared to 456.14 in annexin 1 - 
/- cells. This indicates that cells lacking annexin 1 -/- cells are slightly larger than 
wild type cells.
To compare the two cell types within the same experiment, wild type cells were 
labelled with CFDA, a fluorescent marker (see Materials and Methods section
2.14). Fluorescently-labelled wild type cells and non-labelled annexin 1 -/- cells 
were mixed and the two populations were separated into two distinct groups, based 
on fluorescence using FACS (Fig. 7.3B). As observed in the previous experiment, 
annexin 1 -/- cells (shown in black) were located further along the X axis than wild 
type cells (red). This provides further evidence that there is a difference in size 
between the two JACRO cell lines. However, this small difference is not sufficient 
to explain the large increase in cell area, indicating that the annexin 1 -/- cells had a 
more spread out and flattened phenotype. This was confirmed using scanning 
electron microscopy (Fig. 7.4). JACRO cells were serum starved for one hour 
before being fixed and embedded for scanning electron microscopy (see Materials 
& Methods section 2.13).
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Figure 7.2. Annexin 1 -/- cells have a greater area than wild type cells. JACRO cells were 
plated on 3cm Mattek™ dishes for 24 hours and serum starved overnight. Several fields 
of cells were taken for each experiment and typical images shown for each cell type (A). 
Cell area (pm2) and cell perimeter (pm) were measured for each cell and the mean 
calculated (B, C). JACRO annexin 1 -/- cells had a much greater area and perimeter than 
wild type cells. Graphs show the mean ± SEM of 4 independent experiments. Bar = 
50pm. *** p<0.005. 198
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Figure 7.3. Loss o f annexin 1 alters the size o f JACRO cells. JACRO cell size was 
analysed using FACS analysis, comparing forward scatter (X axis) against side scatter 
(Y axis) (A). Average forward scatter values, for wild type (417.62) and annexin 1 -/- 
(456.13) cells, are marked with an asterisk. B - JACRO wild type cells were incubated 
with CFDA as a fluorescent marker and mixed with non-fluorescent -/- cells. Wild 
type (red) and annexin 1 -/- (black) cells were separated using forward scatter (X axis) 
against fluorescence (Y axis) (Bi). To analyse the relative sizes of the two cell types, 
forward (X) and side scatter (Y) were compared (Bii). Annexin 1 -/- cells showed a 
small increase in cell size, seen as a shift along the X axis.
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Wild type cells had many surface protrusions spread over the entire surface of the 
cell, while annexin 1 -/- cells had fewer protrusions and these were concentrated 
towards the centre of the cell, rather than distributed evenly over the entire cell 
surface. The annexin 1 -/- cells extended very flat extensions that were larger and 
flatter than those observed in wild type cells. These flat projections (lamellipodia) 
had very few surface protrusions and were very thin, as shown by the presence of 
visible actin stress fibres within.
To determine whether loss of annexin 1 had any effect on formation of intracellular 
actin, JACRO wild type and annexin 1 -/- cells were serum starved, fixed, 
permeabilised using 0.5% TxlOO and incubated with fluorescent phalloidin, to label 
actin (Fig. 7.5). Actin stress fibres were seen in both cell types, but there was more 
actin staining in wild type cells. In wild type cells, cortical actin was visible as a 
thick band near the edge of the cell. However, cells lacking annexin 1 contained far 
less cortical actin as wild type cells. This loss of cortical actin could be responsible 
for the change in cell shape.
7.2.2 EGF-induced motility is enhanced in JACRO annexin 1 -/- cells
JACRO cells were seeded onto 3cm Mattek™ dishes, to reach subconfluency, and 
serum starved overnight. For imaging, cells were either incubated in fresh serum 
free medium or serum free medium containing EGF. Cells were imaged every 5 
minutes for 90 minutes. The area and perimeter of each cell were measured at each 
time point of EGF stimulation, and the mean per experiment calculated. EGF 
stimulation did not induce a significant change in area or perimeter of JACRO cells. 
At each time point, the differences between wild type and annexin 1 -/- cell areas 
and perimeters were statistically significant (Fig. 7.6).
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Figure 7.4. Cells lacking annexin 1 are flatter and more spread out. JACRO wild 
type (A & C) and annexin 1 -/- (B, D, E) cells were seeded onto glass coverslips 
overnight and serum starved for 1 hour. Cells were fixed for scanning electron 
microscopy. Low magnification (A & B) confirmed the difference in cell area 
previously observed. Higher magnification (C & D) revealed differences in cell 
surface protrusions. White arrowheads point to areas lacking surface protrusions, 
white arrows point to actin stress fibres visible within a very flattened 
lamellipodium. Annexin 1 -/- cells were flatter and more spread out, compared to 
wild type cells. Bars = 10pm (A, B, E) or 1pm (C, D).
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Figure 7.5. Loss o f annexin 1 reduces cortical actin. JACRO cells were plated 
onto glass coverslips overnight and serum starved for 1 hour. Cells were fixed, 
permeabilised using 0.5% TxlOO and intracellular actin stained using 
phalloidin-547. These are typical images of regular actin staining in wild type 
cells and annexin 1 -/- cells, which show a loss of cortical actin. Bars = 20pm.
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Figure 7.6. EGF stimulation does not alter the area o f JACRO cells. JACRO cells 
were plated onto 3cm Mattek™ dishes and serum starved overnight. Images of 
unstimulated cells were taken. Cells were stimulated with EGF and images taken at 
different time points. The area (A) and perimeter (B) of each cell was measured and 
show that EGF stimulation did not induce a change in either cell line. Graphs show 
the mean ± SEM of 4 independent experiments.
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Whilst imaging live JACRO cells for cell area and perimeter measurements, it was 
observed that annexin 1 -/- cells appeared to move more in response to EGF. To 
investigate this further, JACRO cells were imaged, in the absence or presence of 
EGF, every 5 minutes for 90 minutes. The movement of each cell was tracked over 
time using MetaMorph (v5). The nucleus was used as the central point of the cell 
and any movement of this point was recorded and plotted along an XY axis divided 
into 10pm sections.
Figure 7.7A shows a typical cell tracking experiment for the JACRO cell lines, in 
the absence or presence of EGF stimulation. Each colour represents a different cell 
and the difference between unstimulated and EGF-stimulated cell movement is 
clear in both cell lines. The data shown here also shows that EGF-stimulated 
annexin 1 -/- cell motility was significantly increased compared to EGF-stimulated 
wild type cells.
To quantify the effect of EGF stimulation on cell motility, the total distance (pm) 
moved, and the mean velocity of movement (pm/sec), for each were recorded. 
Both unstimulated JACRO cell lines moved a short distance, but there was no 
difference between cell types (Fig 7.7B). EGF stimulated JACRO cells moved 
significantly further and faster than unstimulated cells (approximately 2-fold 
increase after EGF stimulation) (Fig. 7.7B & C). However, the mean total distance 
moved by EGF-stimulated annexin 1 -/- cells was significantly increased compared 
to that of EGF-stimulated wild type cells (1.5-fold increase). The same significant 
increase was observed when comparing the mean velocity of EGF-stimulated 
annexin 1 -/- and wild type cells. These data confirm that cells lacking annexin 1 
show enhanced motility in response to EGF.
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Figure 7.7. EGF-induced cell movement is enhanced in annexin 1 -/- cells. Serum 
starved JACRO cells were imaged every 5 minutes for 90 minutes in the absence or 
presence of EGF (lOOng/ml). Cell movement was tracked using the nucleus as the 
central point of the cell. Figure A shows typical cell tracks for unstimulated and EGF- 
stimulated wild type and annexin 1 -/- cells. Each bar is 10pm. The total distance (pm) 
per cell was recorded and the mean per experiment calculated (B). The mean velocity 
(pm/sec) of cell movement was also determined (C). Cells lacking annexin 1 moved 
further and faster, than wild type cells, in response to EGF stimulation. Graphs show 
the mean ± SEM of 4 independent experiments. * p<0.05; ** p<0.01; *** p<0.005
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7.2.3 Re-expressing annexin 1 decreases annexin 1 -/- cell area
To confirm that the change in cell area was due to the loss of annexin 1, JACRO 
annexin 1 -/- cells were transfected with an annexin 1-GFP chimera using 
nucleofection (see Materials and Methods section 2.4.3). Post-transfection (-36 
hours), cells were serum starved overnight. Cells were washed and incubated in L- 
15 medium without phenol red to visualise annexin 1-GFP in transfected cells. 
Cells expressing annexin 1-GFP were smaller than non-expressing annexin 1 -/- 
cells (Fig. 7.8A). To quantify this difference, the area and perimeter of each cell 
were measured (Fig. 7.8B & C). The mean area and perimeter of cells expressing 
annexin 1-GFP were significantly reduced compared to non-expressing annexin 1 - 
/- cells from the same experiments (1.5-fold reduction). The mean area and 
perimeter of annexin 1 -/- cells expressing annexin 1-GFP were comparable to 
those of wild type JACRO cells (data from previous experiment is included in 
Figure 7.8 for comparison). Annexin 1-GFP expressing cells were slightly larger 
than wild type cells but this difference was not significant.
7.2.4 Re-expressing annexin 1 inhibits enhanced EGF-stimulated cell motility
Re-expression of annexin 1-GFP in annexin 1 -/- cells reversed the observed 
increase in cell area to wild type levels. To determine whether annexin 1 re­
expression could reduce levels of EGF-stimulated motility, annexin 1 -/- cells were 
transfected with annexin 1-GFP, as described in 7.2.3. Fields of unstimulated and 
EGF-stimulated cells, containing both annexin 1-GFP expressing and non­
expressing cells, were imaged every 5 minutes for 90 minutes. There was no 
difference in cell movement between unstimulated wild type, annexin 1 -/- or -/- 
cells expressing annexin 1-GFP. However, after EGF stimulation the mean 
distance travelled by annexin 1-/- cells expressing annexin 1-GFP was significantly 
reduced compared to non-expressing -/- cells (1.5-fold decrease) (Fig. 7.9). The 
distance and velocity of -/- cells expressing annexin 1-GFP was similar to the data 
collected for wild type cells, included in Figure 7.9 for comparison.
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Figure 7.8. Re-expression o f annexin 1 reverses increased cell area. JACRO annexin 
1 -/- cells were nucleofected with annexin 1-GFP for 36 hours and serum starved 
overnight. Images of annexin 1-GFP expressing and non-expressing cells (*) were 
taken (A). The area and perimeter of each cell was measured (B, C). Wild type data 
from previous experiment is included for comparison. Cells expressing annexin 1-GFP 
were significantly smaller than non-expressing annexin 1 -/- cells. Graphs show the 
mean ± SEM of three independent experiments. *** p<0.005. Bar = 50pm
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Figure 7.8. Re-expression o f annexin 1 reverses increased cell area. JACRO annexin 
1 -/- cells were nucleofected with annexin 1-GFP for 36 hours and serum starved 
overnight. Images of annexin 1-GFP expressing and non-expressing cells (*) were 
taken (A). The area and perimeter of each cell was measured (B, C). Wild type data 
from previous experiment is included for comparison. Cells expressing annexin 1-GFP 
were significantly smaller than non-expressing annexin 1 -/- cells. Graphs show the 
mean ± SEM of three independent experiments. *** p<0.005. Bar = 50pm
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Figure 7.9. Enhanced EGF-stimulated cell movement in annexin 1 -/- cells can be 
reversed by re-expression o f annexin 1. JACRO annexin 1 -/- cells were transfected 
with annexin 1-GFP for 36 hours and serum starved overnight. Cells expressing 
annexin 1-GFP and non-expressing -/- cells were imaged every 5 minutes for 90 
minutes in the absence or presence of EGF. The total distance moved by each cell was 
recorded and the mean per experiment calculated (A). The mean velocity of each cell 
was also determined (B). Wild type cell data from the previous experiment is included 
for comparison. The movement of cells expressing annexin 1-GFP was reduced 
compared to non-expressing annexin 1 -/- cells. Graphs show the mean ± SEM of 
three independent experiments. * p<0.05, ** p<0.01, *** p<0.005.
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7.2.5 EGF-stimulated phosphorylation o f annexin 1 is not required for reversal o f 
the cell size phenotype
Re-expression of annexin 1-GFP in annexin 1 -/- cells reversed both the increased 
cell area and the enhanced EGF-stimulated cell motility phenotypes. To investigate 
whether EGF-stimulated phosphorylation of annexin 1 was required for annexin 1 
to function in these phenotypes, JACRO annexin 1 -/- cells were transfected with a 
mutant (Y21F) annexin 1-GFP chimera, lacking the EGFR phosphorylation site, for 
36 hours and serum starved. To observe the effect on cell area, several fields of 
cells were imaged for each experiment. Similar to cells expressing wild type 
annexin 1-GFP, cells expressing Y21F annexin 1-GFP were smaller than non­
expressing annexin 1 -/- cells (Fig. 7.11a). The area and perimeter were measured 
for each cell and the mean calculated for each experiment (Fig. 7.11b&c). Cells 
expressing Y21F annexin 1-GFP were approximately 2-fold smaller than non­
expressing cells from the same experiments. The mean area of annexin 1 -/- cells 
expressing Y21F annexin 1-GFP was consistent with that of cells expressing 
annexin 1-GFP, and also that of JACRO wild type cells (data from previous 
experiment is included in Figure 7.11 for comparison). The same effect was 
observed on the mean length of cell perimeters.
To confirm that this reversal of cell size was annexin 1 dependent, annexin 1 -/- 
cells were also transfected with pGFP-Nl, using the same methods as previously 
described. Cells were serum starved and measured the following day. 
Measurement of cell area and perimeter revealed that cells expressing pGFP-Nl 
were slightly smaller than non-expressing cells, but this difference was not 
statistically significant (Fig. 7.11). Importantly, the mean area of annexin 1 -/- cells 
expressing pGFP-Nl was significantly larger than JACRO wild type cells or 
annexin 1 -/- cells expressing either annexin 1-GFP or Y21F annexin 1-GFP.
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Figure 7.10. EGF-stimulated phosphorylation o f annexin 1 is not required to reverse 
the increase in cell area. JACRO annexin 1 -/- cells were nucleofected with Y21F 
annexin 1-GFP or pGFP-Nl for 36 hours and serum starved overnight. Images of 
cells expressing annexin 1-GFP, pGFP or non-expressing cells were taken (A). The 
area (B) and perimeter (C) of all cells was measured and the mean per experiment 
recorded. Data from wild type cells and annexin 1 -/- cells expressing annexin 1-GFP 
have been included for comparison. Expression of Y21F, but not pGFP, reduced the 
mean cell area and perimeter. Graphs show the mean ± SEM of three independent 
experiments. * p<0.05, *** p<0.005.
7.2.6 Inhibition o f EGF-stimulated motility requires tyrosine phosphorylation o f 
annexin 1
The reversal of the cell shape phenotype observed in annexin 1 -/- cells is not 
dependent upon EGF-stimulated annexin 1 phosphorylation. To investigate 
whether EGF-stimulated phosphorylation of annexin 1 is required to reverse the 
enhanced motility phenotype observed in EGF-stimulated annexin 1 -/- cells, 
JACRO annexin 1 -/- cells transfected with Y21F annexin 1-GFP were imaged, in 
the absence or presence of EGF, every 5 minutes for 90 minutes. There was no 
difference in movement of unstimulated Y21F annexin 1-GFP expressing annexin 1 
-/- cells or non-expressing -/- cells (Fig. 7.12). However, when these cells were 
stimulated with EGF, there was a significant increase in cell movement compared 
with unstimulated cells, in both expressing and non-expressing cells. There was no 
difference between EGF-stimulated movement of annexin 1 -/- cells expressing 
Y21F annexin 1-GFP or non-expressing cells. EGF stimulated annexin 1-/- cells 
expressing Y21F annexin 1-GFP moved further than wild type JACRO cells (1.5 
fold further) and also moved faster (1.8 fold). Thus, expression of Y21F annexin 1- 
GFP failed to reverse the increased motility observed in annexin 1 -/- cells after 
EGF stimulation, indicating that EGF-stimulated phosphorylation is required for 
annexin 1 to inhibit cell motility.
7.3 Discussion
7.3.1 Annexin 1 regulates cell shape through modulation o f the actin cytoskeleton
These results show that annexin 1 plays a role in the regulation of cell shape, as loss 
of annexin 1 leads to a greater cell area accompanied only by a small increase in 
cell volume. This indicates a more spread, flattened phenotype, which was 
confirmed using scanning electron microscopy. Analysis of intracellular actin 
revealed little difference in the formation of stress fibres within JACRO cells. 
However, annexin 1 -/- cells showed a significant loss of cortical actin when 
compared with wild type cells. This loss of cortical actin is the likely cause of the 
difference in cell shape. Increased cell spreading can be induced by increased 
stress fibre formation and/or enhanced numbers of focal adhesions to the substrate.
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Figure 7.11. EGF-stimulated phosphorylation o f annexin 1 is required to inhibit 
EGF-stimulated cell motility. JACRO annexin 1 -I- cells were nucleofected with Y21F 
annexin 1-GFP for 36 hours and serum starved over night. Y21F-expressing and non­
expressing cells were imaged every 5 minutes for 90 minutes in the absence or 
presence of EGF. The total distance (A) and velocity (B) of each cell was measured, 
and the mean calculated per experiment. Data from wild type cells and annexin 1 -/- 
cells expressing annexin 1-GFP are included for comparison. Expression of Y21F did 
not inhibit the enhanced motility phenotype in annexin 1 -/- cells. * p<0.05, ** 
p<0.01, *** p<0.005.
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These changes would normally result in a decreased level of cell motility, yet in 
stimulated annexin 1 -/- cells an enhanced level of cell motility was observed. 
Therefore, it is more likely that the difference in cell shape is mediated through a 
change in the membrane-cytoskeleton due to the loss of annexin 1.
Annexin 1 binds to negatively charged phospholipids on the inner leaflet of the 
plasma membrane in a Ca2+ dependent manner, where Ca2+ ions act as a bridge 
between the protein and the membrane (Rosengarth et al., 1998). Atomic force 
microscopy of annexin 1 has indicated that it can self-aggregate on the surface of 
membranes and form discrete domains (Janshoff et al., 2001). As annexin 1 also 
binds F-actin, it is likely that these domains are important in the 
stabilisation/maintenance of the plasma membrane-cytoskeleton. Loss of annexin 1 
may alter this stabilisation, thus reducing the rigidity of the plasma membrane 
resulting in a more flattened phenotype. Annexin 1 modulates the effect of profilin 
on actin nucleation and so, as well as providing a direct physical link between 
membrane and actin filaments, annexin 1 may influence cell shape through effects 
on actin nucleation (Alvarez-Martinez et al., 1996; Alvarez-Martinez et al., 1997). 
Further evidence that annexin 1 may mediate its effect through profilin is provided 
by the finding that both annexin 1 and profilin are present in EGF-stimulated actin 
based cellular protrusions, in ruffles and extending lamellipodia respectively 
(Campos-Gonzalez et a l, 1990; Buss et al., 1992).
7.3.2 Annexin 1 inhibits EGF-stimulated fibroblast motility
The role of annexin 1 in EGF-stimulated cell motility has not been investigated 
until now, although several groups have reported that extracellular annexins 1 and 2 
can inhibit the migration of cells in the inflammatory response (Balch and Dedman, 
1997; Perretti et al., 2002). EGF-induced fibroblast migration is a carefully 
orchestrated sequence of events, triggered by intracellular signalling cascades 
extending from the activated EGFR, which in turn control actin polymerisation and 
organisation of the cytoskeleton. EGF stimulation of cells results in the tyrosine 
phosphorylation of many proteins, including PLCyl, which localises to the leading 
edge of EGF-stimulated cells (Goldschmidt-Clermont et al., 1991; Chou et al.,
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2003). At the leading edge, PLCy induces PIP2 hydrolysis, which results in the 
localised release of gelsolin and its preferential accumulation into actin networks, 
thus driving cytoskeletal rearrangements and protrusions (Banno et a l , 1992; Chen 
et a l , 1996a; Chou et a l , 2002). Further evidence to suggest that actin severing 
activity and motility are linked comes from studies where the overexpression of 
gelsolin directly increases cell motility (Cunningham et a l , 1991). Also, 
fibroblasts lacking gelsolin show decreased rates of motility accompanied by a 
decrease in EGF-stimulated ruffling and failure to form lamellipodia (Azuma et a l , 
1998).
In response to EGF, fibroblasts initially send out actin-based extensions in all 
directions (ruffles) (Ridley et a l , 1992). Moments later, actin-based structures 
form at the leading edge of the cell, first filopodia then lamellipodia (Nobes and 
Hall, 1995; Kozma et al., 1995; Chou et a l , 2002). Annexin 1 has previously been 
shown to be recruited to EGF-stimulated ruffles (Campos-Gonzalez et a l, 1990). 
The data presented here suggests that the localised recruitment of annexin 1 to the 
leading edge of the cell has an inhibitory effect on ruffling/lamellipodia extension. 
This is somewhat unexpected as, although the roles of annexins in regulating actin 
remodelling are not entirely understood, existing data suggests that they are more 
likely to promote actin assembly than to inhibit it. Annexin-actin interactions tend 
to be associated with localised sites of rapid actin assembly, such as phagosomes, 
pinosomes and ruffles, and those annexins that bind actin have also been shown to 
bundle actin in vitro (Ikebuchi and Waisman, 1990; Kusumawati et a l, 2000; 
Merrifield et a l, 2001). In addition to gelsolin release at the leading edge, EGF- 
stimulated hydrolysis of PIP2, through PLC, also releases profilin (Banno et a l, 
1992; Chou et a l, 2002). Profilin is known to sequester G-actin and is an important 
protein in accelerating the ADP-ATP exchange on G-actin monomers, thus 
replenishing the pool of ATP-actin in the cell. Profilin also nucleates the formation 
of new actin filaments, possibly by increasing nucleotide exchange (Theriot and 
Mitchison, 1992) and is concentrated at the leading edge of cells, like annexin 1 and 
PLCy (Buss et a l, 1992). Thus, modulation of profilin activity by locally recruited 
annexin 1 could be expected to inhibit formation of actin filaments by reducing the 
pool of ATP-actin in the cytosol.
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7.3.3 Possible actin-independent mechanisms for annexin 1 inhibition o f motility
The inhibitory effect of annexin 1 on EGF-stimulated motility may not be mediated 
by direct interaction with actin or actin-binding proteins. Unlike many substrates of 
the EGFR kinase, annexin 1 does not become phosphorylated until EGFR has 
become internalised into MVBs. It has previously been suggested that annexin 1 
may play a role in the accumulation of EGFR on the internal vesicles of MVBs 
(Futter et al., 1993) and data presented in Chapter 3 provides evidence to support 
this hypothesis, showing that annexin 1 is involved in EGF-stimulated inward 
vesiculation within MVBs. Furthermore, it has been proposed that inward 
vesiculation within MVBs might play a direct role in attenuating signalling from 
the EGFR by removing the catalytic domain of the EGFR from the cytoplasm 
(Futter et al., 2001). Taken together, these hypotheses would predict that loss of 
annexin 1 would increase numbers of EGFR on the perimeter membrane of MVBs 
and, thereby, increase signalling from the EGFR kinase. Data presented in Chapter 
5 shows that loss of annexin 1 alters the amount or kinetics of EGFR degradation, 
and this is accompanied by prolonged signalling through the MAPK pathway. 
Increased signalling from the EGFR kinase could, therefore, induce enhanced 
motility in response to EGF in annexin 1 -/- cells. Growth factor stimulation leads 
to disruption of focal contacts to allow movement of the cell. The ERK1/2 MAPK 
pathway has been proposed to play a role in this process, as it can also be activated 
by integrins (Klemke et al., 1997). Additionally, EGF-activated MAPK is able to 
phosphorylate integrins, which would disrupt binding to the extracellular matrix 
(Hughes et al., 1997). In either case, prolonged MAPK signalling could result in 
enhanced cell motility.
Other studies of EGF-mediated fibroblast motility have investigated a range of 
influencing factors, including matrix proteins and growth factor gradients. The data 
presented here were collected from experiments performed using cells grown on 
glass. Several groups have shown that the efficient disruption of the interaction 
between the actin cytoskeleton and the extracellular matrix (ECM) is important in 
cell motility. EGFR activation and fibronectin were shown to integrate in order to 
control cell migration (Maheshwari et al., 1999). However, it is not known whether 
annexin 1 or annexins play a role in this interaction with ECM.
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EGF-stimulated cell motility is considered to be an excellent model for many 
reasons. Firstly, EGFR is ubiquitously expressed on the surface of many 
mammalian cells and many downstream signalling pathways of EGFR have been 
well characterized. Secondly, EGFR is closely related to other motility-signalling 
receptors and activates many of the same downstream molecules. Therefore, 
information derived from EGF-stimulated motility experiments should also be true 
for other receptors. Finally, EGFR signalling of motility has been investigated in 
both physiological (wound healing) and pathological circumstances (tumour 
invasion) (Chakrabarty et al., 1995; Turner et al., 1996; Turner et al., 1997). 
Whether annexin 1 plays a role in wound healing is unknown, but the loss of 
annexin 1, and the closely related annexin 2, have been reported in several types of 
tumours (Gerke and Moss, 2002).
7.3.4 Summary o f findings
In summary, these data provide evidence for a regulatory role for annexin 1 on the 
shape of fibroblasts, possibly through its interaction with F-actin and profilin. A 
second novel function for annexin 1 has been described here, in the regulation of 
EGF-stimulated cell motility. The exact nature of this inhibitory role is undefined, 
but is dependent upon EGF-stimulated phosphorylation of annexin 1. It seems 
likely to be mediated either through annexin 1 interaction with profilin and/or the 
role of annexin 1 in downregulation of EGFR. That annexin 1 plays a role in cell 
motility has been suggested by various groups investigating monocyte cell 
migration (Perretti et al., 2002), albeit in a different cellular context. Again the loss 
of annexin 1 in tumours may lead to enhanced migration of cancerous cells, 
although this effect has only been reported for annexin 2 (Liu et al., 2003).
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Chapter 8 -  Conclusions, Perspectives and Future Work
8.1 Conclusions
8.1.1 EGF stimulates MVB formation and inward vesiculation
EGF stimulation is known to induce receptor downregulation by enhancing receptor 
internalisation (Wiley et al., 1991). The data presented here shows that EGF also 
stimulates both MVB formation and inward vesiculation, suggesting that EGFR- 
mediated phosphorylation of downstream molecules is necessary for these 
processes to occur. Through the discovery of the vps proteins in yeast, and 
subsequently their mammalian homologues, many proteins have been implicated in 
MVB formation and/or receptor sorting. Recently Hrs, a protein phosphorylated 
after EGF stimulation, was proposed to couple the processes of EGFR sorting and 
formation of internal vesicles (Urbe et al., 2003). However, use of wortmannin, to 
inhibit PI3K, was shown to uncouple these processes by allowing receptor sorting 
in the absence of internal vesicle formation (Futter et a l , 2001). Aside from Hrs, 
the EGFR tyrosine kinase has multiple downstream targets, but within MVBs two 
major substrates were identified; the EGFR itself and annexin 1 (Futter et al., 
1993).
8.1.2 Annexin 1 mediates EGF-stimulated inward vesiculation in EGFR-containing 
MVBs
The membrane binding properties of annexin 1, coupled with the finding that it is a 
substrate for EGFR tyrosine kinase only within MVBs, led to the proposal that 
annexin 1 is involved in the formation of internal vesicles within MVBs (Futter et 
al., 1993). Despite the localisation of annexin 1 to endosomes (Futter et al., 1993; 
Seemann et al., 1996b; Seemann et al., 1997; Pol et al., 1997; Rescher et al., 2000), 
little evidence to support this hypothesis had been reported. The data presented 
here demonstrate that annexin 1 mediates inward vesiculation in response to EGF 
stimulation, but only in a sub-population of MVBs that contain EGFR. As a small 
number of internal vesicles containing EGFR form in the absence of annexin 1, it is
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clear that annexin 1 is not required for the formation of all internal vesicles. 
Ultrastructural analysis of EGF-stimulated cells located annexin 1 to EGFR- 
positive MVBs, both on the perimeter membrane and on internal vesicles with 
EGFR. However, despite these findings the mechanism of action of annexin 1 in 
mediating inward vesiculation is unclear.
8.1.3 Annexin 1 is not involved in EGFR sorting
The processes of receptor sorting and inward vesiculation are believed to be linked 
via Hrs and the ESCRT proteins (Urbe et al., 2003). The data presented here 
provides evidence that these processes can be uncoupled. Although loss of annexin 
1 inhibits the EGF-stimulated formation of internal vesicles, some internal vesicles 
still form and contain EGFR, indicating that receptor sorting occurs prior to inward 
vesiculation, and independently of annexin 1. Additionally, in cells lacking 
annexin 1, no effect was observed on the kinetics of EGF degradation, providing 
further confirmation that EGF and its receptor are sorted for lysosomal degradation 
in the absence of annexin 1. However, in annexin 1 -/- cells EGFR degradation was 
slightly reduced. This small reduction, or delay, in degradation could occur as a 
direct consequence of the inhibition of inward vesiculation. Additionally, MAPK 
signalling was prolonged in annexin 1 -/- cells, although whether this occurred as a 
downstream effect of delayed EGFR degradation, or as a direct effect of loss of 
annexin 1, is not clear.
8.1.4 Annexin 2 is not required for formation o f MVBs or inward vesiculation
Although a recent study reported that annexin 2 is required for the biogenesis of 
MVBs (Mayran et al., 2003), no evidence to support these claims could be found in 
the studies presented here, despite detailed quantitative analysis of MVBs in 
annexin 2 depleted cells. Ultrastructural analysis revealed that annexin 2 is 
primarily associated with small vesicles, many of which also label for TfR. Roles 
for annexin 2 in the positioning of early and recycling endosomes (Harder and 
Gerke, 1993; Zobiack et al., 2003) have previously been reported and it is therefore 
possible that annexin 2 may be involved in the positioning of MVBs. However, as
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no dramatic relocalisation of MVBs was observed here, in cells depleted of annexin 
2, it seems unlikely that annexin 2 is essential for positioning of MVBs.
8.1.5 Annexin 1 inhibits EGF-stimulated fibroblast motility
In addition to the effects observed on EGF-stimulated inward vesiculation, mouse 
lung fibroblasts lacking annexin 1 displayed enhanced levels of cell motility in 
response to EGF, compared with wild type cells. This phenotype could be reversed 
by re-expressing wild type annexin 1. However, expression of a phosphorylation 
mutant annexin 1 construct failed to reverse this enhanced motility, indicating that 
inhibition of cell motility is mediated through EGF-stimulated tyrosine 
phosphorylation of annexin 1.
8.1.6 Annexin 1 is involved in regulation o f fibroblast cell shape
Loss of annexin 1, in mouse lung fibroblasts, led to an increase in cell area, 
compared to wild type cells. This difference was not due to a significant increase in 
cell size, but rather a more flattened phenotype. Annexin 1 is known to interact 
with actin (Glenney, 1986b; Glenney, Jr. et al., 1987) and cells lacking annexin 1 
showed a decrease in the amount of cortical F-actin, which may directly cause the 
observed change in cell shape.
8.2 Perspectives
8.2.1 Roles for different sub-populations o f MVBs
Although EGF stimulates the formation of EGFR-containing MVBs, it is not clear 
whether all of these MVBs are formed de novo or whether some existing MVBs 
receive endocytosed EGFR. The presence of EGFR-negative MVBs is consistent 
with unpublished work (White et a l, under revision), and published data, showing 
that EGFR are only present in certain MVBs and that at least one other population 
of LBPA-containing MVBs exists (Bright et al., 2001; Petiot et al., 2003).
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Additionally, both populations of morphologically similar organelles labelled for 
CD63 and, from this work, it can be concluded that this would be a more accurate 
marker for MVBs than either EGFR or LBPA, which have commonly been used 
(White et al., under revision).
The discovery that separate populations of MVBs exist raises the question of what 
purpose multiple populations of MVB might serve. It is interesting to speculate 
that a MVB containing active EGFR could be used as a “signalling MVB” 
operating in a mobile, yet strictly controlled environment that is spatially separated 
from the plasma membrane. Annexin 1-mediated formation of internal vesicles, in 
response to EGF stimulation, may represent a method of signal attenuation, by 
removing the active receptor tyrosine kinase domain away from other signalling 
proteins in the cytoplasm. EGF-stimulated cells lacking annexin 1 exhibit 
prolonged signalling through the MAPK pathway in response to EGF. Although it 
is unclear whether this prolonged signalling occurs as a direct consequence of 
altered EGFR degradation, this finding supports the proposal that annexin 1 may be 
involved in downregulation of EGFR signalling. Several members of the MAPK 
signalling pathway have been localised to endosomes (Di Guglielmo et al., 1994; 
Pol et al., 1998; Rizzo et al., 2000; Howe et al., 2001; Luttrell et al., 2001) and 
removal of EGFR onto internal vesicles, as the endosome matures, would limit the 
number of downstream signalling molecules available to the activated EGFR 
(Futter et al., 2001). In addition to mediating EGFR signal downregulation, 
annexin 1 could be involved in formation of specific scaffolding complexes e.g. 
those containing pl4/M Pl for MAPK signalling. Thus, annexin 1 could function to 
(i) limit the signalling potential of EGFR and (ii) increase the specificity of 
signalling. However, the nature of the role of annexin 1 in signalling appears to be 
inhibitory, as indicated by the competitive binding with Grb2 for EGFR (Croxtall et 
a l , 2000).
8.2.2 Annexin 2 and endosomal membranes
Despite detailed analysis of MVB formation and inward vesiculation, no evidence 
was found to suggest that annexin 2 plays a role within MVBs, or is present within
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these structures. Annexin 2 is recruited to membrane sites of actin assembly, both 
at the plasma membrane and on endosomes (Merrifield et al., 2001; Zobiack et al., 
2002). Recently, it was shown that annexin 2 specifically binds PIP2 at these sites 
(Hayes et al., 2004; Rescher et al., 2004). In addition to serving as signalling 
precursors phosphoinositides, including PIP2, participate in a number of 
fundamental cellular processes, such as vesicular trafficking and cell motility 
(Cullen et al., 2001; Martin, 2001). PIP2 is necessary for the early stages of 
endocytosis, coat assembly and release of endocytic vesicles and a number of 
proteins involved in these process are able to bind PIP2, including AP-2 and 
dynamin (Jost et al., 1998). Additionally, the formation of PHVrich microdomains 
is dependent on cholesterol (Pike and Miller, 1998), and these domains were shown 
to be preferential sites of membrane-linked, PDVmediated actin assembly, such as 
that occurring during the formation of actin comet tails behind raft-enriched 
vesicles (Rozelle et al., 2000). It is possible that the absence of annexin 2 from 
MVBs is due to the lack of PIP2 enriched microdomains and/or cholesterol in later 
endocytic structures. Consistent with this hypothesis was the finding that 
intracellular receptor trafficking compartments contained little detectable PIP2 
(Haugh and Meyer, 2002). However, the ability of annexin 2 to bind to PIP2 and 
cholesterol enriched microdomains on membranes, coupled with its actin binding 
property, makes it an ideal candidate for mediating membrane-cytoskeleton 
contacts.
Interestingly, in these studies annexin 2 was found associated with TfR-containing 
CCVs, whereas annexin 1 only co-labelled TfR positive endosomes, and was absent 
from CCPs or CCVs. This observation is consistent with that of Turpin et al. 
(1996), who reported that annexins 2 and 6 were attached to CCVs, independently 
of clathrin (Turpin et al., 1998). This indicates that annexin 2, which interacts with 
the endosomal membrane and the clathrin coat, could be involved in the formation 
of a microdomain necessary for clathrin coat function.
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8.2.3 Additional effects o f loss o f annexin 1
In addition to mediating formation of internal vesicles within a sub-population of 
MVBs, annexin 1 was also shown to inhibit EGF-stimulated cell motility. For 
efficient EGF-stimulated cell motility, EGFR tyrosine kinase activity and receptor 
autophosphorylation are essential (Chen et al., 1994a). Therefore, if EGFR 
signalling is dysregulated i.e. prolonged, as observed in EGF-stimulated annexin 1 - 
/- cells, this may result in enhanced motility. Signalling through the MAPK 
pathway was prolonged in annexin 1 -/- cells in response to EGF stimulation, 
however MAPK signalling primarily induces a mitogenic rather than motogenic 
response (Chen et al., 1994b). Nevertheless, prolonged EGF-stimulated MAPK 
signalling in annexin 1 -/- cells could serve as an indication that signalling through 
other pathways is altered, and the activation of these pathways could lead to the 
observed enhanced cell motility. Therefore, the effect of loss of annexin 1 on 
membrane trafficking could directly induce enhanced motility.
The actin-binding properties of annexins have been identified but their exact 
functions are not known. The ability of annexin 1 to bind both actin and profilin 
indicates that annexin 1 is likely involved in some aspect of cytoskeleton 
arrangement (Glenney, Jr. et al., 1987; Welsh et al., 1991; Alvarez-Martinez et al., 
1996). In response to EGF stimulation, cells form actin-based membrane ruffles, as 
a precursor to cell movement, and localisation of annexin 1 to these structures 
provides evidence that annexin 1 is involved in this process (Campos-Gonzalez et 
al., 1990). The data presented here show that annexin 1 has an inhibitory effect on 
cell motility, as observed by enhanced EGF-stimulated cell motility in the absence 
of annexin 1. This could be due to a disruption in cytoskeleton formation, as 
observed by a loss of cortical actin in annexin 1 -/- cells, which might directly alter 
the ability of cells to migrate, by reducing their contact to the substratum. 
Alternatively, cytoskeletal rearrangements could have an indirect effect on cell 
motility, by altering the stability or localisation of intracellular compartments, 
including those involved in signalling.
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8.2.4 Annexins and cancer
The studies reported here have concentrated primarily on the effects of loss of 
annexins 1 and 2 on membrane trafficking, specifically of EGFR. Cells lacking 
annexin 1 demonstrated enhanced levels of EGF-stimulated motility and prolonged 
signalling through the MAPK pathway. Increased receptor tyrosine kinase 
signalling is often observed in cancer and is caused by a variety of factors, 
including gene amplification, increased transcription, increased translation or 
mutations that promote ligand-independent autophosphorylation (Bache et al., 
2004b). Enhanced signalling can also be due to a failure of efficient receptor 
downregulation and/or deactivation and this has been shown to cause neoplastic 
growth (Dikic and Giordano, 2003). Therefore, alterations in the expression of 
proteins involved in receptor downregulation could result in aberrant receptor 
signalling. Both annexins 1 and 2 are downregulated in a number of cancers, 
including prostate cancer (Paweletz et al., 2000; Liu et al., 2003; Xin et al., 2003; 
Smitherman et al., 2004) and human oesophageal squamous cell carcinomas 
(Paweletz et al., 2000; Zhi et al., 2003; Fang et al., 2004; Luo et al., 2004). 
Similarly annexin 1 expression is inhibited in B-cell non-Hodgkins lymphoma, 
giving rise to the proposal that annexin 1 possesses tumour suppressor activity 
(Vishwanatha et al., 2004). Liu et al. (2003) reported that annexins 1 and 2 may be 
endogenous suppressors of prostate cancer cell migration and that their reduced or 
lost expression may contribute to prostate cancer development and progression (Liu 
et al., 2003). The data presented in Chapter 7, investigating the effect of loss of 
annexin 1 on EGF-stimulated cell motility, provides further evidence in support of 
this theory, especially as re-expression of annexin 1 reversed the enhanced motility 
phenotype observed.
However, the roles of annexins 1 and 2 may be tissue or cell type specific, as in 
other forms of cancer their expression is upregulated. In human hepatocellular 
carcinoma annexin 1 is overexpressed, is localised mainly in the cytoplasm of cells 
and is tyrosine phosphorylated (Masaki et al., 1996). Recently, annexin 1 was 
identified as differentially expressed on the surface of lung endothelial tumour cells 
in rats (Oh et al., 2004). In this rat model, radiolabelled monoclonal anti-annexin 1
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antibodies were used to determine whether annexin 1 expression was tumour 
specific. The antibodies specifically labelled the tumour, with little labelling 
observed elsewhere. Additionally, the survival rate of rats injected with 125I- 
labelled anti-annexin 1 antibodies was increased, compared to that of control rats, 
indicating that this method allowed antibody-directed delivery of low levels of 
radionuclides to tumours, resulting ultimately in their destruction (Oh et al., 2004). 
As annexin 1 is also selectively detected in certain types of human solid tumours, it 
may act as a target for novel therapies.
8.2.5 Annexin 1 and inflammation
Annexin 1 has been extensively investigated with respect to its role in 
inflammation. The anti-inflammatory action of the glucocorticoid family is 
mediated through the induction of annexin 1, which has been shown to inhibit PLA2 
and thus arachidonic acid release (Croxtall et al., 1996; Croxtall et al., 1998). The 
annexin 1 -/- mouse has been used to investigate the effect of annexin 1 on 
glucocorticoid action (Hannon et al., 2002). Although viable, these mice exhibited 
enhanced expression of the pro-inflammatory proteins, COX2 and CPLA2 . While 
dexamethasone treatment of wild type mice inhibited the first phase of oedema, 
which is PMN (polymorphonuclear leukocyte) dependent, no inhibition was 
observed in annexin 1 -/- cells. Further evidence for a role for annexin 1 in 
glucocorticoid action has come from investigations using the annexin 1 -/- cell line, 
derived from the annexin 1 knockout mouse (Croxtall et al., 2003). Expression of 
COX2, CPLA2 and several annexins were shown to be upregulated in annexin 1 -/- 
cells, a similar profile to that observed in the mouse model. These findings indicate 
that although annexin 2 is upregulated, it is unable to functionally compensate for 
the loss of annexin 1 in glucocorticoid action (Croxtall et al., 2003).
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8.3 Future work
The work described here has provided functional evidence for the roles of annexin 
1 in EGF-stimulated inward vesiculation, EGFR-mediated signalling, and control of 
EGF-stimulated cell motility. Additionally, the role of EGF stimulation in MVB 
formation has been explored. The data collected during investigations of annexin 2 
have ruled out the possibility that annexins 1 and 2 perform the same functions, and 
have shown that annexin 2 is not involved in MVB formation or inward 
vesiculation. Despite answering some of the questions relating to annexin 1 
function, further work is required to address the specific mechanisms by which 
annexin 1 mediates its effects.
8.3.1 Ubiquitin and annexin 1
Ubiquitination of EGFR is believed to be a major sorting signal into the lysosomal 
degradation pathway and away from the recycling pathway. Data presented here 
showed that annexin 1 is delivered to the lysosome, raising the question of whether 
annexin 1 is also ubiquitinated. If annexin 1 is ubiquitinated, this would also enable 
it to interact with UIM-containing proteins, including Hrs and TsglOl. To 
investigate whether annexin 1 is ubiquitinated, immunoprecipitations should be 
performed using either anti-annexin 1 or anti-ubiquitin antibodies, followed by 
western blotting with the other antibody. In addition, the effect of EGF could be 
investigated on the ubiquitination of annexin 1. Although annexin 1 was observed 
in MVBs from unstimulated cells, none was observed in lysosomes from these 
cells, indicating that EGF-stimulation induces annexin 1 delivery to the lysosome.
8.3.2 Does annexin 1 interact with the ESCRTcomplexes?
It is unknown whether annexin 1 upregulates the existing ESCRT-mediated process 
of inward vesiculation, or whether it is involved in the generation of new internal 
vesicles via a different mechanism. In the absence of annexin 1, a small number of
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internal vesicles containing EGFR still form. A similar phenotype is seen in MVBs 
from cells depleted of Hrs (Raiborg et al., 2002) or TsglOl (Aghakhani et al., under 
revision). As receptor sorting occurs in the absence of annexin 1, this indicates that 
annexin 1 functions downstream of Hrs, which is known to mediate sorting of 
ubiquitinated EGFR (Raiborg et al., 2002). Therefore, it is possible that the 
formation of internal vesicles observed in the absence of either annexin 1 or 
ESCRT proteins is mediated by the presence of the remaining protein (either 
ESCRTs or annexin 1, respectively). To further investigate whether annexin 1- 
mediated inward vesiculation is dependent upon ESCRT function, RNAi 
technology could be used to deplete cells of both annexin 1 and a component of 
ESCRT, such as TsglOl, and observe the effect on EGF-stimulated inward 
vesiculation. If annexin 1 and ESCRTs mediate internal vesicle formation via 
independent mechanisms, inhibiting the function of both would be predicted to 
result in a complete inhibition of inward vesiculation.
The ESCRT complexes are known to assemble on endosomal membranes and 
function to sort ubiquitinated receptors to the degradative pathway (Babst et al., 
2000; Babst et al., 2002a; Babst et al., 2002b). It has not been investigated whether 
ESCRT complexes are involved in the formation of all MVBs or just in a specific 
sub-population. Regardless of the ubiquitination status of annexin 1, it is possible 
that annexin 1 interacts with one or more components of the ESCRT complexes. 
However, no evidence exists to link annexin 1 and ESCRT proteins. Therefore, to 
investigate whether annexin 1 interacts with ESCRT proteins, EGF-stimulated cell 
lysates should be immunoprecipitated with anti-annexin 1 antibodies and then 
blotted with antibodies against members of the ESCRT complexes.
8.3.3 Investigating the mechanism o f annexin 1 action
The models of annexin 1 mediated, EGF-stimulated inward vesiculation, described 
in Chapter 3, are based on the formation of the annexin 1-S100A11 heterotetramer. 
Although both annexin 1 and S100A11 have been localised to endosomal 
membranes, this complex has proved elusive during standard isolation protocols. 
Unlike the formation of the annexin 2-S100A10 complex, S100A11 requires Ca2+
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to bind annexin 1 and this Ca2+ dependency could explain the difficulty in isolation 
of the complex. Having established that annexin 1 is required for the formation of 
internal vesicles within MVBs of EGF-stimulated cells, it would be interesting to 
investigate whether this process is affected by RNAi-induced depletion of 
S100A11. Additionally, the effect of loss, or depletion, of annexin 1 on S100A11 
levels should be investigated, as RNAi-induced annexin 2 depletion simultaneously 
decreased expression of S100A10 (Zobiack et al., 2003). This could be further 
explored using a mutant annexin 1, lacking S100A11 binding sites.
The role of Ca in annexin 1 membrane binding is still somewhat controversial. 
Futter et al. (1993) showed that annexin 1 associates with the plasma membrane 
and MVBs in a Ca2+ independent manner and that EGFR phosphorylation of 
annexin 1 converts it into a Ca2+ dependent species (Futter et al., 1993). In 
contrast, Seemann et al. (1996) used conventional fractionation techniques but 
found no evidence of a pool of annexin 1 associated with endosomes in the absence 
of Ca2+ (Seemann et al., 1996b). Rescher et al. (2000) reported that a specific Ca2+ 
binding site in the second annexin repeat of annexin 1 is required for membrane 
binding (Rescher et al., 2000). However, it is possible that mutation of this site 
also changes the conformation of the protein, which would itself alter membrane 
binding. Therefore, further work is required to address the Ca2+ dependency of 
annexin 1 during endocytosis and specifically during inward vesiculation. To
9 -1-investigate whether annexin 1 requires Ca for EGF-stimulated internal vesicle 
formation, a mutant annexin 1 construct lacking the Ca2+ binding site (Rescher et 
al., 2000) could be expressed in annexin 1 -/- cells, and the effect on inward 
vesiculation observed. As expression of wild type annexin 1 partially relieved the 
inhibition on internal vesicle formation, it would be interesting to observe whether
9 4 - 9 -1-this is also true of the Ca binding site mutant. BAPTA, a Ca chelating agent, is
94 -  9 -4-often used to decrease intracellular levels of Ca . To observe whether Ca is 
required for EGF-stimulated inward vesiculation, cells could be treated first with 
BAPTA, then with EGF and finally the morphology of MVBs observed. BAPTA- 
treated cells could be used for immuno-localisation of annexin 1 and EGFR, to 
observe whether they still localise to MVBs.
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EGF-stimulated phosphorylation of annexin 1 is believed to induce N-terminal 
proteolysis, although the exact mechanism by which this occurs in vivo has not 
been fully investigated (Haigler et al., 1987; Chuah and Pallen, 1989; Ando et al., 
1989). N-terminally truncated annexin 1 has been shown to localise to late 
endosomes in unstimulated cells (Seemann et al., 1996b; Rescher et al., 2000). 
Therefore, it would be interesting to observe where N-terminal proteolysis occurs 
intracellularly. To do so would require the use of specific annexin 1 antibodies, one 
to the core domain and the other to the N-terminal domain that is cleaved. Double 
labelling, using these antibodies, would reveal any differences between the 
localisation of full length annexin 1 and the truncated version. These studies would 
provide further clues to the exact mechanism of annexin 1 in EGF-stimulated 
inward vesiculation. From the current model proposed by Gerke and Moss (2002), 
full length annexin 1 would localise to endosomes and the perimeter membrane of 
MVBs, while the cleaved version would be present on the EGFR-containing 
internal vesicles (Gerke and Moss, 2002). Alternatively, an N-terminally truncated 
annexin 1-GFP construct could be generated and used in fluorescence experiments, 
to investigate the intracellular localisation of this construct.
8.3.4 Is EGF-stimulated tyrosine phosphorylation o f annexin 1 required for inward 
vesiculation?
Although EGFR tyrosine phosphorylation of annexin 1 was shown to be necessary 
for its inhibitory role in EGF-stimulated cell motility, the studies into internal 
vesicle formation and EGFR trafficking were less informative, and further 
investigation into the role of EGFR-mediated phosphorylation is required. 
Transfection of annexin 1 -/- cells with the phosphorylation mutant annexin 1-GFP 
construct could be utilised in two ways: (i) to observe whether a reversion of the 
inhibition of EGF-stimulated internal vesicles formation can be observed, and (ii) 
use of cryo-immuno EM to determine the exact location of this construct. From 
studies shown here, it is predicted that annexin 1 unable to be phosphorylated by 
EGFR would remain on the perimeter membrane after EGF-stimulation and would 
be unable to reverse the inhibition on inward vesiculation. Additionally, an anti- 
phospho annexin 1 antibody could be used both to localise phosphorylated annexin
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1 and compare its localisation with the non-phosphorylated form. This would 
provide further insight as to whether phosphorylated annexin 1 is inside MVBs, or 
whether phosphorylation induces annexin 1 to fall off the perimeter membrane and 
only non-phosphorylated annexin 1 is internalised onto internal vesicles with the 
EGFR.
8.3.5 Is annexin 1-mediated inward vesiculation specific to EGFR or general to all 
tyrosine kinase receptors?
The work described in these studies has focussed on the roles of annexins 1 and 2 in 
EGF-stimulated events, although TfR has also been used as a marker of constitutive 
endocytosis and recycling in unstimulated cells. EGFR is one of several receptor 
tyrosine kinases in mammalian cells and so it would be interesting to investigate 
whether annexin 1, or possibly annexin 2, plays a similar role in the processing of 
other receptors. From the data presented here, it seems likely that the role of 
annexin 1 would be EGF-specific, taking into account its role in formation of 
internal vesicles within EGFR-containing MVBs. EGF-mediated phosphorylation 
appears to act as a switch for activity of annexin 1. However, annexin 1 is also 
phosphorylated in response to HGF (Skouteris and Schroder, 1996). To investigate 
whether other growth factors influence annexin 1 function, cells could be treated 
with FGF, HGF, insulin or PDGF, and the effects observed on MVB formation, 
internal vesicle formation and also on cell motility.
Annexin 2 was originally identified as a substrate for c-src and phosphorylation 
decreases the affinity of annexin 2 for phospholipid membranes (Hubaishy et al., 
1995). Although annexin 2 is a poor substrate for EGFR, it is phosphorylated by 
internalised insulin receptors (IR). Therefore, in a cell type where IR are expressed, 
annexin 2 could be involved in MVB formation and/or IR sorting.
8.3.6 Final Summary
Annexins 1 and 2 were discovered over 20 years ago and implicated in membrane 
trafficking, due to their actin and membrane-binding properties. The studies
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performed here provide, for the first time, functional evidence for a role for annexin 
1 in EGF-stimulated inward vesiculation, although the exact mechanism of action 
remains unclear. However, through the use of modem technologies, such as gene 
knockout and RNAi, it will be possible to investigate in detail how annexin 1 
mediates its effect on inward vesiculation, using the experiments outlined above.
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Appendix 1 -  Supplementary Data
Annexin 1
1 agtgtgaaat cttcagagaa gaatttctct ttagttcttt gcaagaaggt agagataaag
5'caagaagCt Cgagataaag
61 acactttttc a a a a ^ g c a  atggtatcag aattcctcaa gcaggcctgg tttattgaaa 
acac-3'
121 atgaagagca ggaatatgtt caaactgtga agtcatccaa aggtggtccc ggatcagcgg
181 tgagccccta tcctaccttc aatccatcct cggatgtcgc tgccttgcat aaggccataa
241 tggttaaagg tgtggatgaa gcaaccatca ttgacattct aactaagcga aacaatgcac
301 agcgtcaaca gatcaaagca gcatatctcc aggaaacagg aaagcccctg gatgaaacac
361 ttaagaaagc ccttacaggt caccttgagg aggttgtttt agctctgcta aaaactccag
421 cgcaatttga tgctgatgaa cttcgtgctg ccatgaaggg ccttggaact gatgaagata
481 ctctaattga gattttggca tcaagaacta acaaagaaat cagagacatt aacagggtct
541 acagagagga actgaagaga gatctggcca aagacataac ctcagacaca tctggagatt
601 ttcggaacgc tttgctttct cttgctaagg gtgaccgatc tgaggacttt ggtgtgaatg
661 aagacttggc tgattcagat gccagggcct tgtatgaagc aggagaaagg agaaagggga
721 cagacgtaaa cgtgttcaat accatcctta ccaccagaag ctatccacaa cttcgcagag
781 tgtttcagaa atacaccaag tacagtaagc atgacatgaa caaagttctg gacctggagt
841 tgaaaggtga cattgagaaa tgcctcacag ctatcgtgaa gtgcgccaca agcaaaccag
901 ctttctttgc agagaagctt catcaagcca tgaaaggtgt tggaactcgc cataaggcat
961 tgatcaggat tatggtttcc cgttctgaaa ttgacatgaa tgatatcaaa gcattctatc
1021 agaagatgta tggtatctcc ctttgccaag ccatcctgga tgaaaccaaa ggagattatg
1081 agaaaatcct ggtggctctt tgtggaggaa ac— m | a c a  ttcccttgatgg 
tctcaagcta
3'-ggaggaa acCGGGatCC ccttg-5'
1141 tgatcagaag actttaatta tatattttca tcctataagc ttaaatagga aagtttcttc
1201 aacaggatta cagtgtagct acctacatgc tgaaaaatat agcctttaaa tcatttttat
1261 attataactc tgtataatag agataagtcc attttttaaa aatgttttcc ccaaaccata
1321 aaaccctata caagttgttc tagtaacaat acatgagaaa gatgtctatg tagctgaaaa
1381 taaaatgacg tcacaagac
Figure S.l. Human annexin 1 sequence and primers. Human annexin 1 sequence was 
used to design primers to amplify annexin 1 using PCR from an I.M.A.G.E. 
Consortium [LLNL] cDNA clone LD3459615. Start and stop codons are highlighted in 
blue. Primers were designed to contain Xhol (forward primer, pink) and BamHl 
(reverse primer, blue) restriction sites (underlined sequences). Bases in capital letters 
indicate base changes or additions.
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Annexin 1
1 agtgtgaaatcttcagagaaagaatttctc 
31 tttagttctttgcaagaaggtagagataaagacactttttcaaaa 
75 ^Jgcaatggtatcagaattcctcaagcaggcctggtttattgaa 
M A M V S E F L K Q A W F I E  
120 aatgaagagcaggaatatgttcaaactgtgaagtcatccaaaggt 
N E E Q E Y V Q T V K S S K G  
5'-gaatTtgttcaaactgtgaagtc-3'
3'-cttctcgtgcttaAacaagtttgacacttcag-5'
F
165 ggtcccggatcagcggtgagcccctatcctaccttcaatccatcc 
G P G S A V S P Y P T F N P S  
210 tcggatgtcgctgccttgcataaggccataatggttaaaggtgtg 
255 gatgaagcaaccatcattgacattctaactaagcgaaacaatgca 
300 cagcgtcaacagatcaaagcagcatatctccaggaaacaggaaag 
345 cccctggatgaaacacttaagaaagcccttacaggtcaccttgag 
390 gaggttgttttagctctgctaaaaactccagcgcaatttgatgct 
435 gatgaacttcgtgctgccatgaagggccttggaactgatgaagat 
480 actctaattgagattttggcatcaagaactaacaaagaaatcaga 
525 gacattaacagggtctacagagaggaactgaagagagatctggcc 
570 aaagacataacctcagacacatctggagattttcggaacgctttg 
615 ctttctcttgctaagggtgaccgatctgaggactttggtgtgaat 
660 gaagacttggctgattcagatgccagggccttgtatgaagcagga 
705 gaaaggagaaaggggacagacgtaaacgtgttcaataccatcctt 
750 accaccagaagctatccacaacttcgcagagtgtttcagaaatac 
795 accaagtacagtaagcatgacatgaacaaagttctggacctggag 
840 ttgaaaggtgacattgagaaatgcctcacagctatcgtgaagtgc 
885 gccacaagcaaaccagctttctttgcagagaagcttcatcaagcc 
930 atgaaaggtgttggaactcgccataaggcattgatcaggattatg 
975 gtttcccgttctgaaattgacatgaatgatatcaaagcattctat 
1020 cagaagatgtatggtatctccctttgccaagccatcctggatgaa 
1065 accaaaggagattatgagaaaatcctggtggctctttgtggagga 
1110 aac^^acattcccttgatggtctcaagctatgatcagaagactt
Figure S.2. Human annexin 1 sequence and point mutation. Annexin 1 is 
phosphorylated by EGFR on tyrosine 21. To create a mutant construct lacking this site, 
primers were designed to create a point mutation at position 62 (A to T), which would 
result in an amino acid substitution (tyrosine (Y) to phenylalanine (F)). Start and stop 
codons are highlighted in blue. Amino acids are shown for the first part of annexin 1 
sequence to show where the mutation occurs.
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1 10 20 30  40 50  60 70 80 90 100 110 120 130
I ------------------    ♦ -------------------- ♦ -------------------- ♦ ---------------------►--------------------♦ -------------------- 4-------------------- 4---------------------  4---------------------♦ -------------------- 1
A n n e x i n  AHRRHTGGCflflTGGTATCRGflATTCCTCRAGCRGGCCTGGTTTfiTTGfiRflATGRAGRGCflGGRATRTGTTCRRACTGTGRRGTCATCCAflAGGTGGTCCCGGATCRGCG6T6fiGCCCCTRTCCTACCTTC 
(ICS GCNGGCCTGGTTTflTTGRflRflTGRRGRGCfiGGRATRTGTTCRflRCTGTGRAGTCATCCflARGGTGGTCCCGGflTCRGCGGTGRGCCCCTHTCCTRCCTTC
C o n s e n s u s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . GCaGGCCTGGTTTRTTGflflflflTGRRGRGCRGGflRTRTGTTCRRRCTGTGRRGTCflTCCRRflGGTGGTCCCGGRTCRGCGGTGflGCCCCTRTCCTRCCTTC
131 140 150 160 170 180 190 200 210 220 230 240 250 260
I ------------------ 1--------------------- 1---------------------+ -------------------- + ---------------------4-------------------- 4---------------------♦ --------------------     1---------------------4---------------------+ -------------------- 1
Annexin HHTCCRTCCTCGGfiTGTCGCTGCCTTGCRTRRGGCCRTHflTGGTTRflRGGTGTGGflTGRflGCflRCCRTCfiTTGflCRTTCTflflCTRflGCGflflRCflRTGCflCflGCGTCflflCflGflTCflflHGCfiGCRTflTCTCC  
NCS RflTCCRTCCTCGGRTGTCGCTGCCTTGCRTRRGGCCRTflflTGGTTRRRGGTGTGGflTGRflGCRflCCRTCRTTGflCflTTCTRRCTfiflGCflRRRCRflTGCflCflGCGTCRRCRGRTCRRflGCRGCflTflTCTCC 
C o n s e n s u s  RRTCCRTCCTCGGRTGTCGCTGCCTTGCRTRRGGCCATRRTGGTTRflAGGTGTGGRTGRRGCflRCCRTCflTTGRCRTTCTRRCTRflGCaRflRCRRTGCflCnGCGTCRRCRGRTCflRflGCRGCRTATCTCC
261 270 280 290 300 310 320 330 340 350 360 370 380 390I------    +------ ♦-------1-------    ♦------     ♦----  +-------1
A n n e x i n  RG6RRRCRGGRRRGCCCCTGGflT6RRRCRCTTRRGflRRGCCCTTRCRGGTCRCCTT6RGGRGGTT6TTTTR6CTCT6CTRRRRRCTCCRGC6CRRTTT6ATGCTGRTGRRCTTCGT6CT6CCflTGRRGG6  
HCS flGGRRACRGGAARGCCCCT6GATGAflACRCT6RAGAARGCCCTTRCRGGTCACCTT6AGGRGGTT6TTTTRGCTCTGCTRRRRRCTCCRGCGCRRTTTGRTGCTGRTGRRCTTCGTGCTGCCATGRRGGG  
C o n s e n s u s  RGGAAACAGGAAAGCCCCTG6ATGAAACACTeRRGRiVlGCCCTTACRGGTCACCTTGAG6RGGTTGTTTTAGCTCTGCTAAAAACTCCRGCGCAATTTGRTGCTGATGAACTfCGTGCT6CCRTGAflGGG
391 400 410 420 430 440 450 460 470 480 490 500 510 520|------ —♦-------- ♦  ♦   1   ♦ ♦ ♦ -♦ ♦ ♦ 1
A n n e x i n  CCTTGGRflCTGHTGRRGflTRCTCTRflTTGRGflTTTTGGCHTCRAGRflCTflRCflflRGRRRTCRGRGflCRTTRBCRGGGTCTflCRGnGRGGRHCTGRRGHGRGHTCTGGCCRRfiGBCflTRRCCTCflGflCflCfl 
HCS CCTTG6RACTGRTGARGATRCTCTRATTCA6ATTTTGGCRTCAAGARCTRACRRRGRRATCRGRGRCRTTflACAGGGTCTRCflGRGRGGRRCTGRRGRGRGATCTGGCCRflRGACATAHCCTCRGRCRCA 
C o n s e n s u s  CCTTGGRRCTGATGRR6flTRCTCTARTTGRGRTTTTGGCRTCRAGAflCTAACARR6AAATCRGAGRCATTAACRGGGTCTRCAGflGRGGRRCT6flA6RGAGRTCT6GCCRRflGACRTARCCTCAGACACR
521 530 540 550 560 570 580 590 600 610 620 630 640 650I---------1--------- -^-------- ♦---------♦---------♦---------♦--------- ♦---------♦----------►---------♦--------- 1---------♦-------- 1
A n n e x i n  TCTGGAGflTTTTCGGRAC6CTTTGCTTTCTCTTGCTARGGGT6ACC6ATCTGRGGRCTTTGGTGTGAAT6RRGRCTTGGCTGATTCRGRTGCCRG6GCCTTGTATGAAGCAGGRGAAA6GAGAAAGGGGA 
HCS TCTG6AGflTTTTCGGARCGCTTTGCTTTCTCTTGCTAAGGGTGACCGRTCTGAGGRCTTTGGTGTGHnTGRRGRCTTGGCTGATTCAGflTGCCRGGGCCTTGTATGARGCAGGRGRRAGGAGAAAGGGGH 
C o n s e n s u s  TCTGGAGflTTTTCGGAflCGCTTTGCTTTCTCTTGCTRflGGGTGRCCGRTCTGAGGACTTTGGTGTGflfiTGflAGRCTTGGCTGATTCflGflTGCCRGGGCCTTGTATGAAGCRGGflGAflflGGflGABRGGGGA
651 660 670 680 690 700 710 720 730 740 750 760 770 780
| ------------------ 1-------------------- 4-------------------- ♦ --------------------♦ --------------------♦ -------------------- 4---------------------♦ -------------------- + ---------------------4-------------------- 4---------------------(---------------------  I
A n n e x i n  CAGACGTAARCGTGTTCRATRCCRTCCTTACCRCCflGflflGCTRTCCACflflCTTCGCAGRGTGTTTCRGAARTRCACCAAGTACAGTRflGCATGRCRTGflflCAAAGTTCTGGflCCTGGAGTTGAflAGGTGA  
HCS CflGACGTRRRCGTGTTCAATRCCATCCTTACCACCRGRRGCTRTCCRCRACTTCGCRGAGTGTTTCAGARRTRCRCCAAGTACAGTHRGCATGACATGARCHAAGTTCTGGRCCTGGRGTTGAAflGGTGA  
C o n s e n s u s  CRGACGTAARCGTGTTCARTACCATCCTTACCACCRGRflGCTATCCACAACTTCGCAGRGTGTTTCAGflnATRCRCCAAGTACAGTRRGCRTGRCATGflACAHAGTTCT6GACCTGGAGTTGAAAGGTGA
781 790 800 810 820 830 840 850 860 870 880 890 900 910
A n n e x i n  CATTGAGAAATGCCTCACAGCTATCGTGRAGTGCGCCACAAGCAAACCAGCTTTCTTTGCRGAGAAGCTTCRTCAAGCCATGRAAGGTGTT6GAACTCGCCATRAGGCATTGATCAGGATTATGGTTTCC 
HC S CATTGAGflfiATGCCTCNCAGCTRTCGHGRAGNGCGCCCCAAGCAAflCCRGCTTTTTTTMGCflNAARMCNTCCTCRNGCCNTGAA 
C o n s e n s u s  CATTG AGRRATGCCTCaCRG CTATCG nG RAGnGCGCCaCRRG CAAACCAGCTTTcTTTncaaaaRAnCnTCaTCRaGCCaTG AR.... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040
I ------------------1---------------------4-------------------- ♦ --------------------+ -------------------- 4-------------------- ♦ -------------------- ♦ -------------------- ♦ -------------------- + ---------------------►--------------------♦ -------------    I
A n n e x i n  CGTTCTGARflTTGACATGAAT6RTRTCAAAGCATTCTATCAGRAGATGTflTGGTATCTCCCTTTGCCRRGCCRTCCTGGATGRARCCRRflGGAGRTTATGRGRRRATCCTGGTGGCTCTTTGTGGRGGRA 
HCS
C o n s e n s u s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 10 20 30 40 50 GO 70 80 90 100 110 120 130
| -----------------   H -----------------<---------------------------------------- 1------------------- 4--------------------4------------------- * --------------------1--------------------      1
H id
H id A n x lL H 8 8 p r in e r  GCAGGCCTGTCHTTATTGAHAATGAAGHGCAGGAATATGTTCAAACTGTGHHGTCATCCRAAGGTGGTCCCGGATCRGCGGTGAGCCCCTATCCTACCTTCAATCCATCCTCGGRTGTCGCTGCCTTGCA 
C o n s e n s u s
131 140 150 160 170 180 190 200 210 220 230 240 250 260
| ----------------- ,-------------------- ,--------------------,---------------_ ♦ ------------------- ,------------------- 4--------------------4--------------------   1--------------------      1
H id
H id R n x lL H B S p r in e r  TAAGGCCATAATGGTTAAAGGTGTGGATGAAGCAACCATCRTTGACATTCTAACTAAGCAAAACAATGCACAGCGTCAACAGATCflAAGCAGCATATCTCCAGGAAACAGGARAGCCCCTGGATGAAACA 
C o n s e n s u s
261 270 280 230 300 310 320 330 340 350 360 370 380 390
I-----------------   1------------------- 4--------------------1-------------------- 1--------------------1--------------------4--------------------   1--------------------4--------------------1------------------- 1--------------------1
H id  CGCRRTTTGHTGCTGATGHHCTTCGTGCTGCCATGAHGGGCCTTGGAACTGATGAH6ATACTCTARTTG
H id A n x lL H B B p r in e r  CTGHRGAAAGCCCTTACRGGTCACCTTGHG6AGGTTGTTTTRGCTCTGCTAAAAACTCCAGCGCRATTTGATGCTGATGAACTTCGTGCTGCCATGAHGGGCCTT6GHACTGHTGRHGATHCTCTRRTTG 
C o n s e n s u s  .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CGCRATTTGATGCTGATGAACTTCGTGCTGCCATGRAGGGCCTT6GAACTGATGRAGATACTCTARTTG
391 400 410 420 430 440 450 460 470 480 490 500 510 520
| ----------------   1------------------------------   4---------1--------------------4------------------- 4-------------------- 4-------------------+ ------------------- ♦ ---------------    1
H id  RGATTTTGGCRTCARGAACTAACRAHGAAATCAeRGACATTHRCAGGGTCTRCAGflGAGGAACTGAAGRGAGATCTGGCCAARGRCATAACCTCAGACACRTCTGGAGATTTTCGGAACGCmGCTTTC 
H id B n x lL H B 8 p r in e r  AGATTTTGGCATCARGAACTAACAAHGAAATCAGAGACATTAACAGGGTCTACRGHGAGGAACTGHRGRGRGATCTGGCCRHAGHCATAACCTCAGACACRTCTGGAGHTTTTCGGHACGCTTTGCTTTC 
C o n s e n s u s  AGATTTTGGCATCAAGRACTAACARAGAAATCAGRGACATTAACRGGGTCTRCRGAG8GGAACTGAAGRGAGATCTGGCCAAAGACATAACCTCAGACACATCTG6AGATTTTCGGAACGCTTTGCTTTC
521 530 540 550 560 570 580 590 600 610 620 630 640 650
| -----------------  1--------------------4--------------------4------------------- 1--------------------4--------------------4--------------------  4------------------------------   4-------- 1--------------------1
H id  TCTTGCTRHGGGTGflCCGATCTGAGGACTTTGGTGTGAATGRAGRCTTGGCTGATTCAGATGCCHGGGCCTTGTATGRAGCAGGAGAAAGGAGAARGGGGRCAGRCGTRRRCGTGTTCAATRCCHTCCTT 
H id R n x lL H B 8 p r in e r  TCTTGCTAAGGGTGACCGATCTGAGGACTTTGGTGTGAATGAAGACTTGGCTGATTCAGATGCCAGGGCCTTGTATGAAGCRGGAGflAAGGAGARAGGGGACRGACGTRARCGTGTTCAATRCCATCCTT 
C o n s e n s u s  TCTTGCTRAGGGTGRCCGATCTGAGGACTTTGGTGTGAATGAAGACTTGGCTGRTTCRGATGCCRGGGCCTTGTATGAAGCAGGRGAAAGGAGRAAGGGGACAGRCGTAAACGTGTTCHATACCRTCCTT
651 660 670 680 690 700 710 720 730 740 750 760 770 780
| -----------------1--------------------1--------------------4--------------------   1--------------------4--------------------4 -------------------     4--------------------4------------------- 1--------------------1
H id  ACCACCAGAAGCTATCCACAACTTCGCAGAGTGTTTCAGAAATACflCCARGTACRGTAAGCATGACATGARCAHAGTTCTGGRCCTGGAGTTGAAAGGTGACATTGAGRAATGCCTCACAGCTATCGTGA 
H id R n x lL H B 8 p r in e r  ACCACCAGAAGCTATCCRCAACTTCGCAGAGTGTTTCAGAAATACCCCA-GTflCAGTAAGCATGACATGAACMAAGTTCTGGACCTGGAGTTGAARGGTGACATTGAGAAATGCCTCACAGCTATCGTGA 
C o n s e n s u s  HCCHCCAGAHGCTHTCCRCAACTTCGCAGAGTGTTTCRGAAATHCeCCA.GTRCAGTAAGCATGACATGAACaRAGTTCTGGACCTGGAGTTGAAAGGTGACATTGAGAAATGCCTCACAGCTATCGTGA
781 790 800 810 820 830 840 850 860 870 880 890 900 910
H id  AGTGCGCCACMIGCAflACCAGCTTTCTTTGCAGAGARGCTTCATCARGCCATGAAAGGTGTTGGRRCTCGCCATAAGGCATTGATCAGGATTATGGTTTCCCGTTCTGAARTTGACATGARTGRTATCAA 
H id R n x lL H B 8 p r in e r  AGHGCGCCCCAGGCH8CCA6CTTTTCTTTHGC8AAAAMCTTCCTCRHGCCNTGNAAGGHGTTGGA
C o n s e n s u s  RGnGCGCCaCRaGCRAaCeaccTTTCTTTncaaRaAAnCTTCaTCARGCCaTGaRAGGnGTTGGA.... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
911 920 930 940 950 960 970 980 990 1000 1010 1021
| ----------------* -----------------—4------------------- 4--------------------4 ----------------- -4 --------------------  * --------------------  1--------------------4-------------------4 1
H id  RGCRTTCTATCAGAAGATGTATGGTATCTCCCTTTGCCRAGCCRTCCTGGATGAAACCAAflGGAGATTRTGAGRAAATCCTGGTGGCTCTTTGTGGAGGAAACTAAACATT 
H id R n x lL H B S p r in e r
C o n s e n s u s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure S.3. Annexin 1-GFP sequencing. Annexin 1-GFP construct was sequenced as 
described in 2.2.3. Primers were designed to sequence annexin 1-GFP from the multiple 
cloning site (MCS) of pGFP-Nl (top) and from midway through annexin 1 (bottom). 
Primer 1 (From MCS) 5 ’ -CT AGCGCT ACCGG ACT C AG AT-3 ’
Primer 2 (From middle) 5’- TGCTGATGAACTTCGTGCTG-3’
272
1 10 20 30 40 50 60 70 80 80 100 110 120 130
R nnexin  fiRflflflTGGCRRT6GTRTCHGRflTTCCTCflflGCflG6CCTG6TTTfiTTGRRRflTGRRGRGCRGGfifiTRTGTTCRRRCTGTGRRGTCflTCCRRRGGTGGTCCCGGflTCRGCGGTGflGCCCCTfiTCCTRCCTTC 
Y21F 6TTTHMCHTCRHRRflflflNHRGGGGGGNCTGTTMCCflTTGRflflflTGflRGRGCflGGRHTTTGTTCRRRCTGTGRflGTCfiTCCfiBRGGTGGTCCCGGflTCflGCGGTGRGCCCCTRTCCTRCCTTC
C onsensus ..................caaTnncaTCRnflRaaannaaaGcaGnCcBggnccRTTGflRRflTGflRGflGCRGGflflTaTGTTCRRRCTGTGRflGTCflTCCfiflfiGGTGGTCCCGGflTCRGCGGTGRGCCCCTflTCCTRCCTTC
131 140 150 160 170 180 190 200 210 220 230 240 250 260| ►   1       ♦      1   1
R n n e x i n  (VITCCRTCCTCGGRTGTCGCTGCCTTGCATARGGCCflTRRTG6TTAflRGGTGTGGflTGAflGCAflCCRTCRTTGRCRTTCTAflCTRRGCGARRCRRT6CRCRGCGTCflRCflGRTCARRGCfl6CATRTCTCC  
Y 2 1 F  RflTCCRTCCTCGGflTGTCGCTGCCTTGCRTRRGGCCflTRRTGGTTflflflGGTGTGGflTGflRGCflflCCRTCRTTGflCflTTCTRflCTRflGCGflflflCRRTGCflCRGCGTCMRCRGflTCflRRGCflGCRTRTCTCC  
C o n s e n s u s  RflTCCflTCCTCGGRTGTCGCTGCCTTGCRTRflGGCCflTRflTGGTTRRflGGTGTGGflTGflflGCfMCCRTCflTTGRCRTTCTRRCTRRGCGRflRCRRTGCRCRGCGTCaRCRGRTCRRflGCRGCRTRTCTCC
261 270 280 290 300 310 320 330 340 350 360 370 380 390I------♦------           ♦-------         1
R n n e x i n  RGGRflflCflGGRRRGCCCCTGGRTGRRflCRCTTflRGflflfl6CCCTTRCRGGTCflCCTTGRGGn6GTTGTTTTRGCTCTGCTRflflRHCTCCHGCGCRRTTTGHTGCTGflTGRRCTTCGTGCTGCCRTGRRGGG 
Y 2 1 F  RGGRRRCRGGARRGCCCCTGGRTGRRflCRCTTRAGflRRGCCCTTRCRGGTCRCCTTGRGGflGGTTGTTTTRGCTCTGCTRRRRRCTCCHGCGCRRTTTGRTGCTGRTGRRCTTCGTGCTGCCRTGRRGGG 
C o n s e n s u s  AGGflflflCRGGRRR6CCCCTGGflTGRflflCflCTTRRGRRRGCCCTTRCRGGTCRCCTTGRGGflGGTTGTTTTAGCTCTGCTRRRRRCTCCRGCGCRRTTTGRTGCTGRTGARCTTCGTGCTGCCATGRflGGG
391 400 410 420 430 440 450 460 470 480 490 500 510 520
I ------------------1---------------------   1-----------------— ♦ ------------------- ♦ -------------------> --------------------- ♦ --------------------     ♦ ---------------------1--------------------- ►-------------------- 1
R n n e x i n  CCTTGGHRCTGRTGRRGRTRCTCTRHTTGRGHTTTT6GCRTCflRGHRCTflRCflflflG-RflHTCRGHGRCflTTRflCRGGGT-CTRCfiGflGRGGRRCTGRflGRGflGflTCTGG-CCRRflGflCRT-RflCCTCRGR  
Y 2 1 F  CCTTGGAflCTGRTGRRGRTRCTCTRRTTGRGRTTTTGGCRTNHRGRRCTRRCRRRGNRRRTCRGRGRCRTTRRCRGGGTTCTRCNHRGRGGRRCTGRHGRGRGflTCTGGHCCNRRGRCCTTRRCCTCCGfl 
C o n s e n s u s  CCTTGGflHCTG flTGflRGflTRCTCTRATTGflGflTTTT6GCRTnaflGRRCTRRCRflRG.RflHTCRGAG RCRTTRRCRGGG T.CTRCanRG AGG RRCT6RRGRGAGRTCTGG.CCaRRG RCaT.RRCCTCaGfl
521 530 540 550 560 570 580 590 600 610 620 630 640 650
I---------♦---------- ♦----------     ♦-----------►-----------♦-----------♦-----------►-----------♦---------~ I---------- ►-----------1
R n n e x i n  CRCflT-CTG G-flGRTTTTCGGRfl-CGCTTT-GCTT-TCTCTTGCTRRGG GTGRCCGRTCTG flGGH CTTTGGTGTGRRTGRflGflC-TTG GCTG-RTTCHGH TGCCflG GGCC-TTGTBTG-flRG CR-GG RGfl 
Y 2 1 F  CRCNTMCTGGGRGRTTTTCGGRRRCGCTTTTGCTTNTCTCTTGCTRRGGGHGRCCGRTCTGRGGRCTTTGGNGTGRRTGRRGRCCTTGGCTGCRTTCHHRTGCCCGGGCCCTTGNMTGCRRGCRCNGRNR 
C o n s e n s u s  CH CaT.C TG G .flG R TTTTC G G fifl.C G C TTT.G C TT.TC TC TTG C TR H G G G nG R C C G R TC TG H G G R C TTTG G nG TG flflTG R R G R C .TTG G C TG .R TTC anH TG C C aG G G C C .TTG naTG .R flG C R .nG finfl
651 660 670 680 690 700 710 720 730 740 750 760 770 780
I ----------------- ♦ --------------------♦ ---------   ♦ --------------------♦ --------------------♦ -------------------- ♦ --------------------   1---------------------   1------- ---------— ♦ -------------------- 1
R nnexin  RRGGRG-RRRGGGGRCRGR-CGTRflRCGTGTTCnRTRCCRTCCTTRCCRCCflGRRGCTRTCCRCRRCTTCGCAGA-GTGTTTCRGRRRTRCnCCRRGTRCRGTRRGCflTGflCflTGRRCflnRGTTCTGGRC 
Y21F RflGGRRNRRRGGMGRCHGGHCNTRRCCGMGTTCtMRTRCCTCCTTHCRGCCNRRRGCCTTTCCRRRTTTCGGRGRRGGGTTTCRflRRRTNCCCHNflHTHHGGTTNNCTGGRCHTNRRCHTRHTTNNGGGN 
C onsensus AflGGRa.RRR66nGRCaGa.CnTRAaC<xiGTTCaaaaaCaTCCTTaCaaCCaaflRGCcaTcCaaARcTTCGcRGR.GgGTTTCRaRARTaCaCnaRnTanaGTaanCagGRCaTnRRCaaRnTTnnGGan
781 790 800 810 820 830 840 850 860 870 880 890 900 910I------<-------<------- 1-------♦------ ♦-------  ♦-------<-------   ♦------->-------«-------1
R nnexin C-TGGMiTTGRRRGGTGAC8TTGflGRRATGCCTCACflGCTRTCGTGAR6TGCGCCACflf)GCnARCCRGCTTTCTTTGCRGnGRRGCTTCi)TCARGCCRTGARflGGTGTTGGAACTCGCCATRflGGCATTG 
Y21F CGTNGIMTTNNRRGG-GGNHTTGNTNRRTRCMTimC-MTTNTCGCGGRnHMR~CRCHNRRGNRCC-NCTTT-MTTI3IRNflNRRn-11(CCTCC— CCCTGRRRHH-GNCGARCCNCHCTRNNCNCCTCMfl 
C onsensus C.TnGanTTnaRRGG.GanaTTGagaHRTnCnTnaC.i*:TaTCGcGaBanna..CflCaadaaaBCC.nCTTT.nTTGnfinft>flfia.TnCaTCa..CCaTGflRRnn.GncGaHaCnCnCcfinaancCacna
911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040I--------- <-----------    ♦---------- ♦-----------          .----------- ►-----------1
Rnnexin RTCRGGBTTRTGGTTTCCCGTTCTGARATTGRCATGRflTGATRTCRflRGCRTTCTRTCRGRRGRTGTRTGGTATCTCCCTTTGCCAAGCCATCCTGGRTGRRRCCRRAGGRGRTTRTGRGRARRTCCTGG 
Y21F C6CRN  CGG6TTCC
C o n s e n s u s  .......... ..
Figure S.4. Y2IF Annexin 1-GFP sequencing. Y21F annexin 1-GFP was sequenced as 
described in 2.2.3 using the primers described above in Figure S.3. Desired mutation 
(TAT to TTT) marked with an asterix (*).
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Annexin 1
1 agtgtgaaat cttcagagaa gaatttctct ttagttcttt gcaagaaggt agagataaag
61 acactttttc aaaa^^gca atggtatcag aattcctcaa gcaggcctgg tttattgaaa
121 atgaagagca ggaatatgtt caaactgtga agtcatccaa aggtggtccc ggatcagcgg
181 tgagccccta tcctaccttc aatccatcct cggatgtcgc tgccttgcat aaggccataa
LBA1A
241 tqqttaaaqq tqtqqatqaa gcaaccatca ttgacattct aactaagcga aacaatgcac 
LBA1X LBA1C
301 agcgtcaaca gatcaaagca gcatatctcc aggaaacagg aaagcccctg gatgaaacac 
LBA1B
361 ttaagaaagc ccttacaggt caccttgagg aggttgtttt agctctgcta aaaactccag
421 cgcaatttga tgctgatgaa cttcgtgctg ccatgaaggg ccttggaact gatgaagata
481 ctctaattga gattttggca tcaagaacta acaaagaaat cagagacatt aacagggtct
541 acagagagga actgaagaga gatctggcca aagacataac ctcagacaca tctggagatt
601 ttcggaacgc tttgctttct cttgctaagg gtgaccgatc tgaggacttt ggtgtgaatg
661 aagacttggc tgattcagat gccagggcct tgtatgaagc aggagaaagg agaaagggga
721 cagacgtaaa cgtgttcaat accatcctta ccaccagaag ctatccacaa cttcgcagag
781 tgtttcagaa atacaccaag tacagtaagc atgacatgaa caaagttctg gacctggagt
841 tgaaaggtga cattgagaaa tgcctcacag ctatcgtgaa gtgcgccaca agcaaaccag
901 ctttctttgc agagaagctt catcaagcca tgaaaggtgt tggaactcgc cataaggcat
961 tgatcaggat tatggtttcc cgttctgaaa ttgacatgaa tgatatcaaa gcattctatc
1021 agaagatgta tggtatctcc ctttgccaag ccatcctgga tgaaaccaaa ggagattatg
  LBA1D
1081 agaaaatcct ggtggctctt tgtggaggaa ac^^acatt cccttgatgg tctcaagcta
1141 tgatcagaag actttaatta tatattttca tcctataagc ttaaatagga aagtttcttc
1201 aacaggatta cagtgtagct acctacatgc tgaaaaatat agcctttaaa tcatttttat
1261 attataactc tgtataatag agataagtcc attttttaaa aatgttttcc ccaaaccata
1321 aaaccctata caagttgttc tagtaacaat acatgagaaa gatgtctatg tagctgaaaa
1381 taaaatgacg tcacaagac
Figure S.5. Human annexin 1 sequence and RNAi sequences. RNAi oligonucleotides 
were designed against human annexin 1 according to Qiagen protocol. Sequences for 
each oligonucleotide are underlined (LBA1A, B, C, D, X). Sequences for LBA1X and 
LBA1C overlap (double underlined shows overlapping bases). Start and stop codons 
are highlighted in blue.
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Annexin 2
1 atttggggac gctctcagct ctcggcgcac ggcccagctt ccttcaaaU^tctactgtt 
61 cacgaaatcc tgtgcaagct cagcttggag ggtgatcact ctacaccccc aagtgcatat
A2RNAil
121 gggtctgtca aagcctatac taactttgat gctgagcggg atgctttgaa cattgaaaca 
A2RNAil
181 gccatcaaga ccaaaggtgt ggatgaggtc accattgtca acattttgac caaccgcagc
241 aatgcacaga gacaggatat tgccttcgcc taccagagaa ggaccaaaaa ggaacttgca
301 tcagcactga agtcagcctt atctggccac ctggagacgg tgattttggg cctattgaag
361 acacctgctc agtatgacgc ttctgagcta aaagcttcca tgaaggggct gggaaccgac
421 gaggactctc tcattgagat catctgctcc agaaccaacc aggagctgca ggaaattaac
481 agagtctaca aggaaatgta caagactgat ctggagaagg acattatttc ggacacatct
541 ggtgacttcc gcaagctgat ggttgccctg gcaaagggta gaagagcaga ggatggctct
601 gtcattgatt atgaactgat tgaccaagat gctcgggatc tctatgacgc tggagtgaag
661 aggaaaggaa ctgatgttcc caagtggatc agcatcatga ccgagcggag cgtgccccac
721 ctccagaaag tatttgatag gtacaagagt tacagccctt atgacatgtt ggaaagcatc
781 aggaaagagg ttaaaggaga cctggaaaat gctttcctga acctggttca gtgcattcaq
A2RNAi2
841 aacaagcccc tgtattttgc tgatcggctg tatgactcca tgaagggcaa ggggacgcga
901 gataaggtcc tgatcagaat catggtctcc cgcagtgaag tggacatgtt gaaaattagg
961 tctgaattca agagaaagta cggcaagtcc ctgtactatt atatccagca agacactaag
1021 ggcgactacc agaaagcgct gctgtacctg tgtggtggag atgactgaag cccgacacgg
1081 cctgagcgtc cagaaatggt gctcaccatg cttccagcta acaggtctag aaaaccagct
1141 tgcgaa^Jc agtccccgtg gccatccctg tgagggtgac gttagcatta cccccaacct
1201 cattttagtt gcctaagcat tgcctggcct tcctgtctag tctctcctgt aagccaaaga
1261 aatgaacatt ccaaggagtt ggaagtgaag tctatgatgt gaaacacttt gcctcctgtg
1321 tactgtgtca taaacagatg aataaactga atttgtactt taaaaaaaaa aaaaaa
Figure S.6. Human annexin 2 sequence and RNAi sequences. RNAi oligonucleotides 
were designed against human annexin 2 according to Qiagen protocol. Sequences for 
each oligonucleotide are underlined (A2RNAil and 2). Start and stop codons are 
highlighted in blue.
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Chicken Annexin 2
1 cccgccgcca gagcagcctt gcccgccccg gccagcattc tgccaac^^ tctactgtcc
61 atgaaatttt aagcaagctc agtctggaag gagatcattc tctccctcca agtgcatatg
121 ccacagttaa ggcttactca aactttgatg ctgaccggga tgctgcagcc ctggaagcag
5'-ttaa ggcttactca aactttgatg ctgaccg-3'
181 ccatcaagac caaaggtgtg gatgaagtta ccatcatcaa catcctgaca aaccgcagca
241 atgaacagag gcaggatatt gcctttgcct atcagaggag aaccaaaaag gaactttctg
301 cagcacttaa gtctgctctg tcaggtcatt tagaggcagt gatcttgggc ttgctgaaga
3'-tea ctagaacccg aacgacttct
361 caccatcaca gtatgatgcg tctgaactga aagctgccat gaagggcctg ggaactgatg
gtggt-5'
421 aagacacact tatcgaaatc atttgctcac ggacaaatca ggagcttaat gaaattaata
481 gagtctatag ggaaatgtac aaaacagaac tggaaaagga cattatatca gacacatctg
541 gtgacttccg caagctaatg gttgccctgg ccaagggcaa aaggtgtgaa gatacttctg
601 tgattgacta tgaactgatt gaccaagacg ctagggagct etatgatget ggtgtcaaga
661 gaaagggaac agatgttccc aagtggatca acattatgac tgaaagaagt gttccacatc
721 tgcagaaagt gtttgaaagg tacaagagct acagcccata tgatatgttg gagagcatca
781 agaaggaagt taagggagat ctggagaatg ccttccttaa tcttgttcag tgcattcaga
841 acaagcagct atactttgca gacagactct atgattccat gaagggcaag ggaacccgtg
901 acaaggtcct gattaggatt atggtctccc gctgtgaggt tgacatgctg aaaattaaga
961 gtgaattcaa gaggaaatac ggaaaatccc tctattattt catccagcaa gacacaaaag
1021 gtgattacca gagggcgctg ctgaacctgt gtggtggaga ggac^Jaag ctgtgatgtg
1081 ggaaatggaa acgcagagac atgcctatct gctcttcgtt ttactccaac ccccgacaaa
1141 atcgagccgc catgcaaacc cttccctgcc ccaatacctg ccacaccacc gacgccgtgt
1201 gcttctggtg ctgcctgcac ttctcagcag cagcgctctg cttggttctg ccaaacttcc
1261 taacagcgta aagccagaga aactaacatt ccccagagat aaaggttaaa cgtgcttgtt
1321 gaggatgcct ccttgtgtaa tgtttctaat aaaacataaa taaaacag
Figure S.7. Chicken annexin 2 sequence. Chicken annexin 2 cDNA sequence showing 
primers used for RT-PCR (see 2.6), to confirm DT40 annexin 2 -/- cells were not 
expressing annexin 2. Primers are shown in pink (forward) and blue (reverse).
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